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Abstract  
Background 
Single-agent radioimmunotherapy (RIT) has demonstrated efficacy in B-cell 
lymphomas but has been relatively disappointing in solid tumours. To improve 
its efficacy combinations of RIT with new agents are being investigated. One 
rational combination, from preclinical studies, is RIT and a vascular disrupting 
agent (VDA).  
 
Aim 
To complete two Phase I clinical studies: 1) using single-agent RIT in Hodgkin 
lymphoma (HL) and T-cell Lymphomas and 2) combining RIT with 
Combretastatin-A4-Phosphate (CA4P) for solid tumours. Angiogenic cytokines 
and circulating cells were investigated as potential biomarkers for VDA induced 
hypoxia.  
 
Methods 
Two phase I, open-label, non-randomised dose-escalation clinical trials were 
completed. In the lymphomas a murine CD25-antibody conjugated to 
131
I was 
used in 14 patients. In CEA-expressing gastrointestinal tumours an anti-CEA 
(carcino-embryonic antigen) antibody, A5B7 was used with CA4P in 12 patients. 
ELISA (enzyme-linked immunosorbent assay) measured angiogenic cytokines in 
serum and flow cytometry assessed Tie-2 monocytes and EPC’s. Hepatic artery 
embolisation was used as a model for acute tumour hypoxia.  
 
Results 
The 
131
I-CHT25 study demonstrated efficacy with a response rate of 67% at or 
above the MTD (maximum tolerated dose). In solid tumours 
131
I-A5B7 and CA4P 
produced one minor response with a corresponding tumour marker fall. 
Erythropoietin, VEGF (vascular endothelial growth factor) and Tie-2 monocytes 
increased post embolisation and would merit further investigation as potential 
biomarkers. Angiopoietin 2 appeared elevated in both malignancy and liver 
disease and was an independent prognostic factor but did not rise post-
embolisation. This supported previous work suggesting angiopoietin-2 was 
derived from surrounding liver rather than tumour.  
 
Conclusion  
Single agent RIT appears effective in lymphoma but further research is required 
in solid tumours. More potent VDAs have since entered clinical trials but the 
development of biomarkers to determine response will be vital. VEGF, 
erythropoietin, Tie-2 monocytes and EPC’s would merit further investigation for 
that role. 
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Chapter One Introduction to radioimmunotherapy 
 
 
Cancer remains the second commonest cause of death in the United Kingdom; 
only circulatory disease is more prevalent.  Cure may be possible in localised 
disease with a combination of surgery, radiotherapy and chemotherapy (1) but 
is not commonly possible in disseminated disease (2), with the exception of 
germ cell tumours (3), haematological malignancy (4) and more rarely ovarian 
epithelial tumours. High-dose chemotherapeutics have not improved the cure 
rate in common solid tumours (5) either because a tumouricidal dose cannot be 
delivered due to toxicity or because tumours become drug-resistant. 
 
Chemotherapeutics are not specific to cancer cells, instead targeting generic 
processes such as cell division. All rapidly dividing cells are therefore affected 
and toxicity can be severe. The 2008 National Confidential Enquiry into Patient 
Outcomes and Death (NCEPOD) considered patients dying within 30 days of 
chemotherapy and concluded treatment had hastened or caused death in 27% 
(6). Recent research has focused on the need for more targeted agents such as 
radioimmunotherapy (RIT). 
 
1.1 Targeted agents 
 
Monoclonal antibodies contain a targeting moiety and an effector region 
capable of causing tumour cell death. Cytotoxicity can be augmented by 
conjugation to an additional effector molecule like a radionuclide, immunotoxin, 
chemotherapeutic or cytokine. In this chapter, due to considerations of space, 
only radioimmunotherapy will be considered further.  
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1.2 Radioimmunotherapy 
 
Radioimmunotherapy (RIT) is the combination of a monoclonal antibody and a 
radionuclide. The combination of a radioisotope and antibody is a 
radioimmunoconjugate (RIC). In addition to targeting cells with the appropriate 
antigen nearby antigen-negative cells are affected via the ‘cross-fire’ and 
‘bystander’ effects.  
 
Figure 1.1 Radioimmunotherapy 
 
 
 
 
The ‘cross-fire’ effect occurs as radiation may be deposited away from the 
target cell (7). Radiation-damaged cells also cause ‘bystander’ effects on 
neighbouring cells via signalling mechanisms which may produce cell death (8). 
These effects may be advantageous if they affect relatively inaccessible or 
antigen-negative malignant cells but if they damage healthy cells toxicity will 
result. The most sensitive organ to RIT is the bone marrow (9) and in non-
myeloablative RIT bone-marrow sensitivity is often dose-limiting.   
DNA strand breaks 
Radionuclide 
Crossfire  
Effect 
Antibody 
Tumour antigen 
Tumour cell 
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Additional advantages of RIT include the potential presence of a gamma-
emission allowing distribution and targeting to be assessed via imaging. Cell 
internalization of the antibody-antigen complex may also not be required.  
 
1.2.1 Choosing a radionuclide for RIT 
 
A variety of radionuclides have been considered for incorporation into a RIC 
(radioimmunoconjugate) but only 
131
I and 
90
Y are in current widespread use in 
RIT. The physical characteristics of some radioisotopes considered for RIT are in 
Table 1.. Bone-seeking radionuclides such as 
32
P and 
90
Sr used in metastatic 
bone disease are not considered here. 
 
When selecting a radionuclide the emission type is considered as well as the 
linear energy transfer (LET) and the physical half-life. The RIC needs to be 
compatible with the tumour localisation rate of the selected antibody and with 
the character of disease to be treated (minimal residual disease or large-volume 
metastatic) (10, 11). No ideal radionuclide for RIT currently exists. 
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Table 1.1 Radionuclides considered for radioimmunotherapy 
 
Radio-
nuclide 
Emission 
type 
Half-
life 
(days) 
Mean 
Range  
(mm) 
Energy 
Emax 
(keV) 
Imaging 
possible? 
 
Comment 
131
I β− / γ  8  0.4 0.81 Yes Inexpensive 
Radiation safety  
Dehalogenation 
90
Y β− 2.7  2.76 2.3 No Difficult imaging 
Bone seeker 
177
Lu β− / γ 6.7  0.28 0.5 Yes Bone seeker 
186
Re β− / γ 3.8  0.92 1.1 Yes  
188
Re β− / γ 0.7 2.43 2.1 Yes  
67
Cu β− / γ 2.6 0.6 0.57 Yes Long tumour 
retention 
Problematic 
chelator  
212
Bi α / β− / γ 0.04 0.04-
0.1 
6.09 Yes Effective in 
hypoxia  
Unstable 
daughter product 
211
At α 0.3 0.04-
0.1 
5.87 Yes Effective in 
hypoxia  
Unstable 
daughter product 
225
Ac α / β 10 0.04-
0.1 
5.83 Yes  
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1.2.2 Beta-emitters 
 
Radionuclides in current use predominantly emit β-particles. These have a long 
and variable range but a relatively low LET across that range. An extensive 
‘cross-fire’ effect is seen (10, 11). Beta-emitters with a particularly long range, 
such as 
90
Y, are theoretically more suited to bulky tumours or heterogeneous 
antibody expression. In minimal disease, most of the energy from long range 
emitters may be deposited outside the tumour (12, 13). A mathematical model 
found the optimum size for curability assuming a homogenous radionuclide 
distribution was 34 mm for 
90
Y and 3.4 mm for 
131
I (13). 
 
Radio-metals such as 
90
Y or 
177
Lu become trapped in the cell and are more 
resistant to break-down (14) but have complex radiochemistry and require 
chelators such as tiuxetan to bind antibody (15). The halogens such as 
131
I can 
be conjugated to antibody relatively easily but 
131
I is degraded after endocytosis 
(14) with a natural affinity for the thyroid. Potassium iodide administration 
during RIT is required to prevent gland failure. The radiometal 
90
Y preferentially 
deposits in bone, increasing the risk of myelotoxicity (7).  
 
131
I produces high-energy γ-emissions, requiring in-patient shielding post-
therapy, adding to cost and restricting therapy to self-caring patients. Pure β-
emitters such as 
90
Y avoid this problem but their distribution cannot be assessed 
directly via a γ−camera, although 111In can be substituted (16). Both 177Lu and 
67
Cu have γ-emissions of lower energy than 131I and show potential for use in RIT 
(11). A study of the three radioisotopes 
131
I, 
90
Y and 
67
Cu found higher tumour 
doses with the first two but a better normal tissue to tumour ratio with 
67
Cu 
with an improved therapeutic window (14).  
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1.2.3 Alpha-emitters 
 
Alpha-emitters have a short range, of about 1-2 cell diameters (50-60 µm) and a 
high LET across that range (approximately 400 fold higher than β-emitters) so a 
cell can potentially be killed by a single interaction (11). These features make 
them potentially suitable for accessible tumours with homogenous antigen 
expression such as leukaemias (17), tumour vasculature antigens (18) or 
minimal residual disease (19). Difficulties in the production, labelling and 
dosimetry of α-emitters have so far proved challenging either due to their short 
half-lives (20) or for 
225
Ac, with its longer half-life there is a problematic decay 
pattern with  daughter compounds generating toxicity. 
 
Clinical trials of α-emitters have been performed. 213Bi conjugated to an anti-
CD33 antibody in 18 patients with relapsed myeloid leukaemia demonstrated 
tumour targeting with a tumour: normal tissue ratio 1000 fold higher than with 
β-emitters. Circulating blast levels fell in 14 of 15 patients and bone marrow 
blasts in 14 of 18 (17). In melanoma 
213
Bi conjugated to anti-MCSP (melanoma-
associated chondroitin sulphate proteoglycan), an antigen expressed on both 
melanoma cells and pericytes, gave a response rate of 14%, attributed to 
damage of the more easily accessible pericytes rather than cancer cells (18, 21).  
 
1.2.4 Auger emitters 
 
Auger electrons are emitted when a nuclide decays with electron capture 
triggering emissions of orbital electrons (auger electrons) and gamma rays. They 
have short ranges of 1-2µm and a high LET, however they need to be 
internalized into the cell, preferably adjacent to the nucleus, to be most 
effective (22). If internalized their high LET means they can be profoundly 
cytotoxic. Their ‘cross-fire’ effect is negligible although a significant ‘bystander’ 
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effect may be present. They are relatively non-toxic to normal body cells that do 
not bind and internalize the RIC.  
 
Clinical trials have shown benefit with auger emitters. For example Anthony et 
al treated 27 patients with gastroenteropancreatic (GEP) neuroendocrine 
cancers who had failed all conventional therapies, with 
111
In-pentetreotide. 
Clinical benefit was seen in 62% with objective responses in 8%, hormonal 
biomarkers fell in 81% and tumour necrosis occurred in 27% (23). Recent work 
to improve auger therapy has led to the development of fusion proteins 
incorporating a nuclear localisation sequence (NLS) to the RIC. The NLS allows 
for an enhanced translocation of the bulky RIC towards the nucleus where DNA 
(Deoxyribonucleic acid) damage will be greater. Initial in-vitro and animal work 
of this technique look promising (24, 25). 
 
1.2.5 Antibodies for radioimmunotherapy 
 
In 1902 Paul Ehrlich used the phrase ‘a magic bullet’ to describe the concept of 
a specific anti-serum that distinguished healthy from diseased tissue and 
targeted the latter (26). The concept became a reality with the discovery of the 
antibody.  
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Figure 1.2 Antibody structure 
 
Antibody structure of two heavy and two light chains linked by disulphide bonds 
to form a Y shaped structure. VH = Variable Heavy, VL = Variable Light, CH = 
Constant Heavy, CL = Constant Light. Fv = Fragment variable, FAB = fragment 
antigen-binding region, FC = Fragment crystallisable region.  
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Fig 1.1
Antibody Structure
 
  
Two sites allow antibody function. The fragment antigen-binding region (FAB) is 
either side of a flexible hinge, allowing a single antibody to bind two antigens 
generating cross-linking, aggregation and a faster clearance. The Fc (fragment 
crystallisable) region activates the host immune system.  
 
Therapeutic antibodies were initially polyclonal until Kohler and Milstein 
discovered the hybridoma method to isolate monoclonal antibodies (27). 
Currently eleven unlabeled antibodies have been licensed by the FDA (Food and 
Drug Administration) as anti-cancer therapies and a further fifteen are licensed 
for other indications (see Table 1.1). 
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Table 1.1 Antibodies currently licensed as cancer therapeutics by the FDA 
 
Antigen Antibody Trade Name Type Tumour targeting 
CD20 Rituximab Mabthera™ Chimeric B-cell lymphoma 
Her2/neu Trastuzumab Herceptin™ Human Breast  
VEGF* Bevacizumab Avastin™ Human General 
EGFR** Cetuximab Erbitux™ Chimeric General 
CD33† Gemtuzumab Mylotarg™ Human Acute Myeloid 
Leukaemia 
CD52 Alemtuzumab Campath™ Human B-cell Chronic 
lymphocytic 
leukaemia 
EGFR** Panitumumab Vectibis™ Human Metastatic  
colorectal cancer 
CD20 Ibritumomab 
tiuxetan 
Zevalin™ 
(with 
90
Y) 
Murine B-cell lymphoma 
CD20 Tositumomab Bexxar™ 
(with 
131
I) 
Murine B-cell lymphoma 
CD20 Ofatumumab Arzerra™ Human Chronic lymphocytic 
leukaemia 
CTLA-4 Ipilimumab Yervoy™ Human Melanoma 
*   VEGF (Vascular Endothelial Growth Factor) 
** EGFR (Epidermal Growth Factor Receptor) 
†   Subsequently withdrawn due to toxicity.  
 
Antibodies induce cell death via activation of the host immune system (antibody 
dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity 
(CDC), antibody dependent cellular phagocytosis (ADCP)) or by disruption of 
vital pathways for tumour cell survival. Resistance can develop (28), cancer 
patients may have an impaired immune response (29) and tumour penetration 
by these bulky molecules may be poor.   
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I shall now briefly consider the particular radiobiology of RIT and the challenges 
this may present before considering alternative methods to improve RIT for the 
clinic.  
 
1.3 The radio-biology of radioimmunotherapy 
 
When ionizing radiation interacts with a cell, DNA damage may occur. Double 
strand (d-s) DNA breaks are harder to repair as they may lack the intact DNA to 
act as a template. If repair is unsuccessful, cell-death usually occurs on first 
mitosis. Radionuclides with a high LET have an increased chance of causing d-s 
breaks (7, 22). 
 
1.3.1 LET and the dose rate effect 
 
Sub-lethal DNA damage can be repaired. If however a second interaction occurs 
to that same strand or a separate ionising particle affects the opposite strand 
before repair is completed, cell death is likely to result. This concept gave rise to 
the dose rate effect where the higher the frequency of ionising interactions, the 
fewer repairs can be completed and the greater the probability of lethal 
damage (7). RIT has a low dose-rate that declines with time compared to 
external beam radiotherapy (EBRT) and brachytherapy. For example RIT has a 
dose-rate of < 10-20cGy/hr compared to approximately 50cGy/hr with 
brachytherapy (30).  
 
1.3.2 Hypoxia and RIT 
 
Hypoxia increases the resistance of tumour cells to radiation, particularly β-
emitters. In contrast oxygen leads to peroxide formation which prevents 
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tumour cell DNA repair and subsequent recovery. In RIT the hypoxia commonly 
seen in solid tumours contributes to resistance to therapy (31).  
 
1.3.3 Dose heterogeneity  
 
The absorbed tumour dose from RIT is often heterogeneous across a tumour 
due to considerable variability in antigen expression and antigen inaccessibility. 
Micro-thermo-luminescent dosimeters in B-cell lymphoma xenografts found the 
absorbed dose varied by up to 400% (32) allowing possible tumour escape and 
repopulation.  
 
1.3.4 Dosimetry for Radioimmunotherapy 
 
Radiation dosimetry aims to calculate the absorbed dose in a tissue that is 
deposited secondary to an administered activity of radiation. For EBRT clear 
relationships exist between absorbed dose, toxicity and tumour response which 
allow accurate treatment planning. These relationships are less clearly defined 
for RIT. It is possible to give a tracer dose of the intended RIC to allow predictive 
dosimetry to determine the most appropriate administered activity. This 
individualised therapy model for RIT remains challenging (33, 34). Currently 
tracer studies set limits on whole body dose to 0.75-3 Gy (bone marrow 
tolerance) and 20-30 Gy for other organs.  
 
1.3.4.1 Methodology for dosimetry 
 
Serial imaging calculates the radioactivity in tumour and normal tissue after RIC 
administration (34). If the RIC has a γ-emission, a γ-camera can be used. SPECT 
(single photon emission computer tomography) imaging can define regions of 
interest (ROI) and determine radioactivity uptake and clearance in normal 
tissues or tumour as a function of time (cumulated activity). The volume or 
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mass of tissue within the ROI, calculated using CT (Computed tomography), 
together with the cumulated activity give the activity concentration. Serial 
imaging over time allows the area under the curve (AUC) of the time-activity 
curve to be calculated giving the total number of disintegrations (number of 
particles created) during therapy in the ROI and allowing the calculation of total 
absorbed dose.  
 
The most widely used method uses the MIRD (Medical Internal Radiation Dose) 
Committee schema (35). This assumes that absorbed doses to patients can be 
calculated from radioactivity distributions within standard phantoms including 
organs of standard size, shape, position and a homogenous consistency with 
radioactivity evenly distributed. Absorbed doses per unit administered activity 
are calculated as the product of the residence time with an S value. The 
residence time is calculated by dividing the cumulated activity (i.e. the area 
under the time-activity curve) in the tissue by the injected activity. The S value 
includes information on the mean energy of each particle emitted during 
radioactive decay together with the fraction of energy from source organs 
(organs containing activity), which is either absorbed internally or transmitted 
to neighbouring organs. The S values for many radionuclides and source-target 
organs are available for reference (36).  
 
This method ignores the natural variability of organ size, shape and position 
(37). For example, spleen size in lymphoma patients is highly variable with 
recorded measurements from <50 g to >600 g compared to 183 g in MIRD (38). 
MIRD does not consider the radiation dose to normal organs derived from 
tumour or the dose to tumour from normal organs, although it includes the 
dose between normal organs. Longer range γ-emissions that may be deposited 
further from tumour are not included (39).  
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The MIRD assumption of a homogenous activity distribution is not consistent 
with evidence of marked heterogeneity at both the tissue and cellular level (37). 
The kidney has a non-uniform distribution due to its structure and absorbed 
doses for cortex and medulla should be estimated separately. Fused images 
using SPECT-CT and PET(Positron emission tomography)-CT allow more accurate 
estimations of tumour or organ size, shape and position (39).  
 
1.3.4.2 Dosimetry in clinical practice 
 
Current dosimetry methods give only weak correlations between absorbed dose 
and toxicity or response. If the relationship was more predictable a tracer dose 
could determine the therapeutic injected activity (39). Dosimetry is used in the 
therapy of metastatic thyroid cancer with 
131
I. A fixed administered activity of 
7.4 GBq, exceeded the maximum tolerable activity in 22-38% of patients older 
than 70 (8-15% in those younger) (40).  European Association of Nuclear 
Medicine (EANM) guidelines remain empirical, recommending administered 
activities between 3.7-7.4 GBq with adjustments determined by dosimetry. In 
other solid tumours such as neuroendocrine tumours (41) and neuroblastoma 
(42) relationships exist between tumour absorbed dose and response but wide 
variability precludes truly individualised therapy.  
 
In indolent B-cell lymphoma pre-therapy tracer scans are used for 
131
I-
tositumomab but not for 
90
Y-Ibritumomab Tiuxetan which has a more 
predictable excretion.  De-halogenation of 
131
I is variable between patients 
leaving free iodine to concentrate in stomach and thyroid before renal 
excretion. Excretion varied by 46-90% at 48 hrs between patients. This 
variability in excretion could be predicted by a tracer dose. The radio-metal 
90
Y 
is more stable with a more predictable excretion and administered activity can 
generally be determined by patient weight (43).  
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1.3.5 Improving the success of radioimmunotherapy 
 
Considerable interest exists in RIT but challenges remain before it can be 
considered an effective therapy, particularly in solid tumours. Antibody 
engineering is helping to improve pharmacokinetics and immunogenicity but 
other problems remain.  
 
1.3.6 Pharmacokinetics, uptake and clearance 
 
To be effective a RIC needs to diffuse homogenously and in high concentration 
throughout tumour, but remain at low concentration in normal tissues. A bulky 
IgG (Immunoglobulin G) antibody diffuses slowly from circulation into tumour 
exposing normal tissues to greater toxicity. Tumour uptake in a mouse model of 
an antibody against CEA (Carcinoembyronic antigen) called A5B7, was 10-15% 
ID/g by 24 hours in subcutaneous lesions and large metastatic lesions although 
higher in small metastatic lesions (44).  
 
Antibody engineering has produced fragments with faster tumour uptakes, 
clearance and more homogenous distributions in tumour than whole antibodies 
(45). The smallest fragments are the FV’s, which are unstable. A synthetic linker 
between heavy and light chains gives an scFV (single chain FV) with a molecular 
weight of 25 kDa (kilo Dalton) (46). These scFv’s have an improved tumour to 
normal tissue ratio (47, 48) but their rapid clearance gives a low absolute 
tumour absorbed dose. Their low molecular weight may lead to renal filtration, 
increasing the risk of renal toxicity.  Intermediate size fragments are being 
investigated such as the minibodies (49) and small immunoproteins (SIP’s) (50) 
which have lower tumour clearance and lack renal filtration. 
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1.3.7 Antibody affinity and avidity 
 
Antibody affinity expresses the strength of interaction between a single 
antibody site and its specific antigen epitope, including spatial fit, interaction 
size and charge. The avidity is the functional binding between the antibody and 
its antigen. It is the sum strength of all the affinity bonds (functional affinity) 
and takes into account multiple binding interactions with different epitopes.  
 
Antibody engineering can increase affinity and extend binding duration (51, 52). 
At very high affinities antibody remains bound to the nearest antigen and stays 
trapped in the peri-vascular space rather than diffusing through tumour. This 
effect is the ‘binding-site barrier’ (53). It cannot be overcome by increasing 
administered dose due to the toxicity of the radioisotope.  
 
1.3.8 Immunogenicity  
 
Antibodies were initially murine in origin with less ability to activate the human 
immune system (54) and a more rapid excretion due to failure to bind the 
human salvage receptor FcRn (neonatal Fc receptor) (54). At two to three weeks 
post-exposure human anti-mouse antibodies (HAMA) are formed in 50% of 
patients with an intact immune system and nearly always with repeat therapy 
(55). HAMA formation can aid antibody clearance (56) and lead to flu-like 
symptoms, urticaria or mild bronchospasm on retreatment due to IgG reactions 
(57). 
 
Immunosuppressive therapies, such as cyclosporine A, can delay but not 
prevent HAMA formation and have additional toxicities (55). An alternative 
approach is to replace murine antibody protein with human.  
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Figure 1.3 Adapting antibodies to reduce immunogenicity 
 
Murine antibody Chimeric antibody
Humanized antibody
Key 
Murine
Human
 
 
Chimeric antibodies have human constant regions and murine variable regions. 
As most HAMA form against the Fc region a chimeric antibody significantly 
reduces immunogenicity (58). However human anti-chimeric antibodies (HACA) 
may form against the remaining murine protein including the antigen-binding 
site (anti-idiotype antibodies). Chimeric antibodies have a longer half-life than 
murine (up to 10 days), which may not be effected by repeat exposure. 
 
Humanized antibodies retain murine complementary determining regions. 
Antibodies can develop against their specificity determining residues (SDR) but 
are often of low titre and do not preclude re-treatment. Humanized and 
chimeric anti-cancer antibodies in clinical use are listed in Table 1.1  
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1.3.8.1 Two-step approaches 
 
A two-step approach involves separating the administration of the antibody 
from the radionuclide. The antibody is allowed time to localize and bind to 
tumour before a low molecular weight radionuclide is given that binds to that 
initial antibody (59). This method gives high tumour to normal tissue ratios and 
allows safer escalation of the injected activity (59, 60). Rapid radionuclide 
excretion gives a potential for renal toxicity and the administration of two or 
more compounds can increase immunogenicity. The different systems 
developed are more fully discussed in a review by Goldenberg et al (60). 
 
1.3.8.2 Selecting the right tumour  
 
RIT appears most effective in highly vascular tumours with readily accessible 
and homogeneously expressed antigen (61). These include haematological 
malignancy and adjuvant therapy for minimal residual disease.  
 
Solid tumours have a poorly organised vasculature with no accompanying 
lymphatic vessels (62, 63) and an elevated mean interstitial pressure (64) that 
obstructs antibody diffusion. Tumour cells are often poorly perfused and 
acidotic, hypoxic and radio-resistant (65). Antigen may be heterogeneously 
expressed and tumour tissue inherently more radio-resistant. All these 
challenges make RIT more difficult in solid tumours.  
 
1.3.8.3 Selecting the right antigen to target  
 
The identification of a suitable target antigen is vital for the ultimate success of 
antibody therapy (66). An ideal antigen is highly and homogeneously expressed 
on cancer cells although the number and density of antigens required varies. 
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Only 100,000 copies of the CD20 (Cluster of Differentiation) antigen are 
required per cell in B-cell lymphomas (67) but 2.3 x 10
6
 copies per cell are 
needed of the Her2/neu receptor in breast cancer (67).  
 
The antigen should be relatively tumour cell specific. B-cell lymphomas possess 
a unique immunoglobulin idiotype that proliferates as a single unique clone 
(68). In most cases tumour antigen is not restricted to tumour cells but is found 
at a lower density of expression on healthy cells, is expressed during a particular 
developmental stage, is relatively inaccessible (69) or found on cells that are 
continuously replenished and therefore non-essential (70).  
 
An ideal antigen is not shed or secreted, which may enhance renal clearance 
due to complex formation in the circulation (71). The administration of the RIC 
cannot be increased to overcome this antigen ‘sink’ although unlabeled 
antibody can be administered prior to the RIC. Shedding or secretion is less 
problematic for unlabeled antibodies and the shedding of Her2/neu has not 
impaired targeting by trastuzumab (67). In addition the ideal antigen should be 
expressed on the majority of tumours of a particular cancer type or a diagnostic 
test be available allowing patient selection (72). It should not be lost with 
tumour de-differentiation and may be ubiquitous across many tumour types 
(67). 
 
1.3.8.4 Selecting the right patient  
 
Typical patients in Phase I clinical trials have resistant bulky tumours. These 
patients are unlikely to be ideal candidates for RIT which is likely to be most 
effective in small volume, minimal residual disease (73) or haematological 
malignancy (74).  
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1.4 First Hypothesis 
 
Considering the previously published work described here we would expect that 
single agent RIT would be effective in haematological malignancy. In Chapter 
Two I shall present the results of our phase I clinical trial of a chimeric anti-CD25 
antibody conjugated to 
131
I in patients with CD25 expressing lymphomas 
(predominantly Hodgkin’s lymphoma (HL) but also T-cell lymphomas). 
 
Lymphomas are highly radio-sensitive tumours; they are highly vascular with 
less necrosis and hypoxia than solid tumours. Antibody penetration is therefore 
easier with higher absorbed doses anticipated. Although most of the previous 
work is in indolent B-cell lymphomas it is likely that Hodgkin’s lymphoma shares 
those characteristics and therefore shares sensitivity to RIT. 
 
Generally both HL and T-cell lymphomas have a higher proliferation rate than 
indolent B-cell lymphomas. As RIT delivers radiation at a low-dose-rate the cell-
kill it induces might be inadequate to induce prolonged responses. If the results 
are consistent with the previous work a sub-group of patients may have durable 
responses.  
 
1.5 Radioimmunotherapy in Lymphoma 
 
 
Much of the current information about RIT for lymphoma is derived from 
treating patients with indolent B-cell lymphoma. Two radio-labelled antibodies 
are licensed; 
90
Yttrium-ibritumomab tiuxetan (
90
Y-IT) (Trade-name Zevalin®) and 
131
Iodine-tositumomab (
131
I-T) (Trade-name Bexxar®). As many characteristics of 
RIT appear to be class effects, it is worth looking at these 2 agents in greater 
detail. Then in Chapter Two a brief introduction will consider the CD25 receptor 
in greater detail before presenting the results of our phase I study targeting 
CD25-expressing lymphomas with 
131
I.  
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1.5.1 Indolent B-cell Non-Hodgkins-lymphoma (NHL) 
 
Indolent B-cell lymphomas have a typically slow disease course with a relapsing, 
remitting pattern. With each relapse, response rate and duration of response 
decrease (75). Cure is possible in localized disease (76) but 80% present when it 
is disseminated. Combination chemotherapy including high-dose therapy with 
autologous stem cell transplant (ASCT) has had little impact on survival (77) and 
allogeneic transplant is only suitable for young, fit patients (78). Median survival 
has remained stable at 8-10 years (75).  
 
1.5.2 Rituximab for indolent B-cell lymphomas 
 
Rituximab is a chimeric antibody to the cell surface receptor CD20 found on 
both malignant and normal B-lymphocytes but not on progenitor or stem cells. 
Cytotoxicity is via ADCC and activation of complement with induction of 
apoptosis in vitro (79). It is active in indolent B-cell lymphoma with a response 
rate of 48% in relapsed disease (80) rising to 95% when given first-line in 
combination with chemotherapy (81). Although encouraging, the majority of 
patients either fail to respond or subsequently relapse. 
 
1.5.3
 131
I-tositumomab (
131
I-T) (Bexxar™) 
 
131
I-T is a murine anti-CD20 antibody conjugated to 
131
I with a variable renal 
excretion requiring pre-therapy dosimetry. Kaminski et al treated 59 patients 
with relapsed or refractory disease. The response rate was 71% (83% in low 
grade or transformed disease), with a median progression free survival of 12 
months in 42 responders (82). Re-treatment was feasible and induced 
responses in 9 of 16 patients. Response in the first line setting was 95% (83).  
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Toxicity was generally mild and included infusion reactions, nausea and 
tiredness. HAMA occurred in < 10% of heavily pre-treated patients but 63% of 
those treated first-line (83). Potassium iodide was given to reduce thyroid 
uptake of radioactive iodine. With this precaution the incidence of thyroid 
dysfunction (defined as either an elevated TSH (thyroid stimulating hormone) or 
requiring thyroid replacement medication) was less than 10% (82, 84). The 
peripheral blood count nadir was at approximately 6 weeks with grade 4 
neutropenia seen in 14%. The incidence of acute myeloid leukaemia (AML) or 
myelodysplastic syndrome (MDS) was reviewed in a meta-analysis and not 
considered elevated above anticipated levels (85). 
 
1.5.4
 90
Yttrium-ibritumomab tiuxetan (
90
Y-IT) (Zevalin™) 
 
The first RIC to receive a license for relapsed or refractory indolent B-cell 
lymphoma was 
90
Y-IT. It comprises a murine antibody to the 2B8 epitope on 
CD20 (rituximab is the chimeric form). Its predictable excretion allows a 
standard injected activity without pre-therapy dosimetry (86). A randomized 
study of 
90
Y-IT versus single-agent rituximab improved response rates from 56% 
to 80% (74). Response rates were higher in smaller volume disease and at first 
relapse but also seen in patients resistant to rituximab (74%) (87). 
 
It was generally well tolerated. Haematological toxicity correlated with the 
number of lines of prior chemotherapy and the extent of marrow involvement 
with lymphoma (88). Grade IV neutropenia was seen in 30% of patients 
receiving the standard dose of 0.4 mCi/kg (14.8 MBq/m
2
) but was associated 
with sepsis in only 3% (88). This low rate was attributed to the lack of mucosal 
damage and preservation of NK (Natural Killer) and T-cell function (89). AML / 
MDS rates were equivalent to historical controls for chemotherapy-exposed 
patients (90). Elderly patients tolerated RIT as well as the young (91); 
chemotherapy was possible after RIT with no additional toxicity (92).  
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1.5.5 Lessons for the CHT25 clinical trial 
 
Past experience with 
90
Y-IT and 
131
I-T provides useful information for our study. 
Additional benefit was seen with the RIC when compared to the antibody alone 
(rituximab). As CD25-expressing lymphomas share biological characteristics with 
B-cell lymphomas (an inherent radiosensitivity, relatively accessible tumour 
cells, a good vascular supply and a low level of necrosis and hypoxia), we have 
hypothesized they will also be sensitive to RIT. Their higher rate of proliferation 
might however reduce the extent of that response. In the trials of B-cell 
lymphomas a sub-group of patients had long-term durable responses with the 
hope of cure in some individuals.  
 
We would anticipate toxicity to be predominantly haematological with bone-
marrow suppression dose-limiting. Blood count nadir is likely to occur at 6-7 
weeks post infusion. A heavily pre-treated patient group (such as our phase I 
study) would be more at risk of severe bone marrow suppression. There is likely 
to be a lower incidence of HAMA or HACA formation however. Reassuringly any 
subsequent therapeutic options are unlikely to be precluded by RIT.  
 
1.6 Radioimmunotherapy of Solid Tumours 
 
In contrast to the haematological malignancies already discussed, solid tumours 
appear relatively insensitive to RIT.  Multiple trials of single agent RIT in solid 
tumours have been relatively disappointing (7, 93) with a typical response rate 
of 10% (93, 94). A number of factors are likely to be contributory:  
 
• A poorer vasculature with absent lymphatics resulting in an elevated 
interstitial pressure limiting antibody diffusion (64, 95). 
• Greater heterogeneity of antigen expression both within and between 
cells. Areas of under-dosing can lead to tumour re-growth (96). 
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• Antigen secretion into the circulation with immune complex formation 
and faster clearance (71). 
• Increased hypoxia which is inherently radio-resistant (97) 
• Reduced radio-sensitivity of solid tumours (98) 
• A preserved immune system capable of mounting a response to murine 
or chimeric antibody (99). 
 
1.6.1 Colorectal and other CEA-expressing gastrointestinal cancers 
 
To demonstrate the challenges of RIT in solid tumours I shall consider its impact 
in the targeting of CEA-expressing gastrointestinal malignancy in greater detail. 
 
1.6.1.1 CEA as a target for Radioimmunotherapy  
 
CEA is a useful antigen to target in radioimmunotherapy. It is present on 95% of 
all colonic adenocarcinomas (100) and a smaller percentage of other epithelial 
tumours including pancreatic and stomach cancer. In healthy tissue CEA 
expression is restricted to the apical surface of the microvilli in the colon 
epithelium, however in malignancy it is expressed on all cell surfaces. A 
systematically delivered anti-CEA antibody cannot access the luminal surface of 
the normal colon cells due to the presence of tight junctions, allowing for some 
selectivity to malignant cells.  
 
In malignancy CEA is secreted into the circulation and can act as a tumour 
marker. A high serum CEA may reduce tumour targeting as complexes are 
formed in the circulation and cleared (101).  
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1.6.1.2 Clinical trials of RIT in CEA-expressing gastrointestinal cancers 
 
RIT has been investigated in both the adjuvant setting and in advanced disease.  
Studies have tended to be non-randomized with small patient numbers and 
have used a variety of protocols, radionuclides and antibodies making 
comparison between them difficult. Most studies are in patients with bulky 
disease, resistant to conventional therapeutics.  
 
1.6.1.3 Advanced disease 
 
Studies of RIT against CEA-expressing tumours are listed in Table 1.3. All 13 
studies were phase I or single arm phase II trials exploring toxicity and efficacy. 
Median patient number was 16 and only 1 used pre-targeting (102).  
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Table 1.2 Studies targeting CEA in advanced tumours  
Drug Species 
antibody 
Fragment or 
whole  
No 
patients  
Response Comment Reference 
131
I-PK4S Sheep Polyclonal 16 1 PR Clearing 
antibody 
Begent et al 
1989 (103) 
131
I-A5B7 Murine IgG1/F(ab’)2 19 1 CR  
1 PR 
Repeat 
administration 
Lane et al 
1994 (94) 
131
I-NP-4 Murine IgG1 57 1 PR  
4 MR 
7 SD 
 Behr et al 
1997 (104) 
131
I-NP-4 Murine  IgG1 13 7 SD 
6 PD 
Repeat 
administration 
Juweid et al  
1996 (105) 
131
I-COL-1 
/
131
I-CC-49 
Murine  IgG1 14 4 SD Dual antibody 
with IFNα-2b 
Meredith et 
al 1996 (106) 
131
I-IMMU-4 Murine IgG1 6 1 PR With 
hyperthermia 
Mittal et al 
1996 (107) 
131
I-F6 Murine F(ab’)2 10 1 PR 
2 SD  
With bone 
marrow 
rescue 
Ychou et al 
1998 (108) 
 
131
I-FO23C5 Murine IgG1 10 1CR 
2 PR 
4 SD 
 Behr et al 
1999 (73) 
 
188
Re-MN-
14 
Murine IgG1 11 None Repeat 
administration  
Juweid et al 
1998 (109) 
90
Y-T84.66 Chimeric IgG1 22 2 MR 
3 SD 
Repeat 
administration 
Wong et al 
2000 (110) 
90
Y-T84.66 Chimeric IgG1 21 1 MR 
11 SD 
With 5-FU 
chemotherapy 
Wong et al 
2003 (111) 
131
I-MN-14 Humanized IgG1 21 None  Hajjar et al 
2002 (112) 
MN-14 x 
m734 + 
131
Ihapten  
Humanized  IgG1 35 Not 
reported 
Pre-targeted 
RIT 
Kraeber-
Bodere et al 
1999 (102) 
CR: Complete response, PR: Partial response, MR: Mixed response or minor response 
IFN: Interferon, 5-FU: 5 Fluorouracil 
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Initial studies used murine antibodies. Lane et al (94) compared 
131
I F(ab’)2 
fragments with whole antibody. One patient in each arm had a partial response. 
Juweid et al (105) used fragments of the NP-4 antibody and repeat 
administration in patients with metastatic disease < 3cm. Most patients became 
HAMA positive and 7 had stable disease for up to 7 months. The largest trial was 
by Behr et al (104) of 57 patients of whom 12 were thought to derive clinical 
benefit and 1 had a partial response. A higher affinity antibody, MN14, 
conjugated to 
188
Re in 11 patients generated no responses (109). 
 
Subsequent studies used chimeric or humanized antibodies. A dose-escalation 
study with the chimeric antibody cT84.6 generated clinical benefit in 5 of 22 
patients and saw 2 mixed responses (110). The addition of chemotherapy gave 
no increased toxicity and a reduction in HACA formation (111). Eleven patients 
then had stable disease for 3-8 months and 1 had a mixed response. A separate 
study found dose-escalation with stem cell support was feasible, using the F6 
antibody (108). One patient had a partial response in 1 liver lesion and 2 had 
stable disease. 
 
1.6.1.4 Small volume disease or the adjuvant setting 
 
Mathematical (113) and animal models consider RIT as theoretically more 
effective in smaller volume disease. Mayer et al used 
131
I-A5B7 in a mouse 
model and found smaller tumours had a higher absorbed radiation dose and 
grew less rapidly (114). Digital autoradiography studies of 
125
I-A5B7 in mice 
quantified this difference at 15% ID/g in larger tumours compared to 80% ID/g 
in smaller (44). High-resolution digital microscopy and fluorescently labelled 
anti-CEA antibody in nude mice found rapid selective tumour uptake and a 
strong negative correlation with tumour size at 10 minutes and 1 hour post 
administration (p<0.01) but not at 24 hours (115).  
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Behr et al considered adjuvant RIT. Nine patients post liver resection for 
metastatic colorectal cancer were given a single injected activity of 
131
I-hMN-14. 
At 36 months, 7 of 9 patients were relapse free compared to historical controls 
of 33% (116). In addition, 21 patients with chemo-refractory disease < 3cm were 
treated, 16 had a minor response and 3 a partial response. On relapse, 5 
patients were re-treated and 2 had a further response (116).  
 
Liersch et al treated 23 patients who had previously had a liver resection for 
colorectal cancer with 
131
I-labetuzumab (a humanized IgG anti-CEA antibody 
marketed as CEA-CIDE). They were compared to a contemporaneous group of 
patients in the same institution most of whom received adjuvant chemotherapy 
(117). Survival was 58 months with RIT compared to 31 in the control group. 
Ychou et al (118) in a similar patient group gave 
131
I-F6 F(ab’)2 to 13 patients. 
The disease free survival was 12 months with an overall survival of 50 months 
and 2 patients remained alive at 127 months. 
 
These studies appear to confirm that RIT does have activity against solid 
tumours, principally in small volume and minimal residual disease. The 
treatment of bulky solid tumours however remains challenging. New research is 
attempting to improve the efficacy of RIT in a variety of ways. Antibody 
engineering may optimize pharmacokinetics or reduce immunogenicity. New 
targets may be more effective and accessible for RIT. New combinations are 
being investigated. These have included combinations with cytotoxic agents, 
cytokines and radiotherapy.  
  
Our own study is reported in Chapter 3 and utilised the novel combination of a 
131
I-A5B7 anti-CEA antibody together with a Vascular Disrupting Agent (VDA) in 
CEA-expressing gastrointestinal tumours. Our study aimed to investigate the 
hypothesis outlined below.  
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1.6.3 The Vascular Disrupting agents (VDA’s)  
 
 
Vascular disrupting agents target abnormal tumour vasculature leading to 
vessel shut down, ischaemia and haemorrhagic necrosis (119). Two groups are 
currently known. Flavonoids such as DMXAA (5,6-dimethylxanthenone-4-
aceticacid) which act via disruption of the actin cytoskeleton and induction of 
apoptosis. The second group are tubulin-binding agents such as the 
combretastatins. As our Phase I study used a combretastatin this class of agents 
shall be considered in more detail in Chapter 3.  
 
1.6.4 Combining RIT with vascular targeting agents 
 
Tumour-associated vessels are abnormal and can be targeted by the class of 
drugs known as the VDA’s. Vessels are poorly organized with absent lymphatics 
(62) are leaky, tortuous and thin-walled (120) with slow flow that can reverse 
(121). Nutrient supply is often inadequate and tumour centres become hypoxic 
and necrotic. Targeting blood vessels is appealing. Shut-down of a single blood 
vessel can kill thousands of dependent tumour cells, endothelial cells are more 
accessible than most tumour cells and they may be less heterogeneous (122) 
with a lower possibility of drug-resistance. 
 
Compounds that destroy tumour-associated vessels already in existence are 
called vascular disrupting agents (VDA) (119). These agents have profound 
effects in the tumour centre where blood supply is already marginal. The 
tumour centre is the compartment that RIT fails to kill due to hypoxic radio-
resistance and poor penetration. A theoretical possibility of synergy therefore 
exists, and has been demonstrated in animal models (123). This evidence led to 
the design of our Phase I study reported in Chapter 3.  
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1.6.2 Second hypothesis 
 
From the previous work we hypothesized that RIT against cancer-specific 
antigens would be ineffective in solid tumours. RIT would be ineffective due to 
the low absorbed dose achieved due a lack of antibody penetration into 
tumour, the relative insensitivity to radiation of the malignant cells and the 
preservation of the immune system allowing immunogenicity to develop.  
 
We hypothesized that the combination of RIT with a VDA that targets tumour-
specific blood vessels, would act synergistically in solid tumours leading to an 
increased efficacy. Synergy was predicted from their differing modes of action, 
with RIT targeting the outer rim and the VDA the hypoxic poorly perfused centre 
which is inaccessible to bulky antibodies. Evidence of synergy was previously 
seen in animal studies where the combination of RIT and a VDA transformed a 
sub-curative therapy into a curative one (124).  
 
1.7 Biomarkers for the Vascular Disruptive Agents (VDA’s) 
 
 
In chapter 3 we presented the results of a Phase I study of a VDA combined with 
RIT. One of the challenges faced in this study was the lack of a clear biomarker 
for the Vascular Disrupting Agents. This lack makes it difficult to efficiently 
design studies to promote synergy between the two agents. This is especially 
problematic with combinations involving the VDA’s where vascular shut-down 
may prevent RIT access to the tumour. Currently no easy and reliable method 
exists to determine the biological effect of these compounds. 
 
Identifying a surrogate biomarker for the VDA’s would help determine their 
optimal biological dose (OBD) where vascular shut-down is maximal. Such a 
biomarker would be of great use in determining the ideal schedule for drug 
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combinations. Alternatives such as the maximum tolerated dose (MTD) may be 
inappropriate for these agents where their maximum biological effect may 
occur at a lower dose than the MTD. Measuring reduction in tumour size by 
radiology can underestimate any biological effect in drugs that lead to disease 
stability rather than shrinkage. 
 
Currently the biomarker used most commonly in clinical trials has been either 
DCE-MRI (Dynamic Contrast Enhanced MRI) or PET based. There are limitations 
and challenges with these methods. I shall discuss them further in the next 
section.  
 
1.7.1 Imaging as a biomarker 
 
Using imaging to assess anti-vascular agents is appealing as it is non-invasive, 
allows repeat assessment and can directly image the relationship between 
tumour and blood vessels. Both PET and MRI have been important in the clinical 
development of VDAs.  
 
1.7.1.2 Magnetic Resonance Imaging 
 
MRI techniques have the advantages of high spatial resolution and a variety of 
contrast agents with good tissue penetration. Accurate anatomical information 
can be derived about vessel structure as well as function. The technique uses 
the rate of diffusion of contrast from micro-vasculature into the tumour 
interstitial space, which depends on vessel permeability, surface area and blood 
flow (125). Blood kinetics can then be described using the transfer constant 
(K
trans
) and the IAUGC.  The concordance between DCE-MRI and alternative 
methods for assessing vascularity, have been contradictory. Whilst most studies 
have shown a broad correlation with MVD (Microvessel density) (125) and some 
with tissue VEGF (Vascular Endothelial Growth Factor) (126), others have not.  
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DCE-MRI has clinical applications. It can improve cancer diagnosis, monitor 
treatment and predict response to chemotherapy, radiotherapy, anti-androgens 
(125) and anti-angiogenic agents (127). Changes on MRI can be detected after 1 
therapy cycle and at 2 cycles can determine likely treatment effectiveness.  
 
Disadvantages of DCE-MRI include the lack of a standardized approach to the 
procedure. In our clinical trial presented in Chapter 3, it was noted that of 88 
patients considered for the clinical trial 19 were ineligible as their tumours were 
not assessable by MRI. It is expensive, time-consuming, technically challenging 
and currently available in only a small number of centers. 
 
1.7.1.3 Positron emission tomography (PET) 
 
Both PET and SPECT can be used to determine total organ blood flow or organ 
perfusion (127). An isotope such as 
15
O is used, which is short-lived, chemically 
stable and biologically inert. It is given either intravenously as a bolus of 
15
O-
labelled water (128) or by inhalation as 
15
O labelled carbon dioxide. When the 
rate of radioactive decay is balanced by infusion the isotope concentration 
relates to blood flow (127). Tissue concentration (from PET imaging) and arterial 
concentration (obtained either from direct sampling or from imaging blood in 
the cardiac ventricles) are both required (127). 
 
Validation for this technique has mostly been from studies of the brain or 
myocardium rather than malignancy. In addition although blood flow was 
higher in brain tumour tissue than normal tissue there was considerable 
variability (129). Small studies have considered blood flow in breast (130), 
pancreatic (131) cancers and liver metastases (132). High-dose CA4P 
(Combretastatin-4-Phosphate) caused a significant fall in tumour perfusion by 
30 minutes that resolved by 24 hours (133). Alternatively the new VEGF-PET 
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tracer 
89
Zr-ranibizumab could delineate the anti-angiogenic effects of sunitinib 
in a mouse xenograft model (134).  
 
PET is expensive and time-consuming. The short half-lives of the compounds (2 
minutes for 
15
O), require an on-site cyclotron and delivery system. The model 
assumes that labelled water diffuses freely and homogenously throughout the 
tumour, which may be inaccurate (135). The value produced is an average with 
no consideration for fluctuations in flow with time or at the micro-vascular level 
(136). The model is also less reliable at high flow rates (127).  
 
1.7.1.4 Serum biomarkers 
 
The challenges encountered with the imaging modalities has led to research 
into alternative biomarkers. One of the most promising areas being investigated 
are the serum biomarkers. Advantages include the relative ease of collection 
facilitating serial readings. Compared with imaging the cost is lower and the 
analysis can be performed centrally allowing its application to multicentre trials.  
 
1.7.1.5 Circulating angiogenic cytokines  
 
Cytokines are soluble and diffusible glycopeptides that can be secreted into the 
blood, either by tumour cells or associated stromal cells, where they can be 
measured. They play prominent roles in physiological angiogenesis and are also 
vital for pathological angiogenesis.  
 
Cytokine release is stimulated by hypoxia. The development of tumour hypoxia 
(which may be driven by a VDA) leads to accumulation of the transcription 
factor HIF1-α (Hypoxia inducible factor). HIF1-α regulates the expression of a 
number of genes involved in angiogenesis as well as those involved in 
erythropoiesis, glycolysis, iron metabolism and cell survival (137). It is tightly 
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regulated in normoxic tissues (137, 138). Accumulation of HIF1-α in hypoxia 
leads to secretion of the angiogenic cytokines. The hypothesis is that these 
angiogenic cytokines would provide a valid biomarker for the vascular 
endothelial agents.  
 
To investigate this hypothesis a pilot study was completed of five angiogenic 
cytokines, VEGF (Vascular Endothelial Growth Factor), Angiopoietin-1 (Ang-1), 
Angiopoietin-2 (Ang-2), Erythropoietin (Epo) and basic Fibroblast Growth Factor 
(bFGF). The characteristics of these angiogenic cytokines and why they were 
selected are reported with the data from the study in Chapter Four.  
 
In this pilot study, designed to screen for cytokines of potential interest as 
biomarkers it was decided to use a model for the hypoxia generated by a VDA 
rather than the VDA itself. The model selected was Trans-arterial Embolisation 
(TAE) in patients with hepatocellular cancer (HCC).  
 
1.7.1.6 Trans-arterial (chemo) embolisation (TAE) 
 
Trans-arterial embolisation generates extensive tumour necrosis by physically 
obstructing the relevant branch of the hepatic artery that supplies the tumour 
(139). TAE is possible due to the dual blood supply to normal liver tissue. Whilst 
tumour cells mostly derive their blood from branches of the hepatic artery (HA), 
normal liver cells are supplied mainly by the portal vein.  
 
Selective intra-arterial chemotherapy mixed with lipiodol may be administered 
prior to embolisation. Chemotherapy agents used include doxorubicin, 
mitomycin and cisplatin. The combined procedure is called chemo-embolisation 
(TACE). TAE is known to delay tumour progression and lead to objective 
responses in between 15-55% of patients (139). Meta-analysis has 
demonstrated a survival benefit of TACE compared with best supportive care 
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but not with embolisation alone. It is not clear what the optimum protocol 
should be or even which is the best chemotherapeutic agent.  
 
1.7.1.7 Why is TAE an appropriate model to use? 
 
Studies have shown that pro-angiogenic cytokines such as VEGF are stimulated 
post-embolisation secondary to ischaemic necrosis caused by vascular shut-
down. Cytokine levels were higher than in the livers of patients who had 
undergone surgery (140) demonstrating the extent of hypoxia induced. Animal 
models have demonstrated stimulation of HIF1-α release post embolisation, 
with secondary release of other angiogenic cytokines such as VEGF (141). This 
generation of angiogenic cytokines post-embolisation has led to clinical studies 
investigating the use of the multikinase inhibitor, sorafenib, in the period post-
embolisation.  
 
Where embolisation delivers vascular shut-down by physical means, a VDA 
induces it biologically. The embolisation model has the advantage of a clear and 
definite time for vascular shut-down. A VDA can have a more unpredictable 
duration and extent of action on blood vessels. The variability of vascular shut 
down induced by a VDA is demonstrated in Chapter 3. On a practical level, only 
small numbers of patients on phase I studies are currently having VDA’s making 
recruiting the required number of patients for a pilot study feasible. As a 
specialist HCC centre the number of patients having TAE or TACE were a more 
realistic proposition. Any promising candidates could then be taken forward 
into multi-centre studies using the VDA’s.  
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1.7.1.8 Hepatocellular Cancer (HCC) 
 
 
HCC is a highly vascular tumour. It develops secondary to liver cirrhosis at a rate 
of 3-5% of patients per year (142) although chronic hepatitis B can lead to HCC 
with no preceding cirrhosis, probably as viral DNA is inserted into the host 
genome (143). 
 
Cirrhosis itself is a highly vascular condition with up-regulation of VEGF, EGF and 
TGF-α (transforming growth factor). Chronic up-regulation may lead to 
hepatocarcinogenesis (144), progressing through dysplastic foci and nodule 
formation (regenerative then dysplastic) into malignancy. VEGF expression 
increases causing neo-vascularisation  (145). Blood vessels undergo 
arterialisation with increasing expression of CD34 and CD31 (146) and loss of 
sinusoidal fenestration. Hypovascular early tumours derive blood from the 
portal system (139) switching to the hepatic artery as they develop and become 
more vascular. This dual blood supply allows embolisation to be a feasible 
procedure without causing catastrophic necrosis of healthy liver tissue.  
 
1.7.2 Hypothesis Three 
 
 
The third hypothesis is that the known ischaemic necrosis of the tumour 
secondary to TAE will generate secretion of angiogenic cytokines such as VEGF 
secondary to activation of HIF1-α. These cytokines will be secreted into the 
blood where they may have potential as biomarkers to assess the extent of 
vascular shut down.  
 
TAE causes vascular shut down with secondary ischaemic necrosis and hypoxia 
via physical means. It is hypothesized that this model can be used to investigate 
potential biomarkers for the VDA’s which achieve vascular shut down and 
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hypoxia via biological means. Selected biomarkers that show clear potential can 
then be assessed using the limited number of patients currently treated with 
the VDA’s.  
 
1.8 Tie-2 monocytes and Endothelial Progenitor Cells as biomarkers  
 
 
Previous work has shown that a variety of bone-marrow cells are implicated in 
the promotion of tumour growth and angiogenesis. These include tumour-
associated macrophages (TAMs), Tie-2 positive monocytes (TEMs), mast cells, 
neutrophils, eosinophils, dendritic cells, haemangiocytes, myeloid-derived 
suppressor cells (MDSC) and vascular leukocytes (147). The two groups I shall 
consider further here are the Tie-2 expressing monocytes and the Endothelial 
Progenitor Cells. Both groups are thought to be secreted secondary to hypoxia 
and may represent a potential biomarker for a VDA.  
 
1.8.1 Monocytes 
 
Monocytes are derived from the haematopoietic pluripotential stem cell. They 
form 5-10% of blood leukocytes (148) and remain circulating for approximately 
1-3 days before moving into tissues. 
 
Once in tissues monocytes differentiate into macrophages or dendritic cells 
depending on the tissue type. Macrophages have a wide range of functions, 
including phagocytosis, antigen presentation and the release of a wide range of 
factors including cytokines, chemokines, complement components, coagulation 
factors, growth factors, enzymes and prostaglandins (149). Circulating 
monocytes can be attracted to tumours that produce chemokines such as CCL2  
(chemokine ligand 2)(formerly monocyte chemoattractant protein 1) and VEGF 
(150). These are then referred to as tumour-associated macrophages.  
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1.8.1.1 Tumour-associated macrophages (TAMs) 
 
Macrophages are implicated in the initiation and growth of malignancy. Chronic 
inflammation, involving macrophages, increases the risk of cancer development 
and anti-inflammatory agents reduce it (151). Macrophages make up a 
considerable proportion of tumour mass, and are associated with a poor 
prognosis in 80% of published studies (152). During tumour development 
macrophages appear to change character and can enhance metastatic potential. 
Under the influence of IL-4 and IL-10 they become poor at presenting antigen 
and instead produced cytokines that suppress T-cell activity (153, 154). This 
phenotype (termed M2) is normally found in areas of tissue repair and 
remodelling. The traits aided by macrophages are detailed in Figure 1.4. 
 
Figure 1.4: Malignant traits aided by macrophages  
 
The figure is derived from Condeelis et al (155). The wheel can turn in either 
direction; macrophages can contribute to each area equally.  
Inflammation
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Tumour cell
invasion
Intravasation
Seeding 
at distant 
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Tumour cells become more aggressive after co-culture with TAMs in vitro and 
approximately 50 genes are up-regulated (156). TAM ablation reduced tumour 
growth with lower levels of VEGF-A and MMP-9 (Matrix metallopeptidase) 
(157). In lung cancer TAMs were associated with an increased MVD and a 
reduced relapse-free survival (156). TAM density is highest in hypoxic tumour 
where pro-tumour cytokines and mitogenic factors are stimulated (149).  
 
1.8.2 Tie-2 positive monocytes 
 
Approximately 20% of blood monocytes (1-2% of total blood leukocytes) 
express the Tie-2 receptor and can be referred to as Tie-2 expressing monocytes 
or TEMs (158). They have been identified in both humans and mice (159) and 
are strongly pro-angiogenic (160).  
 
1.8.2.1 Identifying a Tie-2 positive monocyte 
 
Typically TEMs are identified by their surface markers. They express the classical 
monocyte markers of CD14, CD16 and CD11b as well as the haematopoietic 
marker CD45. They do not express precursor endothelial cell markers such as 
CD31, CD34, AC133 or CD146 (161). They do not generally express VEGFR2 
although Venneri et al did find VEGFR2 expression in a small subset (< 5%) 
(158). They do not express CCR2 (chemokine receptor 2), the receptor for CCL2 
that regulates the recruitment of macrophages to areas of inflammation (158).   
 
They have been found in a variety of tumours including colon, kidney, lung, 
pancreas and soft tissue sarcomas (158). 
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1.8.2.2 Attracting Tie-2 Monocytes to tumours 
 
TEMs localise to sites of angiogenesis in mouse models (159) and human 
tumours. In humans they tend to localize to the peri-vascular space but also to 
avascular hypoxic tissue (158) and are relatively absent from surrounding non-
tumour tissue. This distribution may reflect their attraction to angiopoietin-2 
released from endothelial cells (162) secondary to hypoxia (158). 
 
Tumour-associated Tie-2 monocytes have up-regulated Tie-2 expression greater 
than have circulating Tie-2 monocytes and are more sensitive to Ang-2 (158). 
Circulating TEMs are thought to be the precursor cells for tumour-infiltrating 
TEMs. If circulating TEMs are collected and injected into tumour, they appear to 
share the same pro-angiogenic properties as tumour-infiltrating TEMs (158). 
 
1.8.2.3 Physiological role of Tie-2 Monocytes 
 
TEMs are thought to play a role in tissue growth and regeneration. In mice post 
partial hepatectomy they are present in granulation tissue and around new 
vessels (163). In diabetic mice with neuropathy injected TEMs clustered around 
affected nerves with some reversal of the condition (164). 
 
1.8.2.4 Tie-2 Monocytes in Malignancy 
 
In mouse tumour models the presence of TEMs is pro-angiogenic, leading to 
more vascularized tumours than in a control group of CD14
+
Tie-2
- 
cells (158, 
159), which did not affect angiogenesis (158). De Palma et al used a transgenic 
mouse, Tie-2-tk, devised so all proliferating Tie-2 expressing cells were 
eliminated on administration of ganciclovir. Mice with TEM ablation showed a 
reduction in tumour growth and angiogenesis. Tumour infiltration by TAMs was 
unaffected suggesting they form two distinct subsets. If ganciclovir was 
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withdrawn, tumour re-growth occurred after a further 2 weeks, suggesting TEM 
reconstitution was required (159).  
 
TEMs have been identified in a variety of malignancies including lung, kidney, 
colon and pancreas (165), typically in the peri-vascular space (158). Circulating 
Tie-2 monocytes are present in patients with neuroendocrine cancer (158). Tie-
2 expression is up-regulated with an enhanced function in these circulating cells 
(166). The presence of Ang-2 or hypoxia altered the secretory pattern of Tie-2 
monocytes with suppression of IL-2 (anti-angiogenic) and IL-12 TNF-α (pro- 
apoptotic) (165).  
 
1.8.2.5 Targeting Tie-2 Monocytes 
 
Tie-2 monocytes have been considered for tumour targeting due to their ability 
to migrate across tissues. De Palma et al labeled TEMs with the gene for 
Interferon-α and obtained responses in orthotopic human gliomas and 
spontaneous mouse mammary carcinomas (167). An increase in apoptosis, 
inhibition of angiogenesis and an improved recruitment and activation of 
immune cells was seen. The agent was well tolerated with no myelotoxicity or 
impaired wound healing (167). 
 
1.8.2.6 Tie-2 Monocytes as a Biomarker 
 
Limited data exists on the efficacy of Tie-2 expressing monocytes as a 
biomarker, either for tumours or for agents such as the VDA’s. Lee et al 
considered marrow Tie-2 and found it was a prognostic factor for survival in 
acute myelogenous leukaemia (168).  
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After a procedure such as TAE, intense hypoxia occurs, with rebound 
angiogenesis. If release of angiopoietin-2 is stimulated this may attract TEMs. 
Conversely the blood level of these monocytes may reflect the tumour volume.  
 
1.8.3 Endothelial Progenitor Cells 
 
 
Endothelial progenitor cells are bone-marrow derived cells circulating in the 
peripheral blood that appear to have a stem-cell phenotype. They have the 
ability to migrate, form primitive tubes and adhere to substratum (169) and 
have a high proliferation rate with the ability to form colonies. EPCs appear to 
be attracted to areas of neo-vascularisation guided by angiogenic cytokines, 
where they differentiate into endothelial cells before incorporation into the 
growing vessel. They were first identified by Asahara et al (170, 171) who 
demonstrated CD34+ve cells in the peripheral blood that could generate mature 
endothelial cells in vitro and in vivo (171). Their primary role appears to be in 
embryogenesis and vasculogenesis, considerable controversy exists as to their 
role in cancer.  
 
In addition to EPCs, circulating endothelial cells (CEC’s) are elevated in cancers 
and fall in responding disease (172). These are cells shed from tumour-
associated endothelium rather than recruited from bone-marrow (173) and are 
differentiated endothelial cells. In patients with gender mismatched bone 
marrow transplants 95% of circulating endothelial cells were of vessel origin and 
only 5-6% of bone-marrow origin. Cells of bone-marrow origin could be 
expanded 1000-fold when cultured in vitro and are thought to represent EPCs 
(174).  
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1.8.3.1 Defining endothelial progenitor cells and circulating endothelial cells 
 
Culture assays remain the gold standard to define a cell as an EPC. This method 
is not always practicable. Instead cell surface markers can be used with multi-
parametric flow cytometry. Unfortunately no cell marker exists that defines an 
EPC with individual markers present on a wide range of cell lineages. Asahara et 
al (171) used the combination of CD34 and VEGFR2 co-expression to define an 
EPC. A variety of other cell markers have also been considered and no current 
standard definition exists of what constitutes an EPC. Different pre-enrichment 
steps and gating strategies have also been attempted. The variety of techniques 
makes it difficult to compare research papers as it is not clear the same cell 
population is being considered. It may be that different sub-populations of EPCs 
exist with differing characteristics and cell surface markers. 
 
Table 1.3 Defining endothelial progenitor cells 
Table adapted from one by Pathak et al (175) 
 
Surface Marker  Endothelial progenitor 
cell 
Circulating endothelial 
cell  
VEGFR1  - + 
VEGFR2 + + 
VEGFR3 +  
FGFR1 +  
Tie-2 + + 
VE-Cadherin (CD144) + + 
E-Selectin +/- + 
CD34 + Dim 
CD31 + + 
CD133 + - 
cKit + + 
CD13  + 
vWF -  
CXCR-4 + + 
CD146 + + 
CD45 Dim - 
+ = expression present; - = expression absent,; blank means no documentation 
vWF= von Willebrand Factor; CXCR-4 = chemokine receptor-4, FGFR1 = fibroblast growth 
receptor-1, VE-Cadherin = Vascular endothelial cadherin 
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As EPCs develop from bone marrow to full differentiation their markers change. 
Some aspects of this pathway are known. EPCs straight after release into the 
circulation express CD133, CD34 and VEGFR2. As they mature into circulating 
EPC’s they lose the marker CD133 (which is also expressed on haematopoietic 
stem cells) and may express mature endothelial markers (176). 
 
CD34 is present on both immature and mature EPCs so cannot differentiate 
between them as is VEGFR2. CD146 is an endothelial cell marker (177) but is 
also present on some mesenchymal cells and a population of activated 
lymphocytes (178). The haematopoietic marker, CD45, is considered low or 
negative in EPCs.  
 
1.8.3.2 Numbers in circulation 
 
The number of circulating EPCs found varies widely depending on the technique 
used. With flow cytometry values are typically 70-210 cells/mL of blood (using 
CD34/133/VEGFR2) (179). With cell culture, higher numbers can be generated 
(180).  
 
EPCs can be cultured by re-plating methods with colonies (CFU-ECs) appearing 
as round cells in the centre. Cells are plated on fibronectin-coated plates with 
tissue culture medium enriched with endothelial growth supplements. A pre-
plating method to remove monocytes and haematopoietic cells can be done 
prior to plating to avoid contamination of the EPC culture. Colonies are seen as 
cell masses with central round cells and spindle shaped cells in the periphery. 
They are reported to express VEGFR2, CD31 and Tie-2 (181). Up to 10
5
 cells can 
be generated by this method (182).  
 
Peripheral blood mononuclear cells (PBMNC) can also be cultured on 
fibronectin plates with angiogenic cytokines for 4-6 days. After that time point 
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non-adherent cells are removed. The adherent cells are considered to be 
circulating angiogenic cells (CAC) and can enhance angiogenesis in vivo. They 
express endothelial markers such as CD31, vWF (von-Willebrand Factor) and 
Tie-2 and possess similar in-vitro characteristics but do not form the 
characteristic colonies as seen above (183). Concern exists that these CACs and 
CFU-EC groups may represent monocytes/macrophages rather than true EPCs 
as they may express colony stimulating factor-1 and can phagocytose 
Escherichia coli (184).  
 
The different types of cell are summarized in Table 1.4. 
 
Table 1.4 Potential endothelial angiogenic cells 
 
 
Cell 
Type 
Profile Origin Morphology 
EPC CD31/CD34/CD133/c-
kit/CXCR2/VEGFR2 
Bone 
marrow 
Immature PB cells. 
20µm 
CFU-EC CD31/CD34/Tie-2/VEGFR2 Culture Colony formation 
CAC CD31/vWF/Tie-2/VE-
cadherin 
Culture No colony formation 
ECFC CD31/CD36/Tie-
2/VEGFR2/VE-
cadherin/vWF 
Culture Cobblestone colonies  
 
 
1.8.3.3 Endothelial Progenitor cells and cancer 
 
 
Bone-marrow derived endothelial cells are present in tumour-associated blood 
vessels. They can restore impaired angiogenesis and are associated with tumour 
progression and the development of metastasis. They are elevated in cancer 
patients and have been considered as a potential biomarker for angiogenesis 
(173, 185, 186). Some EPCs remain in the walls of human umbilical veins, 
 68 
representing a store of stem cells.  If stimulated they can then differentiate into 
endothelial cells or be recruited by cancer cells (187, 188). 
 
1.8.3.4 Incorporation into tumour-associated vasculature 
 
Incorporation of bone-marrow derived endothelial cells into blood vessels has 
been demonstrated in tumour bearing mice (170). The degree of incorporation 
in animal models varies between different tumour types, grades, involved 
organs and mouse strains (189) and may vary with tumour growth rate and 
degree of hypoxia.  
 
If immuno-deficient mice are transplanted with human cancer cell lines the 
percentage of bone-marrow derived cells in tumour endothelium varied from 
non-detectable (163), 10-20% (190) and up to 50%  (191). Duda et al 
demonstrated that EPC-derived vessels were only 1.5% in mammary fat pad 
breast cancers but 58% in a mammary model of brain carcinoma metastases 
(192).  EPCs preferentially localize to the tumour periphery in animal models 
where blood vessel density was highest (193). In HCC they are found in adjacent 
cirrhotic tissue to the tumour possibly under the influence of HIF-1α (194).  
 
The role of EPCs in the formation of tumour endothelium remains controversial 
(195, 196) and their role may vary between different tumour types and at 
different developmental stages. For example Rajantie et al used multi-channel 
laser scanning confocal microscopy in mice to study purported EPCs and found 
that the cells remained  in the peri-endothelium and resembled pericytes rather 
than true EPCs (197, 198).  
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1.8.3.5 EPC incorporation and stage of vessel development 
 
EPC contribution to tumour vasculature changes over time. Mathematical 
models show the proportion of tumour endothelium derived from EPCs rising 
with increasing tumour size so that a 0.5mm tumour has 2% EPC derived, but 
25% at 1mm and 40% at 1.5mm  (188). This finding was confirmed in animal 
models (199, 200), reaching 38% in mice with insulinomas. The more advanced 
cancers appeared more able to recruit bone-marrow derived cells. 
 
Although EPC levels are thought to increase with advancing disease, other 
models consider them most influential in early and late stage disease (201). 
Studies with low levels of EPCs are most often in untreated tumours at neither 
the early or late stage (178). It has been hypothesized that the role of EPCs is to 
generate a transient response to changed circumstances, such as in initial 
relapse post-therapy (178). They appear to rise after chemotherapeutics such as 
taxanes (202) and post-VDAs when they home to the viable tumour rim (202, 
203), and may enhance tumour growth. 
 
1.8.3.6 Enhancing tumour angiogenesis 
 
EPC administration restored angiogenesis in angiogenic-defective (with 
impaired endothelial sprouting) Id-mutant mice with lymphoma (199). In these 
mice EPCs contributed 90% of tumour endothelium. If mice lacked placental 
growth factor, bone-marrow derived cells could also restore VEGF-driven 
angiogenesis (204). Gao et al implanted syngeneic mice, whose bone-marrow 
cells expressed green fluorescent protein, with Lewis lung cancer cells 
expressing red fluorescent protein (205). Bone-marrow derived cells were 
12.7% of total endothelial cells. If EPC recruitment was prevented by 
suppressing the transcription factor Id, neo-vascularisation was reduced, there 
was a decrease in metastases and an increase in survival (205).  
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1.8.3.7 The stimulus to EPC release 
 
EPC recruitment is thought to be secondary to hypoxia and the release of HIF-
1α (206). Other factors considered likely to be involved are VEGF, GM-CSF 
(Granulocyte macrophage-colony stimulating factor), SDF-1 (stromal cell derived 
factor-1) and platelet-derived growth factor (207) as well as the soluble KIT 
ligand which induces proliferation and migration in the bone marrow (208). 
Exogenous VEGF stimulates a rise in circulating EPCs within 24 hours (209) 
possibly via activation of MMP-9 or up-regulation of stromal cell derived factor-
1 (SDF-1) or CXCR4, which is chemotactic for EPCs recruiting them to areas of 
neo-vascularisation (176). Cell homing is enhanced by SDF-1 injection (in the 
presence of VEGF) and reduced by blockade of CXCR4 (210).  
 
A dose-dependent increase in the number of functional EPCs has been seen 
post administration of recombinant human erythropoietin (rHuEPO) both in 
vitro and in human blood (211). In addition the level of circulating EPCs 
correlates with serum erythropoietin (212), plasma VEGFR2 and plasma 
interleukin-8 (213). EPC migration is stimulated by PDGF-1 (Platelet derived 
growth factor), Ang-1 (429), PIGF, nitric oxide, statins, exercise and oestrogens 
whereas a high CRP (C-reactive protein) or TNF-α is associated with a lower 
level (176).  
 
1.8.3.8 EPCs as biomarkers 
 
 
Mouse models show correlation between tumour size and circulating EPCs 
(214). Administering cyclophosphamide to a mouse produced short term EPC 
suppression followed by a rapid increase. If a metronomic schedule was used 
EPCs remained suppressed. Endostatin and VEGFR2 antibodies both led to a 
decrease in EPCs (202) that correlated with tumour response (186) as did 
bevacizumab in rectal cancer (176).  
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EPCs have been studied as a method to determine the optimal biological dose 
of a blocking antibody to VEGFR2 (178) with the dose defined as that producing 
the lowest number of viable EPCs. This method gave approximately the same 
result as that from dose-response studies (800µg per mouse versus 800-1200µg 
respectively). The fall in EPCs did not correlate with tumour size or tumour 
reduction. Optimal biological doses have been determined for other anti-
angiogenic therapies including metronomic chemotherapy schedules (178).  
 
1.8.3.9 Clinical data 
 
The contribution of EPCs to human tumour vasculature remains uncertain. 
Peters et al studied 6 patients who received a sex mismatched bone marrow 
transplant and then developed cancer. The contribution of bone-marrow cells in 
tumour vasculature ranged from 1% in a head and neck tumour to 12% in a 
lymphoma with an average of 4.9% (215). No fusion between bone-marrow 
derived and existing cells was seen by FISH (Fluorescent in situ hybridization) 
analysis.  
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Table 1.5 EPC levels in human malignancy 
 
Table adapted from Ding et al (188).  
 
Tumour type EPC levels Correlated with  
Lymphoma Circulating and biopsy 
derived EPCs  
Response to therapy and disease 
activity  
Igreja et al (432) 
Myeloma Circulating EPCs  Response to therapy and disease 
activity  
Zhang et al (433) 
Acute myeloid 
leukaemia 
Circulating endothelial 
like cells 
Disease activity  
Wierzbowska et al (434) 
Breast cancer  Circulating Tie-2, mRNA, 
circulating EPCs 
Tumour size; Naik et al (435) 
Disease activity; Sussman et al 
(436) 
Response to therapy and survival  
Shirakawa et al (437) 
Colorectal 
cancer 
Circulating EPCs  Treatment response and predict 
recurrence  
Lin et al (438) 
HCC CFU scores, Circulating 
EPCs and tissue-derived 
EPCs  
Recurrence time; Ho et al (439) 
VEGF and prognostic markers; 
Yu et al (409) 
NSCLC Circulating EPCs  Survival, response to therapy  
Dome et al (440) 
Disease activity (441) 
 
 
The level of circulating endothelial progenitor cells has been correlated with 
prognosis in NSCLC with a level of > 1000/ml in peripheral blood associated with 
a poorer survival (216). Responding disease was associated with a greater fall in 
EPCs than in non-responders. In hepatocellular cancer patients had higher levels 
of EPCs (using colony-forming scores) than control groups without liver disease 
or with cirrhosis alone (143). Patients with un-resectable disease had higher 
levels than patients who were suitable for surgery, and in patients undergoing 
potentially curative surgery, higher levels were prognostic for relapse within 
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one year. In breast cancer levels were increased and acted as a prognostic 
marker (217). Levels of CD133, Tie-2 and VE-cadherin mRNA were elevated in 
patients with infiltrating breast cancer (217). On receiving chemotherapy a 28% 
decrease in EPC levels could be seen (218).  
 
If EPCs levels do reflect angiogenesis they may be good biomarkers for drugs 
with anti-angiogenic properties including metronomic chemotherapy. In rectal 
cancer a single infusion of bevacizumab led to a decrease in peripheral blood 
EPCs (219). A reduction in circulating EPCs post anti-angiogenic therapies has 
been demonstrated in lymphoma (220), myeloma (221) and AML (222). Non-
responding patients do not show a fall in circulating EPCs.  
 
1.8.4 Hypothesis Four  
 
Our hypothesis was that the acute hypoxia induced by vascular shut down 
would lead to an increase in angiogenic cytokines. Tie-2 expressing monocytes 
would be recruited from bone marrow either secondary to hypoxia or to the 
hypoxia-induced increase in the angiogenic cytokines.  Tie-2 monocytes levels 
would increase in the circulation and target tumour, promoting further 
angiogenesis. Monocytes expressing Tie-2 would be anticipated to rise in the 
circulation post vascular shut down. Tie-2 monocytes may therefore have 
potential as a biomarker for the VDA’s. 
 
In Chapter Five I report a preliminary study to evaluate the feasibility of 
assessing the level of Tie-2 monocytes in the peripheral blood as a biomarker 
that could in future be used to assess the VDA agents.  
 
Endothelial progenitor cells are known to be recruited to tumours under the 
influence of the angiogenic cytokines and may subsequently enhance 
angiogenesis. Our hypothesis is their levels will rise in the circulation post TAE 
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secondary to hypoxia and ischaemic necrosis. Their level in the circulation may 
have potential as a biomarker.  
 
In Chapter Five I report our preliminary study considering the EPC’s as a 
potential biomarker for the vascular shut down induced by TAE. No standard 
methodology currently exists for identifying EPC’s by flow cytometry, therefore 
3 separate methods were explored to consider their respective feasibilities.  
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Chapter Two 
131
I-CHT25 for CD25 expressing lymphoma 
 
This Chapter will report the data from our phase I clinical trial assessing the 
initial use of radioimmunotherapy in CD25 expressing lymphomas 
(predominantly Hodgkins’ lymphoma). Before presenting the data I shall 
consider the chosen antigen in greater detail and previous attempts at targeting 
it with different molecules.  
 
2.1 Interleukin-2 (IL-2) and its receptor (CD25)  
 
The IL-2 molecule is a 15 kDa globular protein, pivotal to the activation and 
proliferation of T-lymphocytes (223). The binding of effector T-cells to their 
antigens leads to secretion of IL-2 and up-regulation of IL-2R (Interleukin-2 
Receptor) on the cell surface. A positive feedback loop then magnifies clonal 
expansion. The cell with the greatest concentration of IL-2R is the T-regulatory 
cell and IL-2 has a significant role in the maintenance of tolerance.  
 
2.1.1 The interleukin-2 receptor (CD25) 
 
The IL-2 receptor has 3 subunits: see Table 2.1. The alpha subunit is restricted to 
the IL2R whereas the beta and gamma subunits are common to many cytokines. 
 
 
Table 2.1: Subunits of the Interleukin Receptor 
 
Subunit Alt names Weight (kDa)  Gene found 
Alpha CD25 or Tac 55  Chromosome 10 
Beta CD122 75 Chromosome 22 
Gamma CD132 64 X Chromosome 
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The beta and gamma units are required for signalling and receptor complex 
formation. Their ubiquity means they are less useful as targets. The alpha 
subunit is essential for a high-affinity binding site (223). Subunits can bind 
individually but at a lower affinity. Loss of the alpha subunit leads to 
abnormalities of T-cell regulation with an expansion of autoreactive T-cell 
clones, tissue infiltration by T-cells, atrophy and inflammation (224). Episodic 
suppression does not appear to cause this dysregulation (224). 
 
2.2 CD25 expressing lymphomas  
 
 
CD25 is expressed on many lymphoma cells but only a small number of normal 
cells (activated lymphocytes and T-regulatory cells) that represent < 5% of the 
normal T-lymphocyte population at any one time.  It is expressed at extremely 
high density (10
3
 to 10
4
 per cell) in HTLV-1 (human T-cell Lymphotropic virus) 
associated adult T cell leukaemia / lymphoma (ATLL) where it is involved in an 
important growth pathway (225).  
 
CD25 is expressed to a variable extent on other lymphomas. It is highly 
expressed (>75%) in hairy cell leukaemia, peripheral T-cell lymphomas, and 
Hodgkin’s lymphoma (75-90%). In addition it is present on approximately 50% of 
T-cell lymphomas (mixed) and cutaneous T-cell lymphomas, B-cell (intermediate 
and high grade) and 50% chronic lymphocytic leukaemia (226, 227). 
 
The first antibody to CD25 was named anti-tac as it bound to active T 
lymphocytes (228). A humanized anti-tac has since been developed 
(daclizumab) and a chimeric antibody to a separate epitope (basiliximab). 
Patients with any CD25-expressing lymphoma were eligible to enter our study. 
In the following section I shall briefly discuss some of these disease entities.  
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2.2.1 Hodgkin’s lymphoma (HL) 
 
Hodgkin’s lymphoma (HL) cells (Hodgkin or Reed-Sternberg cells) appear to 
derive from B-cells at different developmental stages (229). They make up < 1% 
of tumour bulk; the rest appears to be reactive lymphocytes and other immune 
cells. Current treatment strategies (EBRT and combination chemotherapy) cure 
approximately 80% of patients. In relapsed disease high–dose therapy with 
ASCT can cure approximately an additional 50% (230). Allogeneic transplant has 
not improved survival and has a high mortality rate (231). 
 
2.2.1.1 Targeted therapy of HL 
 
A variety of new targeted approaches have been attempted including the use of 
antibodies, modulation of transcription pathways and anti-EBV (Epstein Barr 
virus) agents. The first RIT trials used polyclonal anti-ferritin antibodies 
conjugated with 
131
I. A phase II clinical trial treated 38 patients and saw a partial 
response rate of 40% with symptomatic benefit in 77% (232). 
 
CD30 is highly expressed in HL and relatively specific so a suitable target. Both 
the murine (Ber-H2) and chimeric (SGN-30) unlabeled antibodies to CD30 had 
no responses in patients with HL although 4 patients had stable disease for 6-16 
months and 1 patient with anaplastic large cell lymphoma had a CR (Complete 
response (233). A humanized antibody showed limited activity with 5 of 72 
patients showing a response in a dose escalation phase I/II study but had no 
clear dose response relationship (234). Studies of this combination with 
chemotherapy are continuing.  
 
The chimeric anti-CD30 antibody, SGN-30, has been attached to monomethyl 
auristatin E, a tubulin inhibitor. In an animal model of HL it appeared potent and 
selective (235) with a synergistic effect with chemotherapy (236) but clinical 
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studies are awaited. Conjugating an anti-CD30 antibody with a radionuclide 
131
I, 
produced a response rate of 6 out of 22 patients (237). 
 
2.2.2 T-cell lymphomas 
 
 
T-cell lymphomas make up approximately 12% of lymphomas (238) and vary 
greatly in their aggressiveness and response to therapy. Their distribution 
depends on the prevalence of viruses such as HTLV-1 and EBV (239). A variety of 
T-cell lymphomas express CD25 including angioimmunoblastic lymphoma (AITL), 
peripheral T-cell lymphoma, unspecified (PTCL-u) and adult T-cell 
leukaemia/lymphoma (ATLL).  
 
2.2.2.1 Adult T-cell leukaemia / lymphoma (ATLL) 
 
ATLL results from infection with the retrovirus HTLV-1. Four subtypes exist 
based on signs, symptoms and prognosis: an acute leukaemia type, nodal 
lymphoma type, chronic leukaemia type or a smouldering course (240). It 
initially responds well to chemotherapy but quickly relapses (240). High dose 
interferon-α combined with zidovudine appeared promising in 2 small studies 
(241, 242) as initial therapy or maintenance. 
 
Initial studies of targeted agents used the unlabeled anti-Tac antibody and 
demonstrated a modest benefit with responses lasting 1-8+ months (243). Anti-
Tac was then radiolabeled with 
90
Y and given to 18 patients (9 in the dose-
escalation phase). Of 16 evaluable patients 9 responded. Mean response 
duration was 9.2 months for the 7 patients in PR (Partial response). Of the 2 in 
CR, one died of leukaemia at 36 months and the other remained relapse-free at 
3 years (244). 
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2.3 CHT-25 clinical trial  
 
 
The CHT25 clinical trial was a single centre, open label, phase I study using the 
monoclonal chimeric antibody, basiliximab, to target CD25.  The antibody was 
conjugated to 
131
I to augment cytotoxicity. The study was primarily dose-finding 
but was designed to gain further information about toxicity and response.  
 
It was estimated that trial recruitment would begin in March 2000 and 
complete by 2003. However recruitment started in December 2002 and 9 
patients were treated by July 2004. The trial was then suspended due to 
regulatory issues arising from the introduction of the EU Clinical Trials Directive 
and only re-opened in June 2006 with recruitment completed in June 2007. It 
was approved by the Central Institutional Review Board (CIRB) and the Royal 
Free Hospital Local Ethics Committee.  
 
2.3.1 Hypothesis  
 
The trial hypothesis was that the RIT product CHT25 would selectively target the 
malignant cells in CD25-expressing HL and T-cell lymphoma leading to tumour 
responses with a low toxicity. As CHT25 is a chimeric antibody, re-treatment 
should be possible without high rates of HAMA /HACA formation.  
 
2.3.2 Trial objectives  
 
The primary objectives were to determine the toxicity profile of CHT25, define 
the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD), 
investigate the localisation, biodistribution and dosimetry of CHT25 in tumour 
and normal tissues and determine the pharmacokinetic profile of the RIC. The 
secondary objectives were to assess preliminary evidence of efficacy and 
immunogenicity.  
 80 
2.4 Methods  
 
2.4.1 The investigational product 
 
CHT25 is a chimeric antibody conjugated to 
131
I. The antibody, basiliximab, was 
derived from the mouse antibody RFT5γ2α . It was produced in vitro by 
continuous culture fermentation of a murine-myeloma cell line which had 
previously been transfected with plasmid borne recombinant gene constructs 
coding for its murine variable and human constant regions (245). CHT25 binds 
to the alpha subunit of the IL-2 receptor with a similar affinity to IL-2 itself. 
Cross-reactivity to normal tissues was excluded by immunoperoxidase and 
immunofluorescent studies with normal tissues (Dr Amlot – personal 
communication).  
 
Basiliximab is a licensed drug to prevent organ rejection in kidney transplant 
patients and has been extensively studied. Toxicology on the antibody used 
rhesus monkeys and concluded the agent was well tolerated with a terminal 
half-life of 5.5 days and 3-4 days on repeat exposure. Human studies at doses of 
20mg administered intravenously revealed no severe reactions, with a longer 
half-life of 13.1 days (range 7-23 days) (245, 246). In a phase I study of 24 
patients and 144 infusions (6 administrations per patient) there was no 
evidence of HAMA or HACA antibody generation using ELISA (Enzyme linked 
immunosorbent assay) or FACS (fluorescence activated cell sorting) inhibition 
analysis and there was no reduction in half-life supporting the lack of an 
immune reaction (246). 
 
A phase III study of 190 patients compared basiliximab to placebo in the 
prevention of transplant rejection (246). A 32% reduction in the number of 
acute cellular rejection episodes was seen in the basiliximab arm with no 
increase in side effects. Basiliximab is licensed for the prevention of rejection 
under the brand name Simulect.   
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2.4.2 Pharmaceutical  
 
Basiliximab was supplied by Novartis as 10mg vials lyophilised for reconstitution 
and stored at 2-8°C. The 
131
I was ordered via the Department of Medical Physics 
and supplied by Amersham or MDS Nordion as a sodium iodide solution in 
standard vials. It was stored in the radioactivity storage area at room 
temperature.  
 
2.4.3 Reconstitution and relabeling 
 
A qualified radio-pharmacist performed the labelling process using the N-
bromo-succinamide/ L-tyrosine technique (247) at the Royal Free Hospital.  
 
2.4.4 Selection of starting dose and schedule  
 
Basiliximab was given at a fixed intravenous dose of 10mg as a targeting dose to 
tumour cells that was previously well tolerated (246). The initial administered 
activity of 
131
I was chosen at 370MBq/m
2
 on the basis of dosimetry calculations 
from previous work (unpublished) with the chimeric B72.3 anti-CEA antibody. 
These calculations assumed the CHT25 distribution in tissues that do not 
express CD25 would be the same as the anti-CEA antibody in tissues that do not 
express CEA.  
 
The intended schedule for the first 9 patients is shown in Table 2.2. Each cohort 
consisted of 3 patients. A 7 day window was required before treating an 
additional patient at the same dose level, and 4 weeks for escalation to the next 
level. 
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Table 2.2 Intended schedule 
 
No of Patients  Antibody 
Treatment (mg) 
Isotope treatment 
(MBq/m
2
) 
Dose increased by 
3 10mg  370  - 
3 10mg 740 2 
3 10mg 1480 2 
3 10mg 2220 1.5 
3 10mg 2960 1.3 
 
The amount of 
131
I labelled to the CHT25 antibody varied slightly as it is not 
possible to label doses with absolute accuracy.  
 
2.4.5 Repeat dosing  
 
Repeat dosing was permitted either at an escalated dose or the same dose if 
these criteria were met: 
 
• A minimum of 4 weeks had elapsed to identify toxicities.  
• Evidence of localisation of CHT25 to tumour; tumour uptake had to be > 
3% injected dose/kg.  
• No DLT’s were observed at the current level; infusion of stem cells or 
bone marrow cells were not required 
• All the eligibility criteria (inclusion and exclusion criteria were still met) 
• Any treatment related toxicities had resolved 
 
Patients who had escalation of their treatment could be included in a second 
cohort at the higher level.  
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2.4.6 MTD-finding phase  
 
If one of three patients in a cohort experienced a DLT the cohort was expanded 
to 6. If in that expanded cohort no additional DLT’s were seen, dose escalation 
could continue unless the DLT was a patient death (drug-related). If 2 patients 
had a DLT or 1 patient had a drug-related death the treatment would de-
escalate to a lower level (the previous dose level or lower) to define the MTD.  
 
After the first 9 patients were treated an interim analysis considered the 
available evidence on efficacy and toxicity. It was decided to explore further 
injected activity levels between 740 MBq/m2 and 1480 MBq/m2 with additional 
cohorts investigated at both 1200 MBq/m2 and 1480 MBq/m2.  
 
2.4.7 Administration of agent  
 
Administration of CHT25 was over 40 minutes via a 1m infusion line and 3-way 
tap with a lead shield for the RIC. The initial infusion rate was 6mg/hour, 
increased to 24mg/hour if no side effects occurred.  
 
 
 
 
 
 
 
 
 
 
 
 84 
2.4.8 Inclusion and exclusion criteria 
 
2.4.8.1 Inclusion Criteria  
 
 
• A histologically proven lymphoma that expressed CD25 on ≥ 50% of 
malignant cells or the surrounding stromal cells in HL.  
• Refractory or relapsed disease post standard therapy or medically 
unfit for standard therapy  
• Measurable disease on imaging; whether X-ray, ultrasound, CT, MRI 
(Magnetic Resonance Imaging) or PET.  
• An age greater than 18 years 
• A life-expectancy ≥ 3 months without therapy  
• A WHO (World Health Organisation performance status ≤ 2;  
• In the first 1-9 patients or if an injected activity of 
131
I ≥ 1480MBq/m
2
 
was given a stem cell harvest was required (minimum 2 x 10
6
/L CD34 
positive cells) or a bone marrow harvest (minimum 1 x 10
6
/L CD34 
positive cells) to allow PBSCT (Peripheral blood stem cell transplant) 
• Adequate organ function; including 
o Neutrophil count > 1.5 x 10
9
/L. 
o Haemoglobin > 10g/dL. 
o Platelet count > 100 x 10
9
/L 
o Plasma creatinine < 150µmol/l; EDTA (Ethylenediamine 
tetraacetic acid) or urine creatinine clearance >50ml/min. 
o Plasma bilirubin < 30 µmol/l, alanine transaminase (ALT) and 
aspartate aminotransferase (AST) < 2 x upper limit of normal (or 
5 x if liver metastases).  
o International normalized ratio (INR)> 1.5. 
o Normal thyroid function or stable on treatment.  
o Adequate cardiac function; ejection fraction > 50% on MUGA 
(Multi-gated acquisition scan) or on echocardiography.  
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• Be able to provide written informed consent; be capable of co-operating 
with therapy and follow up.  
 
2.4.8.2 Exclusion criteria  
 
 
• No previous lymphoma therapy within the previous 4 weeks (excluding a 
stable dose of steroids or palliative radiotherapy to a non-target lesion); 
for nitrosureas or mitomycin C the period was 6 weeks.  
• No bone marrow involvement by lymphoma > 25% on biopsy.  
• Pregnancy, lactation or women of child-bearing age in whom pregnancy 
could not be excluded, those of either sex of child-bearing age unable to 
use adequate contraception for the study period. 
• Serious non-malignant systemic disease, active uncontrolled infection, 
severe respiratory disease or serologically positive for hepatitis B, C or 
Human Immunodeficiency virus (HIV).  
• A positive test for HAMA to CHT25. 
• Any other medical condition that made them unsuitable in the opinion 
of the investigator.   
 
2.4.9 Pre-trial investigations  
 
The pre-treatment investigations required are detailed in Table 2.3. Patients 
were followed up for a minimum of 8 weeks or until all drug related toxicity had 
resolved. Potassium Iodide was administered initially at 100mg three times a 
day for 3 days, reducing to 50mg bd up to day 11. Patients remained in-patients 
with appropriate radiation-protection shielding until safe for discharge.  
Patients were assessed daily as inpatients with haematology, biochemistry, 
symptom history, vital signs, PK (Pharmacokinetic) analysis and γ-camera 
imaging recorded. The follow up protocol is summarized in Table 2.4. 
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Table 2.3 Pre-trial investigations 
Date pre-therapy Nature of investigation 
Within 12 weeks Blood taken for HAMA 
Within 4 weeks (preferably within 2) Baseline evaluations for tumour extent  
(CT/PET) 
Within 2 weeks Informed consent  
Chest X-ray, ECG and bone marrow 
examination, EDTA or 24-urine collection and 
ECHO or MUGA 
Within 1 week Haematological and biochemical indices  
Medical history and examination 
Documentation of WHO status 
Registration with Cancer Research UK Drug 
Development Office 
 
 
Table 2.4 Follow-up protocol 
Follow-up protocol post discharge Nature of investigation 
Twice-weekly  Haematology and Biochemistry 
Weekly  Clinical assessment including physical 
examination (with WHO status) 
T-lymphocyte assessment (first 9 patients only) 
Day 8, 15 and 22 Urinalysis (blood, protein, pH, glucose) 
Day 15, 29, 43 and 57 Plasma clotting screen 
Day 25 and 53 FDG-PET scan 
Day 22, 43 (if planned to re-treat) and 57 HAMA 
Day 29 and 57 Tumour Imaging assessments 
ECG, creatinine clearance, Thyroid function, 
and MUGA or ECHO scan 
 
The blood and urine tests included in the above definition were 
• Haematology; Haemoglobin, white cell count, neutrophils, lymphocytes and platelets. 
• Biochemistry; Sodium, potassium, urea, creatinine, urate, total protein, bilirubin, AST, 
ALT, Alkaline phosphatase, glucose, GGT (gamma-gutanyl transferase) 
• Clotting screen; PT (prothrombin time) APPT (activated partial thromboplastin time) 
• Thyroid function tests; Plasma T4 and TSH (Thyroid stimulating hormone). 
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2.4.10 Toxicity  
 
 
Toxicity was graded according to the National Cancer Institute Common Toxicity 
Criteria (version 2). The worst grade in each cycle was documented. 
 
2.4.10.1 Definition of a dose-limiting toxicity (DLT)  
 
A DLT was defined as a toxic event almost certainly or probably drug related 
(see Table 2.5). In the dose escalation phase bone marrow and stem cells were 
stored and could be re-infused if the neutrophil count fell below 0.2 x 10
9
/l for > 
2 days. In the MTD-finding phase a lower non-myeloablative administered 
activity was given. The definition of a haematological DLT was changed to 
reflect this.  
 
 
Table 2.5 Dose-limiting toxicity 
System Escalation phase  
(9 patients) 
MTD finding (6 patients) 
Bone marrow Grade 4 febrile 
neutropenia 
Grade 4 neutropenia not responding to 
therapy in 10 days 
Grade 3 or 4 neutropenia associated with 
fever / infection 
Grade 4 thrombocytopenia either lasting 
more than 5 days or with bleeding or requiring 
transfusion 
Nervous system Grade 2 or greater neurotoxicity 
Other body organs Any toxicity grade 3 or higher excluding Grade 3 nausea and Grade 3 / 4  
vomiting and / or diarrhoea in patients not optimally treated  
 
Whole body Drug related death 
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2.4.10.2 Definition of Maximum Tolerated Dose (MTD)  
 
The MTD was defined as the dose above that at which either a single drug 
related death occurred or where more than 30% of patients suffered dose 
limiting toxicity.  
 
2.4.11 Response assessment  
 
Tumour response was determined using CT and FDG (fluorodeoxyglucose)-PET. 
These two methods were combined using the Updated International Working 
Group Response Criteria (248, 249) for lymphoma (see Table 2.6). Tumour 
assessments were performed 2 weeks prior to trial entry and then every 4 
weeks. Complete or partial responses were confirmed by a second study 4 
weeks later.  
 
2.4.11.1 CT 
 
Lesions were assessed according to WHO criteria. Bi-dimensional lesions had 
their longest diameter and the perpendicular measurement at the widest point 
recorded for a maximum of 10 lesions.  
 
2.4.11.2 FDG-PET 
 
Imaging was performed using an ADAC Vertex Plus Dual Head Co-incidence 
camera hybrid SPECT/PET camera (Phillips-ADAC, Eindhoven, Netherlands or a 
GE Discovery LS PET-CT (GE Healthcare, Amersham, UK). Two patients had 
diabetes and were unable to tolerate the scanning time on the hybrid camera, 
their 
18
FDG-PET scans were completed with the GE Discovery LS PET-CT. The 
images were assessed visually and with a semi-automated region growing 
program. Visual assessment was by a Consultant in nuclear medicine blinded as 
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to patient identity and scan order to attempt to reduce the subjectivity and bias 
inherent in this approach. 
 
Table 2.6 Cheson criteria 
Response  Definition Nodal mass Organs Bone marrow 
CR** 
Complete 
Response 
All evidence 
disease 
disappeared 
Any size mass allowed if 
PET negative 
Nodules 
disappear 
Infiltrate 
disappeared on 
biopsy/IHC* 
PR
+
 
Partial  
Response 
Regression 
measurable 
disease / no 
new sites 
>50% reduction in 
disease on CT / at least 1 
site remains PET positive  
As nodal Irrelevant if 
positive prior to 
therapy 
SD
++ 
Stable  
Disease 
Failure to 
attain CR/PR 
PET positive sites remain 
and no new sites on CT or 
PET. No change in size CT 
lesions 
As nodal   
PD 
Progressive  
Disease 
Any new lesion 
or increase by > 
50% of 
previous 
lesions.  
New lesions or a >50% 
increase in the size of 
more > than 1 node. 
Lesion PET positive.  
>50% 
increase 
from nadir  
New or recurrent 
involvement of 
bone marrow.  
* Immunohistochemistry; **CR Complete response; + PR Partial response; ++ SD Stable disease  
& 
PD Progressive disease  
 
 
18
FDG uptake can be assessed semi-quantitatively by the SUV (standardized 
uptake value). The mean tissue radiotracer concentration is obtained from a 
region of interest (ROI) and corrected for injected activity. It is compared to a 
homogeneous body distribution of radiotracer (250). Problems with this 
method are in determining where to apply the ROI in the tissue of interest, it is 
unclear if the relevant value is the mean or the maximum count per voxel and 
SUV measurements only record tumour intensity with no account of shrinkage.  
An alternative method pioneered in our department by Dr Alan Green and the 
Department of Medical Physics was a region growing program (251). This 
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program allows the inclusion of both intensity and tumour size to assess 
response. Initially a threshold value was determined, intensity values above the 
threshold were considered to be tumour and those lower were considered to be 
normal tissue. A seed-point was placed in an area of tumour by the operator. 
The placing was determined by visual inspection of tumour on PET images. The 
CT images were available for comparison but no co-registration was feasible 
during this study period.  
 
From the seed-point placed the computer program grows the region outwards 
contiguously including any point that had a voxel above the predetermined 
threshold. An image is then produced of all the included data points. The 
computer program then re-calculates the image from the seed-point that the 
computer has identified as having the highest voxel count. The second 
calculation should ensure that all relevant voxels are included. It continues re-
calculating from alternative seed-points until the results are identical indicating 
there are no further voxels uncounted that are above threshold. The computer 
then gives a numerical value including both voxel intensity and number of 
voxels. This method can then be repeated for a number of target lesions that 
can then be followed up during the study period.  
 
The advantages of this method over using SUV’s are that it includes both 
tumour shrinkage and a reduction in image intensity in assessing tumour 
response. It is also less operator-dependent. With SUV calculations the value 
can be altered by where the operator chooses to measure it from. With a 
region-growing program, wherever the operator places the original seed-point 
the value should be identical.  
 
The disadvantages of this method are its current lack of clinical validation. It has 
not yet been validated in lymphoma so no clarity exists about what constitutes 
response or progressive disease. Green et al have validated it in solid tumours 
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where it was found to discriminate patients at 9-12 weeks successfully into 
those who went on to have a partial response and those with progressive 
disease (251) and clear distinction could be seen as  early as 2-4 weeks. These 
studies have not been carried out in patients with lymphoma.  
 
In addition any tumours that are situated close to a structure that has high FDG-
PET uptake are problematic. The structures of concern classically are the heart 
and the bladder where voxels of interest can ‘bridge’ over into the anatomical 
structure. In addition if FDG-PET uptake is low, this method can show a lack of 
discrimination between low intensity disease and normal tissue. The method 
does not address other concerns with the SUV, namely ensuring scans are 
completed at identical time points post injection, with comparable glucose 
concentrations and at the same temperature.  
 
2.4.12 SPECT and dosimetry data  
 
Patients had Planar and SPECT imaging performed at 4, 24, 48, 72 and 96 hours 
using an ADAC Vertex dual headed gamma camera and reconstructed iteratively 
(OSEM (ordered subsets expectation maximization) algorithm) applying scatter 
and attenuation correction. ROI’s were drawn on tumour and normal organs 
(heart, lung, liver, spleen and kidneys) and average radioactivity uptake was 
calculated using Olinda/XEM (Organ level internal dose assessment/ 
exponential modeling) (35) software. 
 
2.4.13 Pharmacokinetics  
 
Post administration of CHT25, 2.5ml of blood was taken in an EDTA tube at 1, 3, 
6 and 24 hours post infusion and on days 2,3,6 and where possible day 9. Blood 
was stored until safe to analyse. Radioactivity was measured with a Packard 
Cobra 11
th
 Series Auto gamma counter. Data was corrected for decay and 
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expressed as % injected dose/kg.  Mono- or bi-exponential decay curves were 
modelled to the data and log linear regression used to calculate the half-lives.  
 
2.4.14 Soluble Interleukin 2 receptor (sIL-2R) 
 
The sIL-2R assay used a standard ELISA sIL-2R kit (Cellfree® Human). This kit 
used 50µl of serum previously stored at -80˚C. Control samples were prepared 
by serial dilutions of sIL-2R. 50µl of conjugate reagent was added and the plate 
incubated for 2 hours before the unbound reagent was washed off. 100µl of 
TMB (tetramethylbenzidine) substrate was added and the plate incubated for 
30 minutes to allow enzymatic colour change before the stop solution was 
added. The colour intensity was read using a plate reader at 450nm subtracting 
550nm to reach the final result. A curve was constructed using the control 
samples of known concentration and used to calculate the concentration in the 
serum. The value was expressed in pg/ml.  
 
2.4.15 Immunogenicity  
 
HAMA levels were assessed by ELISA pre-study and on days 43 and 57 with the 
murine antibody RFT5 and the non-specific isotype matched antibody RDFR2 as 
positive and negative controls respectively.  
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2.5 Results 
 
2.5.1 Patient Characteristics  
 
 
The CHT25 study opened for recruitment in December 2001 and completed in 
August 2007. In that period 15 patients were treated on study; 1 patient with HL 
was subsequently excluded when a second biopsy revealed dual pathology with 
a CD25 negative B-cell lymphoma. His results were not included. Of the 14 
patients; 11 had HL and 3 had T-cell lymphoma (of which 2 had ATLL). 5 women 
and 9 men were treated. The median age was 42 years (range 27-70). The mean 
number of prior therapies was 4 (range 1-8). Full details are given in Table 2.7. 
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Table 2.7 Patient Characteristics   
Patient characteristics No patients 
Number of patients treated 14 
Sex 
Male 
Female 
 
9 
5 
Age 
Median (range) in years 
 
38 (27-70) 
Tumour type 
Hodgkin’s lymphoma 
ATLL (adult T cell lymphoma/leukemia) 
AITL (angioimmunoblastic T cell 
lymphoma) 
 
11 
2 
1 
Performance Status 
0 
1 
2 
 
8 
5 
1 
Ann Arbour Stage 
I 
II 
III 
IV 
 
0 
3 
2 
9 
B symptoms 
No 
Yes 
 
5 
9 
No of patients receiving ‘x’ prior regimens 
of chemotherapy 
1 
2 
3 
4 
5 
8 
 
 
1 
2 
4 
3 
3 
1 
Previous ASCT (autologous stem cell 
transplant 
No 
Yes 
 
 
5 
9 
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2.5.2 Administered activity received  
 
Table 2.8 details the administered activity given to each patient on study and 
the cumulative administered activity. In total 26 treatment courses were given. 
The first 9 patients followed an escalating schedule from 370MBq/m
2 
to 
2960MBq/m
2 
with escalation allowed in the same patient. 
 
The maximum number of cycles received by a single patient was 4 (patient 4). 
At the highest dose level a treatment related death occurred at 2960MBq/m
2
. 
For safety reasons the next 2 patients had their initial injected activity reduced 
to 740MBq/m
2
 where bone marrow suppression had not been significant. This 
reduction was aimed at excluding patients found to have a low bone marrow 
reserve from an excessive risk of toxicity.  
 
After patient 9 a planned interim analysis was carried out. This considered that 
evidence of responses had been seen at lower doses that were unlikely to be 
myeloablative and (between 740MBq/m
2 
and 1480MBq/m
2
) recommended this 
lower range be investigated further. A dose cohort was therefore added at 
1200MBq/m
2
 with an additional 2 patients treated at 1480MBq/m
2
. In this 
second MTD finding phase no dose escalation was allowed in individual patients 
to allow for a better discrimination between dose levels.  
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Table 2.8 Administered Activity 
Patient 
No 
Course 1 
MBq/m
2 
(MBq) 
Course 2 
MBq/m
2 
(MBq) 
Course 3 
MBq/m
2 
(MBq) 
Course 4  
MBq/m
2 
(MBq) 
Cumulative 
Activity 
MBq/m
2 
(MBq) 
1 370 (663)    370 (663) 
2 370 (573)    370 (573) 
3 370 (659) 740 (1368)   1110 (2027) 
4 740 (1027) 1480 (1858) 2220 (3480) 370(554)* 4810 (6919) 
5 740 (1290) 1480 (2220)   2220 (3510) 
6 740 (1104)    740 (1104) 
7 1480 (2394) 2220 (3560) 2960 
(4553)** 
 6660 (10507) 
8 740 (1093)    740 (1093) 
9 740 (1175) 1480 (2104) 2220 (3239)  4440 (6518) 
10 1200 (2322) 1200 
(2487)* 
  2400 (4809) 
11 1200 (1604) 1200 (1642)   2400 (3246) 
12 1200 (2666) 1200 (2650)   2400 (5316) 
13 1480 (1999)    1480 (1999) 
14 1480 (2620)    1480 (2620) 
 
• * Given as a compassionate treatment as did not meet the re-treatment criteria 
• ** Treatment related death at this administered activity 
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2.5.3 Toxicity  
 
2.5.3.1 Haematological toxicity 
 
Dose-limiting toxicity was haematological. Table 2.9 shows the nadir seen with 
an increasing injected activity. No grade 3 or 4 haematological toxicity was seen 
with the initial administered activity of 370MBq/m
2 
but toxicity increased as the 
administered activity was escalated to 2960MBq/m
2
. Patient 7 (2960MBq/m
2
) 
developed prolonged myelosuppression and despite stem cell support, died 36 
days after cycle 3 of Pneumocystis jiroveci pneumonia. De-escalation occurred 
to 1200MBq/m
2
 which was tolerated well but further grade 4 haematological 
toxicity occurred at 1480MBq/m
2
 with a median platelet nadir of 31 x 10
9
/L 
(range 9-83) and neutrophil count of 1.31 x 10
9
/L (range 0.9-7.5). Patients with 
Grade 4 neutropenia were treated with G-CSF (granulocyte colony stimulating 
factor) to count recovery. Blood transfusion was used to maintain haemoglobin 
between 12-14g/L for 4 weeks post administration to maximize radiation effect. 
Six patients required platelet transfusion at or above the MTD.  
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Table 2.9 Haematological Toxicity 
By administered activity – depth of nadir 
Administered 
activity 
(MBq/m
2
) 
Haemoglobin 
nadir 
(grams/dl) 
(median/ 
range) 
Neutrophil 
nadir 
(x10
9
/l) 
(median/ 
range 
Platelet nadir 
(x10
9
/l) 
(median/ 
range) 
Lymphocyte 
nadir (x10
9
/l) 
(median/range) 
370  
3 treatments 
9.8 (8.4 – 11.4) 3 (2.7-3.7) 187 (74-195) 0.45 (0.31-0.96) 
740 
6 treatments 
9.5 (9-11.5) 4.7 (1.3-
11.3) 
198 (60-384) 0.38 (0.19-1.55) 
1200: 5 
treatments* 
3 patients  
8.8 (7.7-10.2) 1.3 (0.9-7.5) 31 (9-83) 0.2 (0.18-1.55) 
1480 
6 treatments 
8.4 (7-10) 0.8 (0.1-7.8) 15 (8-150) 0.2 (0.1-0.58) 
> 2220: 4 
treatments* 
3 patients  
8.5 (6.3-9.5) 1 (0.34-2.7) 13 (8-36) 0.105 (0.06-
0.21) 
 
 
The pattern of haematological toxicity with CHT25 was similar to that with other 
RIC’s such as 
131
I-T with a nadir approximately 6 weeks after therapy, resolving 
over a number of weeks. The depth and length of the nadir was dependent on 
the injected activity administered. Table 2.10 demonstrates this relationship. 
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Table 2.10 Haematological Toxicity  
By duration of nadir using CTCAE† 2  
Administered  activity 
(MBq/M
2
) 
370 740 1200 1480 > 2220 
Grade 3 Platelets (range)* Nil Nil 3-42 
days 
27-78 
days 
32-176 
days 
Neutrophil count Grade 4 
(range) 
Nil Nil Nil 2-30+
a
 
days 
36
b
 days 
 
*Grade 3 toxicity was considered as grade 4 thrombocytopenia was treated with platelet 
infusion so nadir length cannot be judged. 
a
One patient had allogeneic transplant before count 
recovery.
 
 
b
Treatment related death occurred at 36 days 
† Common toxicity criteria adverse events version 2 
 
 
To demonstrate the course of haematological toxicity, two patient’s counts are 
documented. Figure 2.1 demonstrates the effect of treatment at 1200MBq/m
2
 
with a limited nadir particularly affecting the platelet count with good recovery. 
 
Figure 2.2 demonstrates the effect of receiving a higher injected activity 
(2220MBq/m2) with a subsequent prolonged and lower nadir count. 
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Figure 2.1 Patient 10 
 
Level of platelet count (x10
9
/L), neutrophil count (x10
9
/L) and haemoglobin 
(g/dL) post RIC administration (days)  
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Figure 2.2 Patient 5 
 
Level of platelet count (x10
9
/L), neutrophil count (x10
9
/L) and haemoglobin 
(g/dL) post RIC administration (days)  
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2.5.3.2 Non-haematological toxicity 
 
Non-haematological toxicity was generally mild. The commonest was fatigue 
and a mild elevation of the liver enzymes. A high level of non-neutropenic 
infection was noted; whether this was secondary to an immunosuppressive 
effect of the agent or was the result of the trial patient population (heavily pre-
treated and immunocompromised) is not clear. There was no evidence of viral 
reactivation, as seen with known immunosuppressive regimens. The details of 
all toxicities encountered considered to be certainly, probably or possibly drug-
related are documented in Table 2.11.  
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Table 2.11 Non-haematological toxicity  
 
Drug related toxicity: All toxicity seen that was considered possibly, probably or almost certainly 
drug related. In addition it includes all infectious events regardless of presumed causation 
 
Toxicity Description Gd 1 Gd 2 Gd 3 Gd 4 Overall 
Metabolic Hypernatremia 
Hyponatremia 
Elevated urate 
2 
1 
1 
0 
0 
0 
0 
0 
0 
0 
0 
0 
2 
1 
1 
Constitutional Fatigue 
Fever 
5 
2 
0 
0 
1 
0 
0 
0 
6 
2 
Blood Anaemia 
Lymphopenia 
Leukocytopenia 
Neutropenia 
Thrombocytopenia 
0 
0 
1 
0 
0 
8 
1 
3 
1 
2 
3 
8 
3 
2 
3 
0 
0 
2 
4 
6 
11 
9 
9 
7 
11 
Bleeding Haematuria 
Vaginal bleeding 
(menstrual) 
Petechiae/bruising 
Epistaxis 
2 
0 
 
1 
0 
0 
0 
 
0 
0 
0 
1 
 
0 
1 
0 
0 
 
0 
0 
2 
1 
 
1 
1 
Infection Febrile neutropenia 
Tunnelled line 
infection 
Upper respiratory 
tract infection 
Chest infection 
Urinary tract infection 
Oral Candida 
0 
0 
1 
 
0 
0 
2 
0 
1 
0 
 
1 
1 
0 
2 
4 
1 
 
0 
0 
0 
1 
0 
0 
 
1 
0 
0 
3 
5 
2 
 
2 
1 
2 
Gastro-
intestinal 
Vomiting  
Nausea 
Stomatitis 
1 
3 
0 
0 
0 
1 
1 
0 
0 
0 
0 
0 
2 
3 
1 
Hepatic Elevated liver 
enzymes 
5 0 0 0 5 
Renal Proteinuria 
 
1 0 0 0 1 
Endocrine Hypothyroidism 
 
0 1 0 0 1 
Cardio-
vascular 
Reduction cardiac 
function 
Hypotension on day 1 
0 
1 
1 
0 
0 
0 
0 
0 
1 
1 
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2.5.4 Response data  
 
Objective clinical responses according to RECIST (Response Evaluation Criteria in 
Solid Tumours) were observed in a dose dependent fashion. No responses were 
seen at 370MBq/m
2
 and only one at 740MBq/m
2
. Six of 9 patients treated at a 
single administration of 1200 MBq/m
2
 or higher had a response (3 = CR and 3 = 
PR). Two of the responding patients were receiving concurrent corticosteroids 
(patient 7 and 14), which remained at the same dose throughout the study. 
These two patients had previously progressed on this dose of steroid. Neither 
patient with ATLL received a dose at or above the MTD.  
 
Table 2.12 describes the FDG-PET results from the region-growing programme 
described by Green et al (251). The mean count per voxel for the volume of 
interest grown was calculated. The values are expressed as a percentage of the 
base line value so a reduction in tumour size or volume would give a value less 
than 100%; an increase in size or volume would give a value greater than 100%.  
 
Green et al defined a partial response as a reduction to less than 85% of 
baseline uptake; stable disease between 85-100% and progressive disease 
greater than 110%. A complete response was not defined.  Validation was in 
solid tumours not lymphoma (251). Combining PET and CT was in accordance 
with the International Harmonization Project criteria (249).  
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Table 2.12 Response data 
Best response with imaging at 4 weeks and confirmed at 8 weeks.  
Patient  Administered 
activity 
(MbQ/m
2
) 
FDG-PET 
(visual 
analysis) 
FDG-PET 
quantitative 
assessment  
(baseline =100) 
 
CT 
(WHO 
criteria) 
Combined  
(Cheson 
criteria) 
1 370 Not done Not done Not 
done 
Clinical PD 
2 370 Not done Not done PD PD (CT 
alone) 
3 370 PR 67 (PR) SD SD 
4 740, 1480, 
2220 
CR 0 (CR) PR CR 
5 740, 1480 CR 0 (CR) CR CR 
6 740 PD 394 (PD) SD PD 
7 1480, 2220, 
2960 
PR 0 (CR) PR PR 
8 740 Not done Not done Not 
done 
Clinical PD 
9 740, 1480, 
2220 
SD 137 (PD) SD SD 
10 1200 PR 91 (SD)  SD SD 
11 1200, 1200 PR Not possible PR PR 
12 1200, 1200 CR Not possible SD CR 
13 1480 
 
PD 70 (PR) PD PD 
14 1480 
 
PR 50 (PR) PR PR 
 
* For the experimental region growing program as devised by Green et al (251), 
this method has not been validated in lymphoma. The summary of response 
achieved (CR, PR SD and PD) is therefore based on values obtained for solid 
tumours and may not be applicable to lymphoma. In particular no criteria for 
determining CR was made in their paper as no patient attained a CR. These 
descriptions should therefore be treated with caution and are only given to 
allow comparison with other methods of assessing response.  
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There are some inconstancies between the 3 methods of assessing response. 
The Updated International Working Group Criteria (248) was designed to assess 
masses that remain post treatment. Prior to these criteria solid masses were 
determined as a CR (unconfirmed) which was converted to CR if they remained 
unchanged over 1 year. Using the updated criteria a patient is considered in CR 
if masses fail to take up FDG-PET on PET-CT. The updated criteria have the 
advantage of correlating well with prognosis (249). On these criteria patient 4 
was updated from PR to CR and patient 12 from SD to PR. Conversely in patient 
6 the CT scan did not meet RECIST criteria for progressive disease, but the FDG-
PET did. In this situation the FDG-PET is considered more indicative of the 
patients’ prognosis and this is recognized in the combined scoring (248). The 
combination of FDG-PET and CT as detailed in the final column have now 
become the standard of care in assessing lymphoma response (248). 
 
The semi-automatic region-growing program is consistent with the FDG-PET as 
assessed visually apart from patients 7, 9, 10 and 13. In patient 7 the semi-
automatic program was not able to determine low intensity disease. It had been 
predicted that this would be a likely challenge (251). In patient 9 and 10 whilst 
visual assessment reported SD and a PR respectively, the region growing 
program showed progression and SD respectively. In both these cases the 
patients went on to progress relatively rapidly post therapy suggesting that the 
region growing program may have been more accurate at predicting the lack of 
a long term response. In patient 13 visually progression was seen which was not 
confirmed by the region-growing program. This discrepancy appeared to relate 
to disease close to myocardium making the disease difficult to assess by the 
region-growing method and the results unreliable.  
 
As the semi-automatic region-growing method remains experimental it should 
be treated with caution. Before it can be used as part of standard methodology 
it would need to be validated for use in lymphoma. In addition methods will 
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need to be considered to overcome the problems encountered in patients 7 and 
13. Until that time the gold standard for lymphoma response assessment will 
remain the Updated Working Group Criteria as determined by Cheson et al 
(249).  
 
2.5.4.1 Demonstration of response in 1 patient  
 
Figure 2.3 includes the PET and CT images from patient 14; demonstrating a 
partial response. The patient subsequently went on to have an allogeneic bone 
marrow transplant. 
 
 
Figure 2.3 Response in Patient 14 
 
(A) and (B) pre treatment showing nodal disease (arrowed). (C) and (D) are 4 
weeks post treatment.  
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C D
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2.5.5 Survival data 
 
The median survival post CHT25 was 453 days (range 44-281) with 2 patients 
still alive at 624 and 595 days. The data is shown in a Kaplan-Meier plot in Figure 
2.4 
 
Figure 2.4 Survival. 
 
Fraction of patients surviving over time (days) using Kaplan-Meier method. 
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2.5.6 Dosimetry data 
 
Dosimetry data was acquired for 11 of 14 patients. Figure 2.5 shows the 
biodistribution data, with the decay corrected to collection time, of injected 
dose of radioactivity, at four time points. It is presented in this way with 
absolute activities per organ rather than ratios as the absolute values are 
required to calculate the subsequent dosimetry studies. The data demonstrates 
retention of radiation in tumour over time compared to normal organs.  
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The absorbed radiation dose per injected activity for both normal organs and 
tumour are shown in Figure 2.6 and Figure 2.7. Tumour and normal organ doses 
are not directly comparable. Normal organ doses include radiation dose from 
surrounding organs whilst tumour dose does not, tumour dose is therefore 
underestimated. The low number of patients with tumour dosimetry recorded 
was due to technical difficulties with the camera calibration making the 
measurements unreliable. In two patients it was not possible to reliably 
separate tumour uptake from surrounding tissue. With future studies the 
acquisition of a new gamma-camera allowing co-registration of SPECT data with 
CT will alleviate some of these problems encountered in this study. With the 
caveats above the median muscle to tumour ratio was 1:2 (range from 0.69 to 
7.63 times muscle value). The small tumour data set makes these values difficult 
to interpret.  
 
 
Figure 2.5 Injected activity % (median) 
Mean and ranges of radioactivity uptake by time 
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Figure 2.6 Mean and ranges of radiation dose to normal organs.  
This includes contribution from other organs 
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Figure 2.7 Radiation dose to tumour  
 
This excludes contribution from normal organs. The treatment cycle is 
documented in  brackets after the patient number.  
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Figure 2.8 and Figure 2.9 consider correlations between absorbed radiation 
dose and toxicity and response. Figure 2.8 correlates the red marrow absorbed 
radiation dose to the percentage change in platelet count from start to nadir. 
Only the first cycle of treatment was considered to avoid ambiguity with the 
cumulative effects of radiation. Figure 2.9 correlates tumour absorbed radiation 
dose with response in 7 patients. There is no overlap between the 2 groups 
(those with response compared to those with stable or progressive disease) but 
the number of data points are too few to draw any conclusions. 
  
 
Figure 2.8 Correlation red marrow dose and % change platelet count  
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Figure 2.9 Tumour absorbed dose and response (graph and table) 
Response was determined using the Updated International Working Group 
Response Criteria (Cheson Criteria)(249).  
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Response Values in mGy 
PD or SD 963 736 723 1325 
PR or CR 4945 1991 2350  
 
 
2.5.7 Pharmacokinetics  
 
Table 2.9 shows the pharmacokinetics for 22 treatments; 13 can be modelled 
using a bi-exponential model while 9 fit a mono-exponential. This difference 
may relate to data collection point positioning masking an initial rapid 
clearance. Using the mono- or bi-exponential model as appropriate it is possible 
to calculate the 50% and 90% clearance which was 44 and 193.5 hours 
respectively. For the 13 treatments possible to fit to a bi-exponential model the 
t ½ α was 6.1 hours and the t ½ β was 86.7 hours. As predicted the chimeric 
antibody half-life was longer than the murine anti-CD25 anti-Tac antibody 
labelled with 
90
Y (t ½ α of 3.51 hours and a t ½ β of 54 hours). 
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Table 2.13 Pharmacokinetics 
 A0a, A0b: amplitudes, T½a,T½b: half lives of the 1
st
 and 2
nd
 components of the bi-
exponential curve, %ID/kg: percentage injected dose per kilogram, 50% & 10%: 
time taken for modelled activity to fall to 50 or 10% of initial value. 
Dose 
level 
Patient 
No 
A0a(% 
ID/kg) 
A0b(% 
ID/kg)  
T½a-
(h)  
T½b 
(h)  
50.0%(h)  10.0%(h)  
370 1 0.7 3.6 6.1 98.4 73.5 305.5 
370 3.1 1.9 6.5 3.2 58.3 37 174 
740 3.2  2.7  8 8 28.8 
740 4.1 1.8 8.5 0.4 60.4 43.5 186 
740 5.1 6 7.1 10.7 422.5 60* 1025* 
740 6 1.3 1.4 0.05 46.3 12.5 120 
740 8 3.1 5.5 0.9 57.2 20.5 153 
740 9.1  8.2  44.1 44 144 
1200 10.1 3.1 5.9 0.9 86.7 33.5 234 
1200 11.1  15.5   53 53 176 
1200 12.1 7.4 12.7 17.2 113.9 53 300 
1200 12.2  9.6  37.5  37 126 
1480 4.2 4.5 5.8 1.8 135.6 35 338 
1480 5.2 1.9 2.9 16.4 122.7 51 318 
1480 7.1 2.9 7 6.3 76 39 214 
1480 9.2  8  43.9 44 144 
1480 13  5.5  57.8 58 192 
1480 14 2.8 4.5 17 108.1 51 285 
2220 4.3  3.8   123.4  123 410 
2220 7.2  7.9  66.1 66 220 
2220 9.3 1.9 3.4 10.3 58.8 30 156 
2960 7.3  4.6  58.6  58.5 195 
Median           44 193.5 
 
(*) The long decay shown might have been affected by the small number of blood samples 
 
2.5.8 Soluble IL2-R 
 
The median pre treatment soluble IL-2R (sIL2-R) was 2803.3 U/ml (range 580-
66080 U/ml). This compares with median normal values for the assay of 
521U/ml (range 269 – 1116 U/ml). The level of pre-treatment sIL2-R was not 
found to be a prognostic factor for survival in this small patient sample; patients 
with above median values had a survival of 407 days compared to 485 days, 
which was not significantly different (Kaplan-Meier method, Mantel-Cox x
2 
0.17, 
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p = 0.68). Previous work had shown a patient sub-group with a low sIL2-R and a 
good prognosis (252). Only 1 of our patients fell into this good prognostic 
category.   
 
The molar ratio between the CHT25 antibody and sIL-2R levels in plasma at the 
moment post injection (using plasma volume from standard man) was 
calculated to be a median of 49 to 1 (with a range from 2:1 – 260:1). There was 
no clear relationship between the ratio and response.  
 
The percent change in sIL-2R values were calculated pre and post therapy. 
Patients with falling or stable values had a median survival of 671 days 
compared with 279 in those with a rising value (p=0.0049 Log rank (Mantel-Cox) 
test. The survival curves are demonstrated in Figure 2.10.  
 
Figure 2.10 Survival according to % change in sIL2R pre and post therapy 
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2.5.9 Immunogenicity 
 
Three patients received 3 treatments, 4 had 2 treatments and 7 had 1. One 
patient became HACA positive (patient 1) at 45 days after the 1
st
 treatment. 
There was rapid blood clearance of CHT-25 in patient 3 without positive HACA 
and this was not explained. Patient 9 was non-specifically positive in the HACA 
assay to both irrelevant control antibody and PBS (phosphate buffered solution) 
at baseline; values fell with therapy suggesting non-specific binding. One patient 
post-allograft was ineligible for study entry due to a positive HACA possibly 
representing an immune anti-tumour response.  
 
2.6 Conclusions and Discussion 
 
There is limited experience with chimeric or human antibodies in RIT. This study 
determines the pharmacokinetic, pharmacodynamic, related toxicity and 
tumour response, and reports generally favourable findings at the MTD. The 
patients included had poor prognostic features (Table 2.7) with tumours 
resistant to multiple lines of therapy and concomitant damage to bone marrow. 
 
Dose-limiting toxicity, as predicted, was myelosuppression which was readily 
managed at the MTD. The only treatment related death occurred in a patient 
who received more than twice this dose. The rate of non-neutropenic infection 
was relatively high (Of 10 patients with infections, 3 were neutropenic 
associated). It is unclear whether this rate was due to modulation of CD25-
positive immune cells by therapy or the pre-existing immunosuppression of this 
group. No evidence of viral re-activation was seen but given the associated 
lymphopenia, appropriate microbial prophylaxis may be warranted in future 
studies. It was confirmed that repeat therapy was feasible after haematological 
recovery. Further chemotherapy was not precluded in patients whose tumour 
did not respond.  Two patients underwent high dose procedures after receiving 
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CHT25 (one allogeneic bone marrow transplant and one ASCT) and both had 
successful engraftment.  
 
Response was assessed using 
18
FDG-PET and CT consistent with current best 
practice. Of 9 patients treated at or above the MTD the overall response rate 
was 67% (3 CR and 3 PR).  Two further patients had stable disease while 1 had 
progression. The 2 patients on stable doses of prednisolone responded having 
previously progressed whilst taking that steroid dose. As a phase I study the 
response rate was encouraging. The median survival of 453 days was in part due 
to sustained remissions, some of which were long-term.   
 
Correlation was seen between red marrow absorbed dose and marrow toxicity. 
Variation in the extent of bone marrow damage pre-CHT25 was not considered. 
Baechler et al found the main determinant for haematological toxicity was the 
duration since the preceding chemotherapy regime (253). Flt3-L (Fms like 
tyrosine kinase ligand) levels have been reported as a means of addressing the 
degree of marrow vulnerability (254) and would be worthy of inclusion in future 
trials.  
 
Dosimetry demonstrated a longer retention of activity in tumour compared with 
normal tissues. To exploit this, 
131
I with its physical half life of 8 days was chosen 
as the therapeutic radionuclide. Tumour responses were only recorded in 
patients with absorbed doses ≥ 1990 mGy showing the potential for dosimetry 
studies to identify patients suitable for treatment.  Although the radiation 
appears important for tumour response, additional antibody factors may assist. 
Recent work has considered a possible anti-cancer effect from the depletion of 
regulatory T cells (255) or through other immune effects. Evidence of a direct 
anti-cancer immune mediated antibody effect is currently inconclusive.  Of note 
unlabeled antibody without a RIC showed limited benefit with short lived 
responses (243).  
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The pharmacokinetics and dosimetry data reveal the chimeric antibody 
delivered radiation to normal tissues over a more prolonged time than 
previously reported in the murine CD25 antibody (
90
Y-antiTac) (16). 
 
The serum sIL2 receptor was elevated in our study, although to a variable extent 
between patients. In every patient it was found at a lower concentration than 
its antibody, CHT25 at the time of its administration. The ratio of antibody to 
sIL-2R appeared adequate for targeting (by dosimetry) and generated a high 
tumour response rate. Further improvement may be seen by reducing sIL-2 
levels prior to CHT25 administration to prevent antibody diversion away from 
tumour.  The two successfully licensed RIC’s both administer unlabeled antibody 
prior to the RIC to overcome the CD20 ‘sink’ on normal cells.  An elevated sIL2-R 
level is known to be an adverse prognostic factor in Hodgkin’s lymphoma (252). 
Our study could not confirm that pre-treatment sIL-2R levels were a prognostic 
survival factor although this is not definitive due to the small sample size.   
 
One advantage of arming monoclonal antibodies with 
131
I is that the mean path 
length (0.4mm) of the radionuclide allows for the eradication of adjacent 
antigen-negative tumour cells (‘the crossfire effect’) (10, 11). The longer path 
length of 
90
Y results in a greater proportion of the dose being deposited outside 
small tumour masses and the shorter half life means the prolonged retention of 
antibody in tumor cannot be exploited. There is potential for investigation for 
other radionuclides and combinations of radionuclides. 
 
Previously RIT with 
131
I has been used in phase I/II clinical trials in HL with 
polyclonal anti-ferritin or anti-CD30 directed antibodies (232, 237). The overall 
response rates ranged from 36 to 49 % and the major side-effect, as observed 
here, was haematological toxicity, most notably thrombocytopenia.  
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Unlabelled monoclonal antibody therapy directed against CD25 exploits the 
discordance in IL-2R-alpha expression between tumour cells and normal tissue 
and has an established history in hematopoietic malignancy (243, 244). CHT25 
could be useful in tumours other than HL (226, 227) one patient with a T cell 
lymphoma had a CR in our study. 
 
CHT25 has a potential application in preparation for autologous and allogeneic 
transplantation giving the possibility of long term disease control to a 
proportion of patients with relapsed or refractory disease. Demonstrable 
chemo-sensitivity and maximal reduction in disease burden prior to 
transplantation are critical predictors of outcome (230, 256). In this study we 
induced responses and transplanted patients previously considered 
inappropriate for this treatment. This justifies further investigation of CHT25 
either to render patients eligible for transplant or to improve transplant 
outcome when combined with standard conditioning regimens.  It may have a 
place in the early treatment of poor prognosis patients and in other CD25-
positive lymphomas. 
 
In summary, the CHT25 study demonstrates that RIT with a chimeric antibody 
can be safely administered at a dose of 1200MBq/m
2
 giving objective responses 
in a high proportion of patients with lymphomas expressing CD25. 
Pharmacokinetic and pharmacodynamic parameters relevant to producing this 
effect have been shown. CHT25 appears to have potential as a new treatment in 
this patient group. 
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Chapter Three: RIT of CEA-expressing Malignancy with 
131
I-A5B7 and CA4P 
 
 
Our hypothesis stated that it would be unlikely for single agent RIT to be 
effective in solid tumours, particularly in bulky disease. Instead we decided to 
investigate the combination of a Vascular Disrupting Agent (VDA) with RIT. We 
hoped to demonstrate synergy between the two agents, due to their differing 
modes and sites of action within the tumour. Scheduling of the agents was 
designed to facilitate RIC trapping in tumour. Synergy had already been seen in 
animal experiments between the two compounds with transformation of a sub-
curative therapy to a curative one.  
 
The VDA that was chosen was Combretastatin-4-Phosphate (CA4P), which acts 
by binding tubulin. Initially in this chapter I shall discuss this compound before 
considering the chosen antibody, A5B7, a murine anti-CEA antibody. 
 
3.1 Combretastatin-A4-phosphate (CA4P) 
 
CA4P is a water-soluble pro-drug that is dephosphorylated into CA4, the active 
form, before binding rapidly to β-tubulin causing depolymerisation and 
inhibition of tubulin assembly (257, 258). Newly formed endothelial cells 
become distorted, leading to blood vessel occlusion and a reduced flow. Mature 
cells are relatively unaffected as their actin cytoskeleton is more robust (259). 
CA4P also disrupts endothelial cell signalling via the vascular endothelial 
cadherin pathway (260). 
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3.1.1 Pre-clinical studies  
 
CA4P leads to rapid reductions in tumour blood flow in mice with spontaneous 
tumours, and xenografts (261, 262). The first effects are visible at 10-20 minutes 
with endothelial cell distortion in vitro. Vascular collapse follows at 1 hour 
leading to a core of haemorrhagic necrosis (263). At 6 hours tumour blood flow 
is reduced 100 fold with only minimal changes in normal organ flow (262). 
Tumour blood flow returns to normal by 24 hours post infusion (264) and 
massive tumour necrosis is visible with 90-99% of tumour cells killed (using 
100mg/kg). The effect on tumour growth is minimal as repopulation occurs 
from the viable rim of peripheral tumour cells supplied by normal blood vessels 
(263).  In our combination study we hypothesize these will be killed by RIT.  
 
3.1.2 Clinical studies 
 
Three Phase I studies have investigated CA4P as a single agent in refractory solid 
tumours (265-267) using DCE-MRI (Dynamic contrast enhanced – magnetic 
resonance imaging) to assess blood flow (See  Table 3.1 and Table 3.2). Each 
study used a different dosing schedule; a single dose every 21 days (266), 5 
consecutive doses in 21 days (267) and weekly (265). All 3 studies had a 
reduction in tumour blood flow with little effect on systemic flow. In 2 of the 3 
studies, 1 patient had an objective response. Disease stability or minor 
responses were more common and ranged from 9% (265) to 38% (266).  
 
CA4P was generally well tolerated. The commonest side effects were nausea, 
headache, tumour pain and tiredness. Most toxicity resolved within 2 days. 
Dose limiting toxicities developed between 52mg/m
2
 and 114mg/m
2
 and are 
described in Table 3.2. The MTD was defined as between 60-68mg/m
2
. 
 121 
Table 3.1 Phase One studies of CA4P    
 
Trial  Number  Patient group Monotherapy Response  
Dowlati et al 
2002 (183) 
25 Refractory 
solid tumours 
Single agent 
CA4P 
1 CR* 
11 SD 
Rustin et al 
2003 (181) 
34 Refractory 
solid tumours 
Single agent 
CA4P 
4 SD 
Stevenson et 
al 2003 (182) 
37 Refractory 
solid tumours 
Single agent 
CA4P 
1 PR** 
16 SD 
 
* A patient with anaplastic thyroid cancer who has remained in complete remission for > 5 
years.  
** A patient with metastatic soft tissue sarcoma 
 
Table 3.2 Dose-limiting toxicity with CA4P 
 
 Dose-limiting toxicity encountered (number patients in brackets) 
Dose (mg/m
2
)  60  75 90 114 
Dowlati et al 
(183) 
 Myocardial 
ischaemia (1) 
Prolonged QTc 
(1) 
 Cardiac 
ischaemia and 
dyspnoea (2) 
 
Rustin et al 
(181) 
Small 
bowel 
ischaemia 
(1)* 
  Ataxia (1) 
Dyspnoea, 
vasovagal and 
tumour pain (1) 
Ataxia (2) 
Stevenson et 
al (182) 
  Tumour 
pain (2) 
  
 
* Patient died at day 15 from an ischaemic and /or perforated bowel associated with a tumour 
mass in a previous radiotherapy field. It was defined as treatment related due to possible 
impairment of mesenteric blood supply to an area already compromised by the radiation.  
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3.1.3 Combining a VDA with RIT 
 
Pre-clinical studies of the combination suggest that with optimal timing, tumour 
blood vessel collapse may trap radiolabeled antibody within tumour and 
increase tumour absorbed dose (123, 268). The optimal schedule for the CA4P 
in animal models was 24-48 hours after the radioimmunoconjugate (RIC) (268) 
giving a 90% increase in radiation retention compared to the control of RIT 
alone (123).  
 
In pre-clinical animal models the combination transformed a sub-curative 
therapy into a curative one (with both CA4P (123) and DMXAA (269)), although 
with a narrow therapeutic window. Pedley et al administered CA4P and 
131
I-
A5B7 to nude mice with the colorectal xenograft SW1222. Single agent CA4P 
had no effect on survival, the RIC prolonged survival by 35 days, but the 
combination led to cures in 85% of mice (123) with no viable tumour cells found 
at the implantation site.  
 
3.2 A5B7 Antibody 
 
 
The A5B7 Antibody is a murine monoclonal IgG antibody targeting CEA. In 
normal colonic epithelium it reacts against the cellular apical regions. In colonic 
carcinoma it reacts against both the basal and luminal cellular surface at 
moderate or intense levels. The targeting of the basal region is important as this 
areas is more accessible to antibody (270). Whilst the exact epitope that A5B7 
reacts against remains unknown it is specific to CEA without cross-reactivity to 
liver, erythrocytes or neutrophils (271).  
 
A7B7 has been demonstrated to localise to human colon carcinoma xenografts 
by Pedley et al  (123, 272). A previous single-agent phase I study of 
131
I-A5B7 
found an MTD of 2400MBq/m
2 
with bone marrow toxicity dose-limiting (94). 
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The half-life of 
131
I-A5B7 was 28.6 hours in blood and 59.5 hours in tumour. The 
single-agent response rate was 10%. The MTD of CA4P from single-agent studies 
was between 60-68mg/m
2
 (265, 266) with a mean plasma half-life of 0.2 hours, 
2 hours for CA4 and a further 4.3 hours for the subsequent product CA4G.  
 
3.3 Methods 
 
The A5B7 CA4P study was a two-centre, open-label, non-randomized dose-
escalation study designed to evaluate the combination of RIT, 
131
I-A5B7, and 
CA4P. The patients were recruited from the Royal Free Hospital NHS Trust and 
Mount Vernon Hospital.  
 
3.3.1 Trial Objectives 
 
The primary objectives were to determine the safety profile of the combination 
of 
131
I-A5B7 and CA4P and to determine the relationship between efficacy and 
tumour blood flow reduction by CA4P.  
 
Secondary objectives were to determine the MTD of the combination and to 
assess pharmacokinetics and pharmacodynamics.  
 
3.3.2 Pharmaceutical 
 
A5B7 was produced at the Biotherapeutics Development Unit (Cancer Research 
UK, Clare Hall Laboratories) by purification from tissue culture fluid using 
protein A chromatography and ion exchange chromatography. It was then 
formulated in isotonic phosphate buffered solution (PBS) and stored at 4°C. It 
was radiolabeled with 
131
I at the Royal Free Hospital using the N-
bromosuccinamide method (247), known to have a labelling efficiency of 88-
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94% without loss of immunoreactivity (94). 
131
I was obtained from Amersham 
Pharmacia Biotech as sodium iodide. After labelling drug stability was estimated 
at 4 hours. 
 
CA4P was supplied by Oxigene Inc., to the Cancer Research UK Formulation Unit 
who performed the final labelling operations. It was supplied as a sterile freeze-
dried, disodium salt in amber vials. It is light sensitive and was stored 
refrigerated in the dark.  
 
3.3.3 Selection of starting dose and schedule 
 
The starting doses of both agents were lower than their respective MTDs from 
their single agent studies for safety. For CA4P, 45 (50)* mg/m
2
 was considered 
to be the lowest dose with a reasonable chance of reducing tumour blood flow 
with a planned escalation to 55 (60.5)* mg/m
2
, the MTD recommended by 
Oxigene. The starting dose of 
131
I was 1800 MBq/m
2
, which is 25% below its 
MTD from single agent studies. It was planned to increase to the single-agent 
MTD of 2400 MBq/m
2
. No additive toxicity was anticipated from previous 
animal studies (75, 185) as the two compounds had differing mechanisms of 
action and toxicity profiles. The A5B7 antibody was given at a fixed dose of 
10mg.  
* The CA4P dose is presented as the free acid form concentration and is 90% of the dose 
representing the disodium salt. The equivalent salt form concentration is shown in brackets. 
 
A traditional 3 + 3 dose-escalation strategy was employed. Each dose was 
administered in cohorts of 3 patients. If a DLT occurred the cohort was 
expanded to 6 patients. Dose escalation was allowed providing 0 of 3 patients 
or less than 2 of 6 patients experienced a DLT. A minimum time interval of 7 
days was required before treating a new patient in the same cohort, and 4 
weeks if escalating to a new cohort to allow time to assess for toxicity.  
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Table 3.3 Planned dose escalation schedule  
 
Planned cohort CA4P* (mg/m
2
) A5B7 (mg)  131-Iodine 
(MBq/m
2
) 
1 45 (50) 10 1800 
2 55 (60.5) 10 1800 
3 55 (60.5) 10 2100 
4 55 (60.5) 10 2400 
* The CA4P dose is presented as the free acid form concentration and is 90% of the dose 
representing the disodium salt. The equivalent salt form concentration is shown in brackets.  
 
 
If there was no evidence of disease progression on day 57 and the eligibility 
criteria were still met a patient could be retreated at the same dose. If HAMA 
positivity had occurred, CA4P could be given alone. The initial planned study 
size was 14 patients. If no evidence of efficacy was seen at that point the trial 
would be terminated. If responses were observed a further 11 patients would 
be recruited.  
 
3.3.4 Agent administration  
 
Radiation protection issues meant the DCE-MRI could not be performed after 
administration of the RIC. To assess the vascular response to CA4P it was 
decided to administer CA4P 1-2 weeks prior to the RIC with DCE-MRI 
assessment pre and post and pharmacokinetic assessment. Previous work had 
demonstrated recovery of tumour vasculature 24 hours after CA4P (263) so this 
protocol was considered unlikely to reduce subsequent tumour 
131
I-A5B7 
uptake. 
131
I-A5B7 was given on day 0 with CA4P on days 3, 4 and weekly 
thereafter for up to seven weeks or until unacceptable toxicity or tumour 
progression occurred. The rationale for CA4P on day 3 was based on animal 
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work suggesting this is the optimal schedule to trap 
131
I-A5B7 in tumour (123). 
Day 4 was added to maximise this effect.  
 
CA4P was reconstituted with 11ml sterile water then diluted with 100-150ml 
0.9% saline.  It could then be kept for up to 4 hours if protected from light. A 
line filter removed particulates during the 10 minute infusion time. Patients 
were monitored for 4-6 hours afterwards for cardiovascular instability.  
 
131
I-A5B7 was given intravenously over 30-40 minutes in 50ml 0.9% saline using 
a shielded syringe driver. Radiation protection personnel were present to 
ensure compliance with the Ionization Radiation Regulations. Resuscitation 
facilities were available.  
 
3.3.5 Inclusion and Exclusion criteria 
 
3.3.5.1 Inclusion Criteria 
 
• Histological diagnosis of a CEA-expressing gastrointestinal malignancy. 
Plasma CEA level 10-1000 µg/L or CEA-expression on tumour blocks 
• Measurable disease clinically or on CT / MRI assessable by RECIST 
criteria.  
• Completed or not eligible for standard anti-cancer therapies. 
• Disease suitable for blood flow evaluation by DCE-MRI (> 2cm / not in 
sites that move with respiration or vascular pulsation). Be able to 
tolerate MRI.  
• A normal ECG (Electrocardiography) with a QTc interval < 450msec 
• Age > 18 year 
• Life expectancy > 3 months 
• Performance status (WHO criteria) 0 or 1 
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• Adequate organ function for the study including: 
o Neutrophil count > 1.5 x 10
9
/L 
o Haemoglobin > 9g/dl (to transfuse to > 10g/dl) 
o Platelet count > 100 x 10
9
/L  
o Calculated creatinine clearance (uncorrected) > 50ml/min 
o Plasma bilirubin, ALT and AST < 2 x the upper limit of normal 
(ULN). (5 x ULN allowed for transaminases in the context of liver 
metastasis. 
o INR < 1.1 (or if on 1mg warfarin < 1.5) 
o Potassium and magnesium within normal ranges 
• All > grade 1 toxicity (except alopecia) from prior therapy resolved.  
• Capable of giving written informed consent 
 
3.3.5.2 Exclusion Criteria 
 
• At risk of cardiac complications: a prior history of angina, myocardial 
infarction, congestive heart failure, non-controlled atrial arrhythmias or 
clinically significant arrhythmias, uncontrolled hypertension (> 150/100 
irrespective of medication) or an abnormal ECG.  
• Medication that prolonged the QTc interval, anti-coagulants (excepting 
1mg warfarin for tunnelled central lines) or naproxen.  
• Pregnancy, breast feeding or inability to use contraception.   
• Previous curative doses of radiotherapy to thorax or abdomen at any 
time or post-operatively to the pelvis due to risk of perforation. Pre-
operative radiotherapy to rectum allowed if that section of bowel then 
removed. 
• Serious non-malignant systemic disease: uncontrolled infection, 
hepatitis B and C, HIV, auto-immune disorders, inflammatory bowel 
disease or moderate to severe peripheral neuropathy.  
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• Major surgery in the preceding 3-4 weeks or anti-cancer therapy in the 
past 4 weeks (excluding palliative doses of radiotherapy to non-target 
lesions).  
• Presence of brain metastases 
• Any additional active malignancy excluding adequately treated in situ 
carcinoma of the cervix, uteri, basal or squamous cell cancer of the skin.  
• Positive HAMA or an allergy to iodine or mouse proteins.  
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3.3.6 Pre-trial investigations 
 
All assessments were performed within in the time-scales in Table 3.4.  
 
Table 3.4 Pre-trial investigations  
Date pre-
therapy  
Nature of investigation 
Within 12 
weeks 
Blood taken for HAMA 
Within 4 weeks 
(preferably 
within 2) 
Written informed consent  
CT and if required MRI for disease assessment 
FDG-PET and blood glucose 
Within 2 weeks Tumour markers in serum (CEA and CA19-9 (carbohydrate 
antigen), thyroid function (TSH and free T4 (thyroxine) 
Within 1 week Medical history (symptoms, vital signs, urinalysis, body 
surface area, performance status and physical examination) 
Assessment of drug history 
Basic investigations; ECG, CXR (Chest X-ray), creatinine 
clearance. 
Blood tests (haematology*, biochemistry** and clotting***). 
Register with Cancer Research UK Drug Development Office  
 
Haematology: haemoglobin, white cell count, lymphocytes, neutrophils, and platelet count.  
** Biochemistry: electrolytes, urea, creatinine, urate, total protein, albumin, bilirubin, AST, ALT, 
ALP (alkaline phosphatase), GGT, glucose and magnesium 
*** Clotting includes PT, INR and APPT 
 
3.3.7 Trial follow-up 
 
Patients were followed up for a minimum of 8 weeks or until trial-drug related 
toxicity had resolved (see Table 3.5). Potassium iodide was administered from 
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day -2 until day 11 (50-60mg three times a day) to protect the thyroid gland 
from radioactive iodine uptake. DCE-MRI was performed at 48 and 24 hours 
prior to initial CA4P and 4 hours after. Pharmacokinetic data was collected for 
CA4P on its initial administration and day 1 after 
131
I-A5B7 infusion. Patients 
remained as in-patients until determined safe for discharge by the radiation 
protection team. Whilst they remained in-patients daily SPECT scans were 
performed.  
 
Table 3.5 Follow-up protocol 
Protocol for follow-up 
post discharge  
Nature of investigation 
Weekly Clinical assessment (examination, vital signs,  physical 
examination and performance status) 
Basic investigations including ECG,  
Blood investigations (haematology and biochemistry) 
Day 32 and day 53 Tumour markers, thyroid function, HAMA estimation 
Day 29 and day 57 Disease response assessment by CT and MRI if required 
Day 18, 29 and 57  Disease response by FDG-PET 
 
3.3.8 Toxicity 
 
Toxicity was graded using the National Cancer Institute Common toxicity criteria 
(CTC) (version 2). The highest grade in any one particular cycle was recorded.  
 
3.3.8.1 Definition of a Dose-limiting toxicity 
 
A DLT was defined as a toxic event, almost certainly or probably drug related. 
Any grade 3 or 4 toxicity was defined as dose-limiting, excepting hair loss, grade 
3 nausea, grade 3 or 4 vomiting or diarrhoea in patients not adequately 
supported. Additional DLTs specific to CA4P were cardiac (detailed below) and 
grade 2-4 neurotoxicity. Any death thought to be drug-related was also a DLT.  
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Haematological dose limiting toxicities  
 
• Grade 4 neutropenia (< 0.5 x 10
9
/l) for > 5 days 
• Grade 3 or 4 febrile neutropenia; fever > 38.5°C  and a neutrophil count 
< 1.0 x 10
9
/l 
• Grade 3 or 4 thrombocytopenia (platelet count < 50 x 10
9
/L) 
• Grade 3 or 4 anaemia (Haemoglobin < 8.0 g/dl) 
 
Cardiac dose limiting toxicities (specific for CA4P / not necessarily CTC criteria) 
 
• QTc prolongation of > 500 msec on ECG 
• Grade 2, 3 or 4 ventricular arrhythmia; second or third degree AV block, 
severe sinus bradycardia (< 45 bpm) or tachycardia (>120 bpm), 
persistent supraventricular arrhythmia (e.g. atrial fibrillation or flutter) 
lasting for > 24 hours, ventricular tachycardia (> 9 concurrent beats / any 
length of torsades de pointes) or unexplained recurrent syncope.  
 
3.3.8.2 Definition of maximum tolerated dose (MTD)  
 
 
The MTD was the dose at or below that where DLT’s were found to occur. 
Toxicity was considered manageable at this level, acceptable and generally 
reversible.  
 
3.3.9 Response Assessment  
 
All patients who received 1 cycle were assessed for response with CT at 4 and 8 
weeks post therapy (RECIST criteria). FDG-PET was performed in selected 
patients’ pre-therapy, at 2-4 weeks and 8 weeks post therapy. An ADAC Vertex 
 132 
Plus Dual Head Co-incidence camera hybrid SPECT/PET camera (Phillips-ADAC, 
Eindhoven, Netherlands) was used.  
 
Analysis was with an iterative threshold based region growing program (251). 
The methodology for image acquisition and analysis were described in Chapter 
2. A partial response was defined as a 15% or greater reduction from baseline; 
progressive disease was an increase of ≥ 10% and stable disease between those 
two limits. These ranges have been validated in solid tumours (251).  
 
3.5.10 SPECT and dosimetry data 
 
SPECT scans were performed at 4, 24, 48 and 72 hours post administration of 
131
I-A5B7 with the hybrid SPECT/PET camera. ROI based analysis was performed 
on both tumour and normal tissues and used to calculate dosimetry as 
previously described in Chapter 2.  
 
3.5.11 Vascular parameters with DCE-MRI 
 
All patients had DCE-MRI to assess tumour blood flow. Gadolinium 
diethylenetriampentaacetate (Gd-DTPA) (Magnevist) was used as a contrast 
agent whilst a dynamic series of T1 weighted images were acquired.  Gd-DTPA is 
a paramagnetic agent that enhances MRI signal intensity in proportion to its 
concentration. The rate of leakage of Gd-DTPA into the extracellular space can 
be described with a compartmental model (273). In the leaky, tumour-
associated blood vessels Gd-TPA diffuses more easily and quickly into the 
tumour extracellular space. Rapid uptake with high levels of enhancement over 
time is consistent with perfused tumour (125).  
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Results can be quantified using two methods; K
trans
 and initial area under the 
Gd-DTPA contrast agent time curve (IAUGC) (274). K
trans
 is the volume transfer 
constant between blood plasma and the tumour extracellular space. It reflects 
both tumour blood flow and permeability. In a rat model CA4P led to a 
statistically significant fall in K
trans
 at 1 and 6 hours post administration, 
compared to baseline.  No difference was seen in a control group injected with 
saline (275).  
 
Rustin et al considered DCE-MRI in 21 patients treated with CA4P and 
demonstrated reproducibility between 2 scans prior to therapy and a significant 
mean reduction in K
trans 
at 4 and 24 hours in patients receiving at least 46.8 (52) 
mg/m
2
 or greater . No significant reductions were seen in muscle K
trans
 (274).  
 
Based on these studies (265, 274) patients had two MRI scans prior to study 
entry, to derive a baseline value and assess intra-patient variability. DCE-MRI 
was then repeated 4 hours post using a 1.5T Siemens Symphony scanner.  
 
3.5.12 Pharmacokinetics 
 
Pharmacokinetics for the CA4P administration, were taken with the initial 
administration of CA4P 1-2 weeks prior to the administration of the 
131
I-A5B7. 
Due to radiation safety concerns no further pharmacokinetics were taken for 
the CA4P administrations on Days 3 and 4 post 
131
I-A5B7 to exclude any 
interaction with the RIC. No interaction was expected to occur with the VDA 
pharmacokinetics.  
 
Peripheral blood was taken pre-initial administration of CA4P and then at 5, 30 
and 45 minutes and 1, 2 and 4 hours. It was kept at 4°C and centrifuged within 
30 minutes (3000 rpm for 10-15 minutes). The plasma was stored at -70°C. The 
analysis used non-compartmental models to produce the maximum observed 
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plasma concentration (Cmax), time to reach Cmax (Tmax) and the area under 
the plasma concentration curve (AUC) and terminal elimination half-life (T/half). 
The same values were calculated for CA4.  
 
Blood (1ml) was taken pre-administration of 
131
I-A5B7 and at 5 minutes, 4, 24, 
48, 72 and 96 hours post infusion and stored in the radioactive storage area 
until safe to analyze.  A Packard Cobra 11
th
 series Auto gamma counter was 
used to measure 
131
I activity and decay correction applied to calculate the % 
injected dose/kg blood at each time point.  
 
3.5.13 Immunogenicity  
 
HAMA was tested pre-study entry and on days 32 and 53. Peripheral blood was 
centrifuged at 3000rpm for 10-15 minutes and serum separated into a second 
tube. It was divided into 2 aliquots with 1 analyzed immediately using a 
standard ELISA protocol against positive and negative controls and the other 
stored at -70°C.  
 
3.6 Results 
 
3.6.1 Patient Characteristics  
 
Between January 2004 and April 2007 88 patients were screened and 12 
patients were recruited. The commonest reason for not entering a patient was 
their unsuitability for assessment by DCE-MRI (19 patients), patient refusal (11 
patients), a negative CEA or a serum CEA value > 1000 (9 patients) or a WHO 
score > 1 (9 patients). Of those patients recruited 11, had primary colorectal 
cancer and 1 primary pancreatic cancer. Other characteristics are detailed in 
Table 3.6.  
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Table 3.6 Patient Characteristics  
Patient Characteristics No patients 
Number of patients treated 12 
Sex 
Male 
Female 
 
7 
5 
Age 
Median (range) in years 
 
64 (32-77) 
Primary Tumour site 
Colorectal 
Pancreas 
 
11 
1 
Performance Status (WHO) 
0 
1 
 
6 
6 
Number of patients previously treated 
with 
Biological therapy 
Radiotherapy  
Chemotherapy 
Surgery 
 
 
1 
3 
12 
12 
Number of patients receiving ‘x’ prior 
regimens of chemotherapy 
1 
2 
3 
4 
5 
 
 
3 
6 
2 
0 
1 
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3.6.2 Administered activity received 
 
Although the starting doses of both agents were lower than the MTD defined by 
single-agent studies, two dose-limiting events occurred in the first cohort. Both 
were myelosuppression and attributed to the RIT component. Consequently the 
dose of RIT was de-escalated but the dose of CA4P increased to levels that 
previously had been demonstrated to reduce tumour blood flow. In this second 
cohort a further 3 episodes of dose-limiting toxicity occurred and the study was 
terminated. A full summary of doses and injected activities administered are in 
Table 3.7. 
 
 
Table 3.7 Injected activities / doses administered  
Patient 
Number  
Dose 
Cohort 
131-I-A5B7 
(MBq/m2) 
CA4P 
(mg/m2) 
No 131I-
A5B7 
infusions 
No CA4P 
infusions 
No DLT 
1 1 4 DLT 
2 1 5  
3 1 4  
4 2 16  
5 1 6  
6 
1 
 
1800 
 
45 
1 10 DLT 
7 1 3 DLT 
8 1 8 DLT 
9 
1800 
1 3  
10 Not given  0 1  
11 1 5  
12 
2 
1600 
54 
1 7 DLT 
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3.6.3 Toxicity  
 
All adverse events are described in Table 3.8 with episodes of grade 3 and 4 
toxicity given in greater detail in Table 3.9. In the first cohort 2 patients 
developed grade 4 neutropenia for > 5 days (20 and 7 days respectively). 
Neither patient became septic although one had cellulitis around the site of a 
previous paracentesis.  
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Table 3.8 Summary of all toxicities encountered  
Toxicity occurring in 4 or more patients is highlighted in bold 
 Number of Patients (n=12) 
 All toxicity determined to be drug related  
 A5B7 related CA4P related Attributed both 
Allergic reaction 2 2  
Bone marrow 
Anaemia 
Lymphopenia 
Neutropenia 
Thrombocytopenia 
 
7 
7 
9 
10 
 
0 
2 
0 
0 
 
1 
1 
1 
0 
Cardiovascular 
Sinus Bradycardia 
Sinus Tachycardia 
Cardiac Ischaemia 
Prolonged QTc interval 
Hypertension 
Hypotension 
 
0 
3 
0 
0 
5 
0 
 
5 
5 
2 
1 
7 
4 
 
0 
0 
0 
0 
0 
0 
Coagulation 
Prolonged APTT
a 
Prolonged PT
b 
 
0 
0 
 
0 
0 
 
2 
2 
Constitutional 
Fatigue 
Fever 
Rigors / Chills 
 
0 
5 
3 
 
2 
6 
1 
 
1 
0 
0 
Endocrine 
Low TSH
c 
Hypothyroidism 
 
1 
1 
 
0 
0 
 
0 
0 
Gastrointestinal 
Anorexia 
Constipation 
Diarrhoea 
Nausea 
Stomatitis 
Vomiting  
 
0 
0 
1 
1 
0 
0 
 
1 
0 
1 
5 
1 
2 
 
0 
1 
0 
1 
1 
1 
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Hepatic 
Raised ALT
d 
Raised Alkaline Phosphatase 
Raised GGT
e 
Hypoalbuminaemia 
 
0 
0 
0 
0 
 
1 
1 
1 
1 
 
0 
0 
0 
0 
Neurological 
Ataxia 
 
0 
 
1 
 
0 
Pain 
Tumour Pain 
Non-tumour Pain 
 
0 
0 
 
4 
5 
 
0 
1 
Renal / Genitourinary 
Urinary Frequency / Urgency 
 
0 
 
2 
 
0 
a
 Activated Partial Thromboplastin time, 
b
 Prothrombin, 
c
 Thyroid Stimulating hormone 
d
 Alanine Aminotransferase, 
e
 Gamma glutamyl transpeptidase 
 
 
Table 3.9 Grade 3 or 4 toxicities  
Patient no DLT  Onset Duration Comment 
1 Grade 4 neutropenia 
> 5 days  
Day 51 1 month Cellulitis at 
paracentesis site 
6 Grade 4 neutropenia 
> 5 days 
Day 31 7 days Remained well 
7 Grade 3 ataxia Day 1
st
 CA4P 3 days Steroid with 
subsequent 
CA4P 
8 Grade 4 neutropenia 
> 5 days 
Day 31 7 days Remained well 
12 Grade 4 neutropenia 
> 5 days 
Day 30 and day 
39 
8 and 6 days 
respectively 
Remained well 
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In the second cohort 2 patients developed grade 4 neutropenia for > 5 days (7 
days, then 8 and 6 days in the same patient). There was 1 episode of grade 3 
ataxia occurring within 24 hours of CA4P and continuing for 3 days. Subsequent 
infusions for that patient were pre-medicated with dexamethasone.  
 
Cardiovascular toxicity included hypertension, hypotension, sinus bradycardia 
and tachycardia. Hypertension tended to be mild and self-limiting and only 1 
patient required therapy due to associated grade 2 cardiac ischaemia. Tumour 
site pain post CA4P occurred in 4 patients with a median time to onset of 72 
minutes (range 45-177 minutes). Median duration was 60 minutes (5-240 
minutes). Mild nausea was common and occurred in 5 patients post CA4P 
administration. Two patients had mild allergic reactions to 
131
I-A5B7.  
 
3.6.4 Response Data  
 
Ten patients were evaluable for response on days 29 and 57. Seven patients had 
early progression by day 29; two had stable disease at day 29 but progressed by 
day 57. Patient 4 had stable disease at day 57 and received a second cycle of 
131
I-A5B7 prior to subsequent progression. Patient 6 had a minor response in an 
iliac lymph node with a fall in CA19-9 from 10507 on day 1 to 2033 IU/ml.  
 
As part of response assessment 4 patients had 
18
F-FDG-PET performed. 
Response assessment analysis was performed by visual analysis (blinded to 
patient identity and scan order) and by semi-quantitative analysis (Table 3.10) 
(251). All 4 patients assessed with FDG-PET had progressive disease at 4 and 
then 8 weeks. There was good correlation between FDG-PET and CT.  
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Table 3.10 Response assessment using FDG-PET semi-quantitative analysis 
The semi-quantitative analysis assumes the baseline value is 100 and all the subsequent scans 
are compared to that baseline value. Due to clinical progression there was no day 57 scan on 
patient 11.  
Patient No  Pre treatment Day 29 scan Day 57 scan 
2 100 128 237 
3 100 192 243 
9 100 393 1002 
11 100 214  
 
 
3.6.5 Dosimetry Data 
 
Nine patients had serial SPECT imaging performed for dosimetry. Patient 3 had 
no 4 hour scan, patient 10 did not receive 
131
I-A5B7 and patient 12 only had 1 
scan performed. Patient 4 had two cycles of 
131
I-A5B7 and data was collected for 
both treatments.  
 
Figure 3.1 shows the percentage of injected dose per kilogram in both normal 
organs and tumour. It demonstrates evidence of retention in tumour over time 
in contrast to normal organs.  Figure 3.2 and Figure 3.3 show the median 
absorbed radiation doses to normal organs and tumour respectively. The two 
graphs are not directly comparable, as the tumour-absorbed doses do not 
incorporate radiation doses from surrounding organs due to the limitations of 
the dosimetry program and the lack of co-registered SPECT and anatomical 
imaging. The absorbed dose to tumour is a relative under-estimation. In 
patients 5, 6, 8 and 9 radiation doses in tumour are higher than that found in 
normal organs (excluding lungs). 
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Figure 3.1  Normal organ and tumour % injected activity / kg 
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Figure 3.2 Median absorbed radiation doses to normal organs 
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Figure 3.3 Median absorbed radiation dose to tumour  
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3.6.6 Pharmacokinetics 
 
Pharmacokinetic analysis was performed for both CA4P and 
131
I-A5B7. The CA4P 
data was obtained after the 1
st
 infusion and included both CA4P and its 
metabolite CA4. The conversion of CA4P to CA4 occurred rapidly with an initial 
half-life of < 10 minutes. CA4 itself was then cleared from the plasma with a 
terminal half-life of 2 hours. Over the relatively narrow dose-range of CA4P in 
this study the clearance, half-life and volume of distribution were independent 
of the dose received, whereas peak concentration and the AUC were related to 
dose. These results are consistent with previous studies (265, 266).  
 
In 9 patients, the blood clearance of 
131
I-A5B7 could be modelled using a bi-
exponential model. Patient 10 withdrew prior to RIT administration, patient 11’s 
data did not fit this model and patient 12 had too few data points. In the 9 
evaluable patients an initial rapid clearance was observed with a second slower 
phase. As the parameters of the model varied widely between patients the time 
taken to fall to 50% and 90% was calculated; this was a median of 0.8 hours 
(range 0.3-17.5 hours) and 46 hours (range 2-77 hours) respectively. The 
clearance is faster than previously reported (94). It is likely the previous mono-
exponential model was due to an initial rapid early phase being missed. If the 
second clearance phases are compared the results are broadly similar; a range 
of 9.4-28 hours in this study and a mean of 28.6 hours in Lane et al (94).  
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Table 3.11 Pharmacokinetic data for CA4P at two dose levels 
Patien
t 
Dose CA4Pmax CA4P 
T½ 
CA4P 
T½ 
CA4P 
AUC 
CL Vss CA4max CA4 
T½ 
Tmax CA4 
AUC 
 
 
mg/m
2 
  µM h*** h** 
µmol. 
h.l
-1 
l.h
-1 
l µM h** h 
µmol 
.h.l
-1 
2 45 23.8 0.13 0.54 10.1 18.0  3.91 2.13 2.60 0.3 2.51 
3 45 13.1 0.06 0.064 4.34 34.3  4.08 2.81 1.60 0.2 1.75 
4 45 22.1 0.09 0.30 6.74 36.3  5.48 1.63 4.00 0.2 2.15 
5* 45 27.9 0.08 0.28 7.02 30.9  4.95 1.73 2.20 0.2 1.96 
6 45 27.8 0.1 0.62 7.88 27.6  5.04 5.41 0.81 0.3 4.04 
Mean  22.9 0.09 0.36 7.22 29 4.7 2.74 2.24 0.2 2.48 
SD 
 
6.05 0.02 0.22 2.08 7.2 0.7 1.56 1.19 
0.0
2 
0.91 
7†* 54 28.9 0.09 0.60 8.91 0.0  0.00 1.39 2.00 0.3 2.04 
8* 54 30.6 0.10 0.39 8.89 28.4  5.54 4.11 1.90 0.3 3.10 
9 54 31.8 0.07 0.30 7.97 26.6  3.92 2.97 3.20 0.3 4.14 
10* 54 35.3 0.06 0.30 8.43 36.2  5.05 4.23 1.60 0.2 2.67 
11* 54 28.9 0.09 0.45 8.09 37.1  6.44 4.70 1.60 0.2 4.65 
12 54 30.5 0.16 0.67 10.4 25.5  7.34 1.28 1.20 0.2 1.39 
Mean  31.0 0.09 0.45 8.78 26 4.7 3.11 1.92 0.2 3.00 
SD 
 
2.4 0.03 0.15 0.88 13 2.6 1.49 0.69 
0.0
7 
1.24 
 
† 18 min infusion, * extrapolated back to end of infusion from fit, ** terminal half-life, *** initial 
half-life, § Data from patient 1 missing due to contamination of samples  
AUC; area under the plasma concentration curve, CL; clearance, Vss; steady-state volume of 
distribution, Tmax; time to reach Cmax  
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Table 3.12 Pharmacokinetic data for 
131
I-A5B7 
Dose level 
131
I-labelled 
131
I-A5B7 
(MBq/m
2
) 
Patient 
number 
A0a 
(%ID/kg) 
A0b 
(%ID/kg) 
T½a 
(h) 
T½b 
(h) 
50.0% 
(h) 
10.0% 
(h) 
1800 1 25.3 12.0 0.4 11.5 0.6 19.4 
1800 2 11.5 9.2 0.2 21.5 0.5 46.0 
1800 3 72.9 21.3 0.9 14.9 1.2 17.5 
1800 4 87.3 11.6 0.3 9.4 0.3 2.0 
1800 5 6.6 11.6 9.3 26.6 17.5 71.0 
1800 6 23.3 14.7 0.4 28.0 0.8 54.5 
1600 7 8.6 10.6 10.0 23.0 15.0 59.0 
1600 8 38.5 4.6 0.4 22.3 0.5 3.0 
1600 9 4.3 12.2 1.3 26.8 15.0 77.0 
 Median     0.8 46 
 
A0a amplitude of the 1
st
 component of the bi-exponential clearance model, A0b amplitude of the 2
nd
 
component of the bi-exponential clearance model, T½a Half life of the 1
st
 component of the bi-
exponential clearance model, T½b   Half life of the 2nd component of the bi-exponential clearance model, 
%ID/kg; Percentage of injected dose per kilogram, 50% and 10% time taken for the modelled activity 
to fall to 50 or 10% of it’s initial value.  
 
3.6.7 Dynamic contrast enhanced MRI 
 
Patients had two MRI’s scans prior to study entry to assess intra-patient 
variability and a further MRI 4 hours post CA4P to study vascular change. In all, 
30 lesions were analyzed. By visual examination 9 lesions had a reduction in 
central enhancement at 4 hours. By objective measurement 3 patients (patients 
6, 7 and 10) had a significant or borderline reduction in both IAUGC60 and K
trans
. 
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Of the individual lesions assessed 3 of 30 had a significant or borderline 
reduction in IAUGC60 and 5 of 29 had reductions in K
trans 
(see Figure 3.4). 
 
 
Figure 3.4 Change in K trans with CA4P dose 
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The differences can be explained by tumour mobility and non-uniform 
reductions in central enhancement being easier to assess visually than 
objectively. The degree of responsiveness to CA4P was highly variable but less 
so if lesions in a single patient were considered. As the dose was increased to 
54mg/m
2
 a trend was demonstrated towards a greater reduction in tumour 
blood flow.  
 
3.6.8 Immunogenicity  
 
Nine patients developed HAMA after the first treatment with 
131
I-A5B7. The one 
re-treated patient (patient 4) became HAMA positive afterwards. Of the 2 
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remaining patients: patient 12 did not have a post-treatment measure and 
patient 10 did not receive any 
131
I-A5B7.  
 
3.7 Conclusions and Discussion 
 
The A5B7/CA4P study explored the combination of RIT with a VDA and has 
subsequently been published (276). The combination was considered rational 
due to the differing methods and sites of action within a tumour, as RIT targets 
the tumour rim and CA4P the poorly perfused centre (124). It was supported by 
the success of this combination in eradicating colon carcinoma xenografts in an 
animal model (123). The scheduling of CA4P 48 hours post 
131
I-A5B7 was 
designed to increase the RIC retention in tumour and was based on previous 
work, which demonstrated trapping up to 96 hours post (123).  
 
Although the toxicity profiles were thought to differ and the selected starting 
doses were below the MTD’s from the single agent studies (265-267), dose-
limiting myelosuppression occurred in the first cohort. This myelosuppression 
recurred despite a subsequent dose reduction to 1600 MBq/m
2
, considerably 
lower than the single-agent MTD of 2400 MBq/m
2  
(94). This excess toxicity 
cannot be explained by an increased red marrow absorbed dose as doses were 
similar between the two studies at 0.028 cGy/MBq in Lane et al (94) compared 
to 0.01cGy/MBq in our study. In addition no difference was seen in the 
pharmacokinetics between the two studies to explain such increased toxicity. 
 
An alternative explanation would be that CA4P has an additional cytotoxic effect 
similar to other microtubule-binding agents (277) that combined with radiation 
exposure led to a synergistic toxicity to bone marrow. However the single agent 
studies of CA4P have not demonstrated myelosuppression even at the highest 
doses of 114 mg/m
2
. Two studies combining chemotherapy (paclitaxel and 
carboplatin) with CA4P did not show an increased risk of myelosuppression 
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(278, 279). One study did show an increased risk, when the chemotherapeutic 
(here carboplatin) was administered 1 hour prior to low-dose CA4P (36mg/m
2
) 
(280). This increased toxicity was attributed to a temporary reduction in renal 
blood flow secondary to CA4P, resulting in an impaired carboplatin clearance.  
 
Alternatively it could represent the more heavily pre-treated patient group now 
than in the earlier phase I study by Lane et al (94). When that study was 
completed fewer chemotherapeutics were available as standard therapy with 
most patients having none or 5-FU (5-Fluorouracil) alone. In our study 9 of 12 
patients had 2 or more lines of chemotherapy with a subsequent loss of bone 
marrow tolerance.  
 
The sample size in this study was too small to assess for efficacy. It was 
disappointing that no patients had objective responses as seen in the original 
study by Lane et al (94) of single-agent RIT. This lack of response may be a true 
indicator of lack of efficacy or due to the more heavily pre-treated patient group 
or simply reflect the cohort size. Of note the percentage injected activity/kg in 
tumour in our study was lower than in the single agent study (94) with values of 
2.15% at 4 hours versus 4.4% at 4.25 hours in Lane et al (94). 
 
One patient did achieve a minor response with a corresponding decrease of 
CA19-9 from 10,507 IU/ml to 2,033 IU/ml. This patient had both the highest 
absorbed tumour radiation dose and a significant decrease in IAUGC post CA4P, 
being the only patient to have a significant biological response to both agents. 
The majority of patients failed to demonstrate adequate vascular shut down on 
DCE-MRI, possibly due to the relatively low dose of CA4P administered. Patient 
10, who did achieve the highest K
trans
 recorded, unfortunately did not proceed 
to the RIC due to severe tumour pain secondary to CA4P.  
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Scheduling is vital when combining RIT with other agents to minimise toxicity 
and ensure maximum efficacy. The CA4P was given at 48 hours post RIT to 
ensure trapping of the RIC in tumour as anticipated by previous animal work 
(123). CA4P administration prior to RIT is thought to prevent the RIC accessing 
tumour reducing any likely benefit as occurred when cisplatin was given post-
CA4P (281). 
 
In our study CA4P was administered 1-2 weeks prior to 
131
I-A5B7 to assess 
pharmacokinetics. As blood flow had previously been shown to normalise 24 
hours post-CA4P (262) it is unlikely this administration could impede tumour 
uptake of the RIC. In support of this no relationship existed between the extent 
of vascular shut down on DCE-MRI and subsequent tumour uptake determined 
by dosimetry. The patients with the greatest disruption of blood flow on DCE-
MRI did not have a reduced tumour absorbed dose after 
131
I-A5B7.  
 
Our study demonstrated 
131
I-A5B7 did specifically target tumours. Tumour 
uptake was relatively low at 4 hours compared to normal organs but higher at 
68 hours, a pattern consistent with the slow uptake of a whole antibody. 
Tumour localisation was lower than in the single agent 
131
I-A5B7 study (94). This 
may be due to loss of CEA antigen expression in this more heavily pre-treated 
group of patients. Uptake to normal organs, excepting lung, remained low (< 0.3 
mGy/MBq). The apparent high absorbed dose to lung may be due to difficulties 
in attenuation correction in the thorax, a heterogeneous uptake due to the 
inclusion of blood vessels or the proximity to the heart. 
 
Tumour absorbed dose was likely to be under-estimated in our calculations. For 
target organs the dose from neighbouring organs is included but this was not 
possible for tumours where only the self-dose was calculated. Co-registration of 
SPECT with CT, to allow accurate delineation of size, shape and relative position 
of the organs and tumour will be important in future. In addition tumour uptake 
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is known to be very heterogeneous whereas estimated dosimetry calculations 
assume uniformity. That assumption means dosages to the well-perfused viable 
area of tumour may be under-estimated. Even with these caveats the tumour 
absorbed dose in 4 patients was higher than in all normal organs excepting lung.  
 
In conclusion, the combination of RIT and a VDA was found to be unexpectedly 
toxic and no objective responses were seen. In one patient (patient 6) who 
experienced both a reduction of blood flow on DCE-MRI secondary to CA4P and 
a higher than average tumour absorbed dose on dosimetry there was evidence 
of efficacy with a fall in tumour markers and a minor radiological response.   
 
Improvements in the delivery of RIT and the potency of the VDA may enhance 
efficacy. Possible improvements include the use of humanized antibodies to 
allow repeat dosing, antibody fragments such as minibodies, diabodies or scFv’s 
(45) and more potent VDAs such as DMXAA (269). In addition RIT may be 
directed against better targets such as the more accessible tumour vasculature 
(282). 
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Chapter Four: Biomarkers for Vascular Disruptive Agents  
 
In the Introduction I discussed the need for an adequate biomarker to assess 
the degree of vascular shut down induced by the Vascular Disruptive Agents. A 
biomarker would ensure that the optimal biological dose is used to generate 
maximal vessel shut-down and would enhance the integration of the two 
therapeutic modalities more successfully. I have discussed imaging methods of 
assessing vascular shutdown, particularly DCE-MRI and PET-CT and considered 
their advantages and disadvantages. Finally I considered using serum angiogenic 
cytokines. These have the advantages of being simple to obtain allowing serial 
measurements and having quantitative validated methods of analysis that 
should be possible in standard laboratories.  
 
In this study I decided to investigate four angiogenic cytokines, VEGF (Vascular 
Endothelial Growth Factor), Angiopoietin 1 and Angiopoietin 2, Erythropoietin 
and basic Fibroblast Growth Factor (bFGF or FGF2). In this chapter I shall initially 
summarise the physiological role of cytokines in normal angiogenesis before 
considering each cytokine individually and their role in HCC and post-TAE since 
this is the model I intended to use. I shall then present the results of assessing 
angiogenic cytokines in the context of HCC.  
 
4.1 The role of angiogenic cytokines in angiogenesis  
 
4.1.1 Physiological  
 
Physiological angiogenesis is a tightly regulated process that allows vascular 
remodelling to occur under the influence of a variety of cytokines. It can either 
be sprouting or non-sprouting (283). Non-sprouting angiogenesis occurs by 
vessel splitting via trans-capillary pillars. Sprouting is shown in Figure 4.1. After 
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pericyte removal secondary to angiopoietin-2 (Ang-2), vessels become leaky 
with extravasation of proteases. The basement membrane and interstitial 
matrix dissolves leaving the endothelial cells exposed to cytokines such as VEGF. 
Endothelial cell proliferation occurs and migration towards angiogenic stimuli 
with lumen formation. The pericytes are then replaced under the influence of 
Angiopoietin-1 (Ang-1) to stabilise the new vessel. 
 
 
Figure 4.1 Physiological Angiogenesis 
 
Physiological angiogenesis (adapted from Bach et al 2006)
Endothelial cell
Pericyte
a b c
d e f
Ang-2 VEGF, FGF, EGF
Αvβ3 Integrin, 
VEGF, FGF
FGF,PDGF, TNF-α, 
ephrin 2A PDGF, Ang1/Tie2 TGF-α
g
VEGF/ Ang-1
 
a) Ang-2 binding to Tie2 on endothelial cells (EC) with subsequent pericyte and 
smooth muscle removal 
b) EC proliferation occurs secondary to cytokines such as VEGF 
c) Cell migration occurs secondary to cytokines such as FGF 
d) Tube formation  
e) Mesenchymal cells are attracted to the ablumenal side of the vessel 
f) Cells are induced to differentiate into pericytes 
g)   Vessel stabilisation. VEGF and Ang-1 are survival factors for EC’s 
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4.1.2 Pathological angiogenesis  
 
Angiogenesis is vital for tumours to develop beyond 1-2mm
3
 and to allow 
invasion and metastasis (284). Pro-angiogenic cytokines are either secreted by 
the tumour or secondary to tumour hypoxia or change in pH. For example the 
presence of Angiopoietin-2 in the absence of VEGF leads to tumour vessel 
regression. Subsequent tumour necrosis and hypoxia generates VEGF secondary 
to HIF-1α and the combination with Angiopoietin-2 causes rapid angiogenesis.  
 
Tumours may also co-opt existing vasculature or use vascular mimicry where 
tumour cells act like endothelial cells (285). Endothelial progenitor cells may be 
recruited from the bone marrow and localise to tumour vessels. The result of 
this chaotic angiogenesis is a more disorganised vasculature with areas of 
inadequate blood supply (286).  
 
4.1.2.1 The angiogenic switch hypothesis 
 
This hypothesis considers that the absolute level of any one cytokine is less 
important than their relationship to other cytokines. When pro-angiogenic 
cytokines exceed anti-angiogenic ones, there is a ‘switch’ in the system and 
angiogenesis is favoured. This switch is thought to be essential to the malignant 
process (287).  
 
4.2 Vascular endothelial growth factor (VEGF) 
 
The first angiogenic cytokine to be discovered was VEGF. The protein was 
identified in 1983 and initially called ‘vascular permeability factor (VPF)’ due to 
its role in increasing vessel leakage (288). It was cloned independently by two 
separate groups (289, 290) and renamed VEGF. 
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4.2.1 Structure 
 
The VEGF family consists of 6 secreted glycoproteins named VEGF A to E and 
placental growth factor (PIGF) 1&2 (284). Different isoforms are produced by 
alternative splicing. Shorter isoforms tend to be secreted whereas the longer 
are sequestered in the extra-cellular matrix, from where they can be activated 
by proteases. The commonest isoform is VEGF165 which exists in both a soluble 
and extracellular matrix bound form (287).  
 
VEGF acts via 3 tyrosine kinase receptors and neuropilin-1 and 2. VEGFR-1 (Flt-1) 
and VEGFR2 (KDR or Flk-1) share 44% homology and are predominantly involved 
in angiogenesis (287). They are located on endothelial cells and various 
haematopoietic cell lineages. VEGFR-3 (Flt-4) is predominantly involved in 
lymphangiogenesis (287). 
 
4.2.2 Function 
 
VEGF is a pivotal protein in angiogenesis and vasculogenesis. Its inactivation in 
mice leads to early embryonic lethality (291). Post-utero VEGF-A appears 
necessary for wound healing, ovulation, menstruation, pregnancy and 
regulation of blood pressure (287). VEGF-B is thought to be redundant; its loss 
causes no defects in embryogenesis. VEGF C&D are necessary for 
lymphangiogenesis whilst VEGF-E is exclusively a viral protein (287).  
 
VEGF release is regulated by various genes (e.g. Ras), transcription factors (e.g. 
HIF) growth factors and cytokines (e.g. IGF-1). Activation of VEGF triggers 
endothelial cells to proliferate, survive, migrate and differentiate, vascular 
permeability is enhanced and protein extravasation promoted from blood 
vessels (284) as well as mobilisation of endothelial progenitor cells from bone 
marrow.   
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4.2.3 Tumour expression of VEGF 
 
VEGF is over-expressed in many tumours. Expression is greatest next to areas of 
necrosis (292), in malignant cell cytoplasm and on associated endothelial cells. 
High expression correlates with a poorer prognosis and the presence of late 
stage disease in many cancers including lung, breast, colorectal, gastric, 
pancreatic, HCC (Hepatocellular cancer), prostate and ovarian cancer (284). In 
some cancers it is an independent prognostic factor for survival (293) whilst no 
relationship was found in others (292). 
 
4.2.4 Secreted VEGF 
 
VEGF is found in higher concentrations in the serum or plasma of cancer 
patients than in healthy individuals (294). It is thought to be tumour-derived as 
levels fall post surgical resection (294). The level of secreted VEGF have been 
found to correlate with a poorer prognosis and an advanced stage of disease 
(284, 295) in breast, small cell lung (where it was an independent prognostic 
factor), non-small cell lung, colorectal, gastric, HCC, prostate, bladder, renal cell 
and ovarian cancer (284).  
 
High VEGF levels have predicted a poorer response to chemotherapy (296), 
radiotherapy and immunotherapy (297). Human circulating VEGF falls on 
tumour resection, with some evidence of a rise on relapse (284). In gastric 
cancer VEGF levels could distinguish between a partial response and progressive 
disease (298).  
 
However other studies have not confirmed that VEGF correlates with prognosis 
and in many tumour types, including ovarian cancer, the data remain 
contradictory (299) with little consensus as to the value of VEGF. In HCC a 
recent meta-analysis of 8 studies found did predict a poorer overall survival and 
 157 
progression-free survival in patients with an elevated serum VEGF but all but 
one of those studies was carried out in the Asian population with a differing mix 
of aetiologies (300). Although VEGF levels are higher in advanced disease in 
these tumour types (284) it has proved disappointing as a biomarker. Levels of 
VEGF are variable and often remain low even in advanced disease. When they 
do rise they often rise relatively late in the disease process, making them 
unsuitable as a biomarker.  
 
4.2.5 Measuring secreted VEGF – serum or plasma? 
 
Serum VEGF is higher than plasma VEGF as it includes VEGF derived from 
platelets during coagulation (284). Platelets are thought to scavenge circulating 
VEGF, thereby restricting it to sites of coagulation (e.g. wounds) and preventing 
general EPC (Endothelial progenitor cell) recruitment (301). In support of this, 
platelet VEGF levels are higher in cancer patients (302) and tumour VEGF 
expression correlates well with the platelet-derived VEGF level (301). George et 
al used the serum VEGF normalized by the platelet count (303), considering 
plasma samples potentially more inaccurate as their lower values were closer to 
the limits of detectability by ELISA.  
 
4.2.6 Angiogenic cytokines in HCC: VEGF 
 
In HCC both tumour and tumour-associated endothelial cells over-express VEGF, 
the latter also over-express VEGFR-1 (Vascular Endothelial Growth Factor 
Receptor) and VEGFR-2 (304). Expression is highest at tumour boundaries (305) 
and correlates with MVD and hypervascularity. In animal models stimulating 
VEGF led to tumour growth and neo-vascularisation (304). Some human studies 
correlated VEGF expression with more invasive tumours and a poorer prognosis 
(145) but other did not. VEGF interacts with other cytokines and Moon et al 
demonstrated correlation between VEGF protein and Ang-2 mRNA (306). 
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Serum and plasma VEGF rise in HCC (307). An elevated serum VEGF predicts a 
poorer outcome post resection (308), TACE (trans-arterial chemo-embolisation) 
(309) and radio-frequency ablation (RFA) (310). In a meta-analysis, where all but 
1 study was in the Asian population, an elevated serum VEGF was associated 
with a poorer survival (300). Serum VEGF is an independent prognostic factor 
and associated with other poor prognostic factors such as portal vein 
thrombosis and advanced tumour stage (307). 
 
4.3 Angiopoietins 1 and 2  
 
Angiopoietins are secreted glycoproteins. Four family members have been 
identified (Ang1-4) of which Ang-1 and Ang-2 are the best characterized (311) 
sharing 60% homology. They both interact with the Tie-2 (tyrosine kinase with 
immunoglobulin and epidermal growth factor homology domains-2) receptor as 
competitive inhibitors binding on the same site with similar affinity (311). Ang-1 
is an agonist whereas Ang-2 is the antagonist so Tie-2 activation depends on the 
relative balance of Ang-1 and Ang-2.  
 
The Tie-2 receptor is almost exclusively expressed on endothelial cells and 
haematopoietic cells. As tumour cells express Ang-1 and Ang-2 an autocrine / 
paracrine feedback loop may exist (312).  
 
4.3.1 Angiopoietin-1 (Ang-1) 
 
4.3.1.1 Structure of Angiopoietin-1 
 
Alternate gene splicing produces 3 forms of angiopoietin-1 but only one can 
activate Tie-2. It exists in a coiled-coil structure allowing dimerization and super-
clustering into heterogeneous multimers. At least 4 subunits are required to 
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activate Tie-2 (313) but larger clusters are less effective. The coiled-coil 
structure can bind and inactivate other angiopoietins.  
 
Angiopoietin-1 is widely expressed in many cell types and tissues including peri-
endothelial cells (smooth muscle and pericytes), fibroblasts, megakaryocytes 
and platelets (311). It is constitutively expressed in healthy individuals (314).  
 
4.3.1.2 Function of angiopoietin-1 
 
Ang-1 has a central role in promoting blood vessel development, remodelling 
and maturation, acting in a paracrine manner (315). It enhances endothelial cell 
survival, quiescence and maturation, encourages recruitment of peri-
endothelial cells (pericytes and smooth muscle cells) and localization of cell 
adhesion molecules leading to vessel stability (316, 317). It reduces vessel 
permeability and is anti-inflammatory. In cell line work Ang-1 promotes 
endothelial cell migration, tube formation and cell survival but not proliferation 
(318).  
 
Knock-out of Ang-1 in mice leads to early embryonic death. Vasculature is 
abnormal, lacking complexity and with poor association between endothelial 
and support cells (319). Post embryogenesis Ang-1 is thought to maintain the 
mature quiescent vasculature. The relationship with Ang-2 appears context 
dependent and in the brain Ang-1 appears to increase vascularisation in synergy 
with VEGF (320).  
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4.3.2 Angiopoietin-2 (Ang-2) 
 
4.3.2.1 Structure of Angiopoietin-2 
 
Angiopoietin-2 also has a coiled-coil structure and a fibrogen like domain found 
in other proteins such as fibrinogen and tenascin (311). It interacts with the Tie-
2 receptor in an autocrine manner (314) and its expression is tightly regulated. 
Ang-2 is secreted by endothelial cells at sites of vascular remodelling with 
secretion induced by shear stress, hypoxia and VEGF release. Ang-2 may be 
stored in specialized endothelial-cell granules, the Weibel-Palade bodies and 
secreted as required (162).  
 
4.3.2.2 Function of Angiopoietin-2 
 
Ang-2 binds to Tie-2 and prevents Ang-1 from activating it (311). Ang-2 is vital 
for vascular remodeling. In the presence of VEGF vascular sprouting and 
angiogenesis occur, but in its absence there is vascular regression such as in 
atretic follicles (319). Ang-2 generates a destabilized vasculature with 
dissociated support cells and greater access for cytokines such as VEGF.  
 
Mice deficient in Ang-2 appear to develop normally in-utero (except those with 
C129 genetic backgrounds) but die within 2 weeks of birth (321). Abnormalities 
are seen in the neonatal eye and in post-natal lymphatics. Mice with over-
expressed Ang-2 have similar defects (and embryonic lethality) to those with 
knocked out Ang-1 or Tie-2 (322). The normal expression of Ang-2 is restricted 
post-natally to sites of vascular remodelling, the ovaries, uterus and placenta 
(323). Ang-2 levels increase up to 15-fold with hypoxia (324). 
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4.3.3 Summary of angiogenic cytokines in various vessel states 
 
Bach et al considered how the effects of a single cytokine depend on the values 
of other angiogenic cytokines (325)(see Table 4.1).  
 
Table 4.1 Summary of angiogenic cytokines in various vessel states 
 Maturation  Regression  Proliferation 
Ang-1 High Low  Low  
Ang-2 Low High High 
VEGF High Low High 
 
4.3.4 Angiopoietins and Cancer  
 
4.3.4.1 Angiopoietin-2 
 
Colorectal and gastric cancer cells transfected to over-express Ang-2 and grown 
in nude mice generate larger, more vascular and more invasive tumours that are 
more likely to metastasize (325, 326) than controls. Blocking Ang-2 led to 
tumour stasis or response (325). Combining Ang-2 with VEGF in a murine model 
of HCC decreased apoptosis and increased MMP (matrix metallopeptidase)-2 
and 9 rather than enhancing tumour cell proliferation (327). The pro-angiogenic 
effect of Ang-2 on tumours appeared more important in early development 
than their later stages (328).  
 
Ang-2 expression is elevated in many human cancers (see Table 4.2) including 
renal, gastric, breast, angiosarcoma, colon, pancreatic (neuroendocrine and 
adenocarcinoma), HCC and NSCLC (Non-small cell lung cancer) (325).  
Expression appears greatest in the more vascular tumours and adjacent to areas 
of hypoxia and necrosis. The Ang-2 source may be the tumour-associated 
endothelial cells rather than tumour cells (314). Its over-expression is often 
associated with a more advanced stage and a poorer prognosis.  
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Table 4.2 Tumour over-expression of Angiopoietin-2 
Tumour type Association Ang-2 over-expression Reference 
Gastric Increased stage and vascular 
involvement. Poorer survival  
Etoh et al (246) 
 
Breast Lymph node spread, shorter PFS and 
poorer survival.  
Correlated with Her-2 over-expression 
Sfiligoi et al (249) 
 
HCC Poorer survival, increased MVD and 
tumour size.  
Mitsuhashi et al (250) 
 
NSCLC Increased stage. Poorer survival 
(especially if high VEGF). Independent 
prognostic factor 
Takanami et al (251) 
Tanaka et al (252) 
 
Bladder  Poorer survival and worse grade and 
stage 
Oka et al (253) 
 
Prostate Higher Gleason score, increased risk 
of metastatic disease, poorer survival  
Lind et al (254) 
 
Colorectal Ang-2 expression higher in metastatic 
disease. 
Tait et al (244) 
 
† PFS: Progression Free Survival 
 
4.3.4.2 Angiopoietin-1 
 
Ang-1 over-expression in tumour-bearing mice leads to smaller tumours, fewer 
and more mature tumour-associated blood vessels with a greater coverage by 
peri-endothelial cells and a reduced permeability (325).  
 
Ang-1 expression is highly variable between tumour types and its role in tumour 
angiogenesis somewhat controversial (316). Many tumour types express high 
levels of Ang-1, which theoretically should reduce angiogenesis and tumour 
growth (314, 329, 330). High Ang-1 expression in renal cancer was associated 
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with low-grade tumours and a better prognosis. Other studies have found no 
differences in Ang-1 expression between tumour and normal tissue (324, 331). 
A reduced Ang-1 (and normal Ang-2) expression has been found in ovarian (332) 
and colorectal cancer (333).  
 
4.3.4.3 Ratio of Angiopoietin-2 / Angiopoietin-1 
 
As the angiopoietins are competitive inhibitors their ratio might be more 
accurate than their individual levels. In HCC a high Ang-2/Ang-1 ratio was 
associated with a larger tumour size, portal vein thrombosis and a higher MVD 
(334). An increased ratio is seen in NSCLC (335), prostate cancer, oral squamous 
cell cancer and ovarian cancer (325) amongst others (see Table 4.3).  
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Table 4.3 Ratio of angiopoietin expression in tumour tissue 
Adapted from Tait et al (244) 
Tumour  Ang-1 Ang-2 Ratio 
Ang2:Ang1 
Reference 
Breast  
 
 
Up 
Down 
Up 
Up 
Down 
Up 
Up 
Up 
Not clear 
Sfiligoi et al (249) 
Currie et al (261) 
Canine et al (262) 
HCC No change 
No change 
Up 
Up 
Up 
Up 
Up 
Up 
Up 
Up 
Up 
Up 
Tanaka et al (257) 
Mitsuhashi et al (250) 
Moon et al (263) 
Sugimachi et al (264) 
Colon No change 
No change 
No change 
Up 
Up 
Up 
Up 
Up 
Up 
Yoshida et al (265) 
Ahmad et al (259) 
Ogawa et al  (266) 
Lung Down 
Up 
Up 
Up 
Up 
Up 
Up 
Not clear 
Not clear 
Wong et al (260) 
Tanaka et al (252) 
Hatanaka et al (267) 
Gastric No change Up Up Etoh et al (246)  
Ovarian No change 
Down 
Up 
No change 
Up 
Up 
Zhang et al (268) 
Hata et al (258) 
Melanoma No change Up Up Pomyje et al (269) 
Renal  No change Up Up Currie et al (270) 
 
4.3.4.4 Secreted angiopoietins in cancer 
 
Serum angiopoietin-2 levels are higher in many cancer patients than in normal 
healthy controls. An elevated angiopoietin-2 is present in ovarian cancer (336), 
colorectal cancer (337), gastric cancer (338), cervical cancer (339), melanoma 
(340), neuroendocrine tumours (341) and lung cancer (342). It is often 
associated with poor prognostic clinico-pathological features and may itself be 
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an independent prognostic factor (337). In colorectal cancer patients given 
bevacizumab, a low serum Ang-2 was associated with better response rates, 
longer progression-free survivals and a reduction of 91% in the hazard of death 
(343).  
 
Secreted angiopoietin-1 has been less extensively studied. In many tumour 
types it is not significantly different to healthy controls (341, 344, 345). Park et 
al found a reduced serum Ang-1 level in lung cancer and a negative correlation 
with MVD. An elevated Ang-1 was associated with an improved disease specific 
and relapse free survival (342). 
 
4.3.4.5 Angiogenic cytokines in HCC: Angiopoietins 
 
Ang-1 and 2 are expressed in HCC tumour cells with Ang-2 present in the most 
poorly differentiated tumours and adjacent to areas of cirrhosis (305, 306, 331, 
346). In some studies Ang-2 is higher in HCC cells, in others in the adjacent 
cirrhosis (334). Zeng et al reported Ang-2 expression as similar between normal 
liver, cirrhotic liver and HCC on a background of cirrhosis (347). The reason for 
these discrepant findings remains unclear although it may relate to tumour 
heterogeneity with expression profiles of the tumour rim differing from the 
hypoxic centre.  
 
Ang-2 expression in HCC correlates with a more aggressive tumour grade, 
poorer prognosis (305), an increased vascularity and an earlier recurrence (346). 
Ang-1 expression had no impact on prognosis or survival (346).  Wada et al 
found both Ang-1 and Ang-2 expression were elevated in HCC.  Patients with a 
high Ang-2: Ang-1 ratio had a worse prognosis and a higher MVD (334). 
 
Scholz et al (348) found serum Ang-2 was elevated in cirrhosis and further 
elevated in HCC. The addition of Ang-2 to AFP (alpha fetoprotein) improved the 
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diagnosis of HCC in patients with cirrhosis. Serum Ang-2 did not correlate with 
clinico-pathological characteristics in this retrospective study, unlike in the 
tissue expression data.  
 
4.4 Basic fibroblast growth factor (bFGF) 
 
FGF-2 (basic FGF or heparin binding growth factor-2) belongs to a large family of 
18 fibroblast growth factors that are grouped into 6 subfamilies with sequence 
homology of 30-50% (349). 
 
4.4.1 Structure of b-FGF 
 
Basic FGF has a core region of 120-130 amino acids in 12 anti-parallel β−strands. 
It contains the heparan sulphate glycosaminoglycan binding site, heparan 
sulphate is necessary for successful signaling (350) via trans-membrane tyrosine 
kinase receptors (349). 
 
4.4.2 Function of b-FGF 
 
The function of bFGF remains controversial. If the bFGF gene is knocked out in 
mice, vascular tone is reduced and there is a weaker response to 
vasoconstrictors, with some reduction in cortical neurones (351) but the mice 
are viable. bFGF may have a role in inflammation leading to smooth muscle 
hyperplasia (352). It causes fibroblast proliferation and can stimulate 
angiogenesis by encouraging endothelial cell migration and proliferation, tube 
formation and disruption of the basement membrane (353). Basic FGF appears 
to act synergistically with VEGF (354). 
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4.4.3 B-FGF in cancer 
 
Basic FGF is over-expressed in many cancers (355), including lung, colon, gastric, 
pancreatic, HCC, bladder and head and neck (284). In some studies bFGF was 
associated with more advanced disease and a poorer prognosis but others 
showed no difference (284, 356). An elevated b-FGF may be associated with an 
improved prognosis as more aggressive tumours may lose b-FGF-expressing 
myoepithelial cells. In ovarian cancer B-FGF appears to promote fibroblast 
production and more indolent tumours (357).  
 
Serum bFGF is elevated in some cancer patients and is thought to be tumour 
derived (284). Its significance is unclear. In breast cancer no correlation could be 
determined between elevated serum bFGF and prognosis or tumour stage 
(358). In NSCLC patients on radiotherapy an elevated bFGF was associated with 
a better outcome, attributed to more fibrosis (359). Results in colorectal and 
prostate cancer were inconclusive (284). Studies in HCC and renal cancer had a 
positive correlation between high serum bFGF and advanced stage (284, 360). In 
head and neck cancer serum bFGF predicted survival post chemo-radiotherapy 
and was an independent prognostic marker (361). In cervical cancer bFGF rose 
prior to disease relapse and is being investigated as a biomarker (362). 
 
4.4.3.1 Angiogenic cytokines in HCC: bFGF 
 
bFGF expression is elevated in HCC compared to normal or surrounding liver 
(350) and correlates with MVD but not hypervascularity as determined by 
angiography (363). Poon et al found a correlation between serum bFGF and risk 
of recurrence post resection (364) but this has not been confirmed (365). Serum 
bFGF could be correlated with advancing stage in HCC but values were not 
different from patients with Cirrhosis alone (360).  
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4.5 Erythropoietin 
 
Erythropoietin (Epo) is a glycoprotein hormone (366) produced mainly in the 
foetal liver and adult kidney. It acts to regulate the production of red blood cells 
by the bone marrow, acting via its specific receptor EpoR (Erythropoietin 
receptor).  
 
4.5.1 Structure of Erythropoietin 
 
Erythropoietin is comprised of 165 amino acids. Its receptor is a member of the 
type I cytokine receptor super-family that includes receptors for many 
interleukins and haematopoietic growth factors (367). EpoR expression is tightly 
regulated with its mRNA (messenger ribonucleic acid) having a short half-life of 
90 minutes (368). 
 
4.5.2 Erythropoietin Function 
 
Erythropoietin secretion is stimulated by hypoxia (HIF-1 (368)), hypoglycaemia, 
intracellular calcium, insulin, oestrogen, androgenic steroids and other 
cytokines (369). Erythropoietin stimulates erythroid cells to proliferate and 
differentiate into mature cells and reduces apoptosis thereby increasing blood 
haemoglobin (370). Mice with the erythropoietin gene knocked out die in-utero 
with abnormal liver erythropoiesis, angiogenesis defects and increased 
apoptosis of endothelial and myocardial cells (371). Activating mutations cause 
a primary erythrocyotosis.  
 
Erythropoietin is expressed on erythrocytes but also stem cells in the embryonic 
nervous system, uterus and ovary (372). It may protect cells from ischaemia and 
toxic stress (368) via an anti-apoptotic mechanism (373). EpoR is found on 
endothelial cells with activation causing endothelial cell proliferation and 
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migration in vitro (374). Exogenous Epo can lead to in vivo neo-vascularisation 
in chick embryos (375). 
 
4.5.3 Erythropoietin in Cancer 
 
The exogenous administration of erythropoietin in cancer patients increases 
haemoglobin levels and improves quality of life (376) but two randomized 
studies found patients on Epo had a poorer outcome (377, 378) possibly due to 
stimulation of cancer growth. A third randomised study found any stimulatory 
effect was only present in tumours that expressed EpoR (378). 
 
An elevated EpoR expression is found in many tumour types as shown in Table 
4.4 but expression may not indicate receptor activity. Activity can be 
demonstrated by downstream signalling and proliferation secondary to 
exogenous Epo. Downstream signalling has been identified in cell lines (379) 
although with low levels of proliferation. Blocking signalling in xenografts 
reduced tumour vascularity (368), tumour cell survival and angiogenesis but had 
no effect on red blood cell formation.  EpoR activation has been detected in 
melanoma (380), uterine and cervical carcinoma (381). In contrast, four studies 
of exogenous Epo in cell lines expressing EpoR found no increase in tumour cell 
proliferation (382-385) and no signal transduction. 
 
In patients exogenous Epo improved tumour oxygenation independently of 
haemoglobin (386), which may reduce the hypoxic stimulus for cytokine release. 
Sensitivity to chemotherapy and radiotherapy increased with no increase in 
MVD or tumour growth in animal models (387, 388). Therefore the poorer 
results in the randomized studies of exogenous Epo remain controversial.  
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Table 4.4 Erythropoietin and Erythropoietin Receptor Tumour  Expression 
Table adapted from Hardee et al (316). It details whether either Erythropoietin 
(Epo) or the Erythropoietin Receptor (EpoR) were found expressed on tumour 
cells. The methods used are also identified in column 2. IHC was expressed semi-
quantitatively in these studies.  
Primary tumour  Method used Expression of: Reference 
Breast  IHC Epo
+
 and EpoR
+
 Acs et al (309) 
Melanoma IHC Epo
+
 and EpoR
+
 Kumar et al (310) 
Cervical SCC 
Cervical ADC 
RT-PCR 
RT-PCR 
Epo
+
 and EpoR
+
 
EpoR
+
 
Yasuda et al (317) 
Yasuda et al (317) 
Endometrial 
carcinoma 
IHC Epo
+
 and EpoR
+
 Acs et al (318) 
Ovarian ADC RT-PCR Epo
+
 and EpoR
+
 Yasuda et al (317) 
Gastric ADC IHC EpoR
+
 Ribatti et al (319) 
Colon tumour  RT-PCR, WB EpoR
+
 Arcasoy et al (320) 
Head and neck  IHC Epo
+
 and EpoR
+
 Arcasoy et al (321) 
Lung ADC and SCC RT-PCR, IHC Epo
+
 and EpoR
+
 Dagnon et al (322) 
Prostate ADC IHC Epo
+
 and EpoR
+
 Acs et al (311) 
 
IHC: Immunohistochemistry; RT-PCR: Reverse transcription polymerase chain reaction; WB: 
Western blot 
 
4.5.3.1 Angiogenic cytokines in HCC: Erythropoietin 
 
In a murine model of HCC erythropoietin expression was higher in tumour cells 
than cirrhotic ones and absent in mice with cirrhosis without HCC (372). In 
human HCC, Epo and EpoR were strongly over-expressed on tumour-associated 
endothelial cells with weaker expression on sinusoidal cells in adjacent cirrhosis 
(389). Epo/EpoR expression was found to positively correlate with tumour grade 
and vascularity.  
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Erythrocytosis is present in 2-12% of patients with HCC and increases with 
advancing tumour stage. It is associated with an elevated serum erythropoietin 
(390, 391).  
4.6 Cytokines post TAE 
 
As discussed in the Introduction we decided to use a model to represent 
vascular shut-down. The model we chose was Trans-arterial embolisation (TAE). 
TAE has the advantage of a more definitive time of vascular shut-down and 
there are greater numbers of patients undergoing this procedure compared to 
the small numbers of patients on a Phase I study of a VDA.  
 
It is known that TAE leads to profound tumour hypoxia which would be 
anticipated to stimulate pro-angiogenic cytokine release (392). Indeed this may 
be an important mechanism by which tumour vasculature recovers post TAE 
(393).  
 
In an animal model of TACE, both VEGF and HIF-1α were observed to rise post-
procedure by day 7 (394).  This rise in VEGF could be attenuated by blocking 
HIF-1α transcription. Shim et al found serum VEGF rose at day 1-2 post TACE 
returning to baseline by day 21 (395) and was an independent prognostic factor 
in HCC. If VEGF increased by > 50% post TACE there was a higher risk of extra-
hepatic disease within 6 months and a poorer prognosis (308). Post TACE the 
highest VEGF expression is at the boundaries between necrotic and viable 
tissue. bFGF is not known to rise post TAE and there is no data on the 
angiopoietins and erythropoietin.  
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4.7 Methods 
 
In this study we analysed serum concentrations of VEGF, Ang-1 and -2, bFGF 
and erythropoietin in a cohort of patients with HCC and two control cohorts, 
one with cirrhosis and the other healthy controls. We performed univariate and 
multivariate analysis to identify factors predictive of survival and, in a subset, 
explored changes in serum cytokine levels before and after trans-arterial 
embolisation. 
 
4.7.1 Sample collection and analysis 
 
Venous blood (6ml) was collected in serum separator tubes, kept at room 
temperature and allowed to clot for 30 minutes being centrifuged at 2400rpm 
for 15 minutes. They were aliquoted into 100µl portions and stored at -80˚C 
until analysis. Freeze-thaw cycles were avoided. 
 
Serum cytokine concentrations were determined by the relevant Quantikine 
Immunosorbent assay kit according to manufacturer’s instructions. The Ang-1, 
Ang-2 and VEGF assays were all Quantikine®, the Erythropoietin was 
Quantikine® IVD® and the FGF Basic assay was Quantikine® HS (R&D systems, 
Minneapolis, MN). These assays have previously been shown to be 
reproducible. They are quantitative sandwich immunoassays using an 
immobilized murine monoclonal antibody and a second monoclonal or 
polyclonal antibody, both to react with the relevant cytokine and having no 
cross-reactivity to other cytokines. The cytokine concentration was determined 
by interpolation to a standard curve generated from known standard 
concentrations of cytokine. Face-masks were worn to prevent contamination of 
the samples as VEGF, Ang1&2 and bFGF (alkaline phosphatase) are present in 
saliva. All samples were assayed in duplicate. A typical method is described 
below.  
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VEGF 
A known VEGF (recombinant VEGF165) concentration (2000 pg/mL) was used to 
create a dilution series. 100 µL of sample was used per well (coated with murine 
monoclonal anti-VEGF antibody) and 100 µL of assay dilutent (buffered protein 
base). Incubation was for 2 hours at room temperature after which the plate 
was aspirated and washed using a multi-channel pipette. A minimum of 6 
washes was performed after which the plate was inverted against paper towels 
to dry. 200 µL of VEGF conjugate was added (polyclonal anti-VEGF antibody 
conjugated to horseradish peroxidase) and incubated and washed as described 
above. 200 µL of substrate was added (50:50 mix of hydrogen peroxide and 
chromogen; mixed within 15 minutes of use and protected from light). The 
plate was incubated for 25 minutes in the dark before 50 µL of 2N sulfuric acid 
was added to stop the reaction. The plate was read with a microplate reader at 
450nm and wavelength correction at 550nm. Values could then be read from a 
standard cure generated from the dilution series. Differences in methodology 
with the other cytokines are detailed below.  
 
Differences with the other cytokines  
• Patient serum was diluted (15 fold for Ang-1 and 5-fold for Ang-2). When 
the concentration was read from the standard curve it was multiplied by 
the dilution factor 
• A horizontal orbital microplate shaker (500 +/- 50rpm) was used for 
incubation for Ang1 &2 
• The antibody conjugate used monoclonal antibodies for Ang1&2 
conjugated to horseradish peroxidase, polyclonal for erythropoietin and 
conjugated to alkaline phosphatase for bFGF.  
• The incubation times differed slightly between cytokines  
• The substrate for bFGF used lyophilized NADPH (Nicotinamide adenine 
dinucleotide phosphate) with amplifier.  
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• The plate for erythropoietin was read at 450nm with correction at 
600nm and 490nm / 650nm for bFGF  
 
4.7.2 Statistical analysis 
 
The data was analyzed using GraphPad Prism 5 software (Software, San Diego, 
CA). Cytokine values were compared between the groups using a Mann-
Whitney U test. Data was expressed using median values. The Kaplan-Meier 
method was used to estimate overall survival curves and survival curves were 
compared using the log-rank test. For univariate and multivariate analysis all 
variables are analysed as continuous variables other than sex, ascites, and 
alcohol and viral aetiology which were categorical.  
 
As a small pilot study formal power calculations were not undertaken prior to 
collecting samples. This was due to the likely anticipated small sample size. Due 
to the relative rarity of patients undergoing TAE or TACE for hepatocellular 
cancer – it was anticipated that collecting data from approximately 50 patients 
would take 2 years. For a pilot study it would be unfeasible to collect data for 
longer durations. However as a pilot study it was accepted that it would not be 
powered to allow definitive comparisons between groups but only allow 
identification of promising cytokines for future investigation. Assessing how our 
data fits in with other groups data sets (that are themselves small) will also aid 
our selection of promising cytokines for future study.      
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4.8 Results 
 
4.8.1 Patient characteristics 
 
Between October 2006 and June 2008, serum was collected from 46 patients 
with HCC and 51 patients with cirrhosis attending the oncology and hepatology 
clinics at the Royal Free Hospital in London.  The number of samples collected 
for this pilot study was determined by the number of patients visiting the 
oncology HCC clinic of a period of 2 years. As a pilot study to determine the 
feasibility of the approach no power calculations were done in advance. As such 
it is not powered to make definitive direct comparisons but instead to consider 
promising cytokines to investigate further. 
 
In addition samples were taken from 50 healthy controls including staff 
volunteers. Inclusion criteria for the patients with HCC were age over 18 years 
and a diagnosis of HCC based on histology or the criteria defined in the 
American Association for the Study of Liver Diseases (AASLD) guidelines (396). 
Evidence of cirrhosis was determined either radiologically or histologically. The 
study was approved by the Local Ethics Committee and written informed 
consent was obtained for all subjects. 
 
Patient characteristics are shown below in Table 4.5. Most patients with HCC 
were male, had a background of hepatitis C infection and were in Child-Pugh 
class A. They had multifocal disease confined to the liver with a maximum 
tumour dimension of 20-50mm.  The cirrhotic control group had a lower 
proportion of patients with hepatitis C but otherwise there were no notable 
differences with the two groups.  
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Table 4.5 Patient Characteristics  
* Signs of portal hypertension included splenomegaly, varices and collateral vessel formation and 
ascites.  
 Characteristics  Patients with 
HCC (n = 46) 
Patients with 
Cirrhosis (n = 51) 
Age (years) Mean (range) 61 (38-79) 57 (21-76) 
Sex  Male  
Female 
37 
9 
34 
17 
Aetiology  
(some patients 
have more than 1 
aetiology) 
HBV† 
HCV‡ 
Alcohol 
Autoimmune* 
Haemochromatosis 
NASH* 
Idiopathic 
5 
27 
10 
2 
2 
3 
5 
2 
24 
13 
4 
2 
3 
4 
Albumin (g/dL) Median (range) 38 (24-50) 37 (27-51) 
Bilirubin (µmol/L) Median (range) 18 (6-67) 24 (6-136) 
Serum αFP (µg/L) Median (range) 21 (2-100000) 3.3 (2-55) 
Platelets (x10
9
/L) Median (range) 125 (43-349) 109 (20-430) 
Child-Pugh score A 
B 
C 
29 
16 
1 
34 
16 
1 
Maximum 
diameter (1 
patient no scan 
available 
Median(range) mm 
≤ 2cm (no patients) 
2-5cm 
> 5cm  
34 (10-140) 
5 
26 
14 
N/A 
Staging I 
II 
IIIa 
IIIb 
4 
8 
5 
2 
N/A 
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IVa 
IVb 
23 
3 
Distribution Unifocal  
Multifocal 
19 
27 
N/A 
Portal 
hypertension** 
Yes:  
No:  
29 
14 
N/A 
Therapy Embolisation 
Chemo-
embolisation 
Other  
25 
10 
11 
N/A 
Okuda stage (397) One 
Two 
Three 
22 
15 
9 
N/A 
CLIP score (398) 
(Cancer of the 
liver Italian 
program) 
Early  
Intermediate  
Advanced 
10 
31 
5 
N/A 
† Hepatitis B virus;   ‡ Hepatitis C virus  * Non-alcoholic Steatohepatitis 
 
 
Thirty three patients had treatment with TAE or TACE and further serum 
samples were collected at defined time points following treatment to assess 
changes in serum cytokine levels.  In order to reliably control for the 
angiographic procedure involved in TAE, a proportion of the healthy volunteers 
were selected from those undergoing routine cardiac angiography provided 
they had had no recent severe chest pain, recent diagnosed myocardial 
infarction, elevated cardiac enzymes and were known not to have pulmonary 
hypertension or chronic inflammatory conditions. 
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4.8.2 Baseline cytokine values 
 
Baseline cytokine values (median and dot plot) are provided in Figure 4.2. 
Patients with HCC or cirrhosis have higher serum Ang-2 and erythropoietin 
levels than healthy controls. Patients with HCC or cirrhosis also had lower serum 
Ang-1 levels and therefore a higher ratio (Ang-2 / Ang-1) compared to healthy 
controls. There was no difference between patients with HCC and healthy 
controls with respect to VEGF and bFGF. 
 
Comparing the HCC and cirrhotic control groups, Ang-2 tended to be higher and 
Ang-1 lower in HCC patients compared with cirrhotics but the difference was 
non-significant. Similarly there were no significant differences between VEGF 
levels and Erythropoietin between the groups. For bFGF, the concentration was 
lower in HCC than cirrhotics which was also lower than normal healthy controls 
but statistical significance was not reached.  
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Figure 4.2 Baseline Cytokine Values 
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Figure 4.3 VEGF versus VEGF/Platelet number 
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In Figure 4.3 VEGF levels from patients with HCC and those with cirrhosis alone 
were compared using two methods, firstly VEGF values alone and secondly 
VEGF divided by platelet count as recommended by Poon et al (301). Using 
neither method is there a statistically significant different between the two 
sample groups. 
 
4.8.3 Association between serum cytokines and clinical parameters 
 
Cytokine levels were not affected by age or sex. Interestingly both Ang-2 and 
VEGF were positively correlated with a raised AFP and increasing tumour size 
over 8cm but not with the number of tumours (see Table 4.6). Patients with 
Child Pugh class B / C disease had higher Ang-2 levels although the difference 
was small in absolute terms. By contrast the level of Ang-1 was not correlated 
with any of the factors measured.  The level of erythropoietin and bFGF were 
both correlated with aetiology such that those with non-viral aetiology had 
higher serum Epo and bFGF.  bFGF was also correlated with increasing size of 
the dominant lesion. Whereas serum VEGF was not statistically higher in 
patients with HCC and a viral aetiology, using Serum VEGF / Platelet count this 
did reach significance.  
 
For patients with cirrhosis Ang-2 was elevated in those with Child-Pugh stage 
B/C while Ang-1 was reduced resulting in a highly significant difference in Ang-
2/ Ang-1 ratio between the two groups (see Table 4.6).  
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Table 4.6 Association between cytokines and clinical parameters  
:in HCC (A) and cirrhosis (B)  
(statistically significant associations are in bold).  
 
A) 
 
 No in  
brackets 
Ang-1 
pg/ml 
Ang-2 
pg/ml 
Ang1/2 
ratio 
VEGF 
pg/ml 
VEGF/ 
plts 
Epo 
MIU/ml 
bFGF 
pg/ml 
Age <60 (20) 
>60 (25) 
14938 
20340 
P= 0.1 
 
6584 
6628 
P=0.9 
0.41 
0.46 
P = 0.8 
192 
217 
P=0.1 
1.39 
1.59 
P=0.41 
11.9 
12.9 
P=0.7 
2 
1.9 
P=0.6 
Sex M (37) 
F  (8) 
18600 
16413 
P= 0.5 
 
6641 
6574 
P= 0.6 
0.43 
0.42 
P=0.98 
217 
185 
P=0.09 
1.56 
1.43 
P=0.35 
11.9 
14.5 
P=0.7 
2.2 
0.7 
P=0.08 
Cause Viral 
(29) 
Other 
(16) 
15575 
21725 
P=0.1 
6645 
5873 
P=0.5 
0.44 
0.24 
P=0.1 
205 
223 
P=0.6 
1.56 
1.87 
P=0.88 
10.2 
16.4 
P=0.005 
1.4 
6.3 
P=0.02 
αFP 
µg/ml 
<20.6 
(23) 
>20.6 
(22) 
18295 
17870 
P=0.86 
4638 
9863 
P=0.000
2 
0.28 
0.59 
P=0.000
8 
133 
247 
P=0.004 
1.11 
2.42 
P=0.003 
11.1 
15 
P=0.09 
2 
2.1 
P=0.76 
Child- 
Pugh 
A (29) 
B/C (17) 
18850 
14418 
P=0.31 
 
5365 
12799 
P=0.002 
0.28 
0.58 
P=0.002 
194 
246 
P=0.13 
1.4 
2.73 
P=0.16 
12.1 
13 
P=0.4 
2.4 
1.9 
P=0.6 
Size 
largest 
nodule 
(mm)  
≤ 3 (18) 
3-8 (18) 
≥ 8 (9) 
16483 
17740 
28830 
P=0.1 
 
6655 
4814 
12890 
P=0.008 
0.53 
0.28 
0.44 
P=0.07 
211 
192 
391 
P=0.02 
2.43 
1.16 
2.32 
P=0.15 
10.6 
13.1 
16 
P=0.4 
1.2 
2.1 
5.3 
P=0.03 
No of 
nodule 
1 (19) 
2-5 (18) 
≥ 5 (8) 
15575 
17565 
26230 
P=0.3 
 
6123 
6781 
4568 
P=0.3 
0.38 
0.57 
0.32 
P=0.09 
217 
208 
200 
P=0.9 
1.77 
1.56 
1.76 
P=0.84 
14.4 
12.5 
10.1 
P=0.5 
2.7 
1.6 
1.9 
P=0.7 
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B) 
 
 No in  
brackets 
Ang-1 
pg/ml 
Ang-2 
pg/ml 
Ang1/2 
ratio 
VEGF 
pg/ml 
VEGF/ 
plts 
Epo 
MIU/ml 
bFGF 
pg/ml 
Age <60 (33) 
>60 (18) 
16541 
17450 
P=0.14 
6997 
4472 
P=0.55 
 
0.49 
0.26 
P=0.13 
208 
217 
P=0.99 
1.78 
1.71 
P=0.4 
18.46 
14.66 
P=0.94 
2.92 
3.47 
P=0.35 
Sex M (34) 
F (17) 
17150 
15630 
P=0.73 
6677 
4720 
P=0.33 
 
0.33 
0.39 
P=0.92 
226 
152 
P=0.23 
1.93 
1.55 
P=0.79 
13.38 
21.22 
P=0.12 
3 
4.91 
P=0.17 
Aetiology Viral 
(26) 
Other 
(25) 
14450 
18450 
P=0.07 
6209 
4990 
P=0.68 
0.46 
0.33 
P=0.36 
232 
135 
P=0.17 
2.58 
1.29 
P=0.003 
13.56 
14.66 
P=0.92 
3.12 
3.47 
P=0.72 
αFP 
µg/ml 
< 4 (29) 
> 4 (18) 
16250 
16833 
P=0.61 
4720 
9045 
P=0.02 
 
0.33 
0.56 
P=0.35 
168 
245 
P=0.16 
1.41 
2.34 
P=0.23 
17 
10.86 
P=0.38 
3.11 
2.47 
P=0.74 
Child- 
Pugh 
A (34) 
B/C (17) 
17450 
15487 
P=0.27 
4077 
10014 
P=0.0001 
 
0.26 
0.68 
P=0.03 
232 
132 
P=0.08 
1.98 
1.55 
P=0.32 
15.39 
13.93 
P=0.93 
3.3 
3.3 
P=0.59 
Platelet 
count 
< 140 
(32) 
> 140 
(19) 
 
13153 
32650 
P<0.0001 
7146 
3802 
P=0.02 
0.56 
0.11 
P<0.0001 
160 
303 
P=0.003 
2.14 
1.36 
P=0.23 
15.24 
14.66 
P=0.34 
2.75 
4.08 
P=4.08 
 
 
4.8.4 Association with prognosis 
 
The median follow-up for patients with HCC was 574 days (range 13 to 1344 
days) with no patients lost to follow up. Survival curves were generated for each 
cytokine dividing the population into two groups; those above, and those below 
the median value for the whole population (see Figure 4.4).  
 
Patients with angiopoietin-2 levels above 6628pg/ml had a significantly worse 
median overall survival of 459 days compared to 923 days for those below. 
Similarly for patients with VEGF levels above 208pg/ml median survival was only 
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293 days compared with 923 days for those below. Ang-1, bFGF and Epo levels 
had no prognostic significance.  
 
Univariate analysis (Table 4.7) confirmed that known prognostic factors for HCC, 
namely liver function markers (bilirubin and ascites), and tumour factors (AFP 
and number and size of nodules) correlated with adverse prognosis. Of the 
cytokines measured only an elevated Ang-2 and VEGF were associated with a 
poorer survival.  
 
Applying multivariate analysis only AFP, bilirubin and Ang-2 remained 
significant. Among these factors Ang-2 was the most discriminating in terms of 
prognosis with a hazard ratio of 5.13 for every 10k unit rise in serum 
concentration.  
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Figure 4.4 Survival Curves (Kaplan-Meier)  
Comparing the 50% of patients below the median value to the 50% above.  
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Table 4.7 Univariate (A) and multivariate (B) analysis 
 
Showing relationship between baseline variables and survival outcome. All  
variables are analysed as continuous variables other than sex, ascites, and 
alcohol and viral aetiology which are categorical.  
 
A) 
Variable HR 95% CI p value N 
Male 2.12 0.47 9.70 0.331 45 
Age 1.00 0.95 1.05 0.852 45 
Albumin 0.85 0.76 0.94 0.001 45 
Bilirubin 1.05 1.02 1.09 0.002 45 
INR (per 10 units) 1.29 0.93 1.80 0.127 44 
Number of nodules 1.11 1.04 1.19 0.003 45 
Max. diameter of tumour 
(cm) 1.21 1.06 1.38 0.005 45 
Log (AFP) 1.33 1.11 1.60 0.002 45 
Ascites 5.52 1.90 16.07 0.002 45 
Alcohol 0.93 0.25 3.37 0.907 44 
Viral 0.89 0.32 2.52 0.829 45 
Ang-1 (per 10k units) 1.17 0.71 1.90 0.539 44 
Ang-2(per 10k units) 6.78 2.87 16.02 <0.001 44 
VEGF (per 10 units) 1.03 1.02 1.05 <0.001 42 
Erythropoietin 1.01 0.97 1.04 0.619 41 
BFGF 1.04 0.90 1.22 0.577 38 
            
 
B 
            
Variable HR 95% CI p value N 
Ang-2(per 10k units) 5.13 1.84 14.29 0.002 44 
Log (AFP) 1.30 1.05 1.61 0.015 45 
Bilirubin 1.04 1.00 1.09 0.036  45  
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4.8.5 Cytokine changes with embolisation 
 
In order to determine if acute tumour hypoxia caused a rise in serum cytokine 
levels blood was collected before and at various time points up to 21 days 
following transarterial embolisation (see Table 4.8). Not all patients provided 
samples at each time point and therefore the baseline values shown are those 
corresponding to each time point. In order to control for the acute effects of the 
angiographic procedure associated with TACE, cytokine levels in patients 
undergoing cardiac angiography were also measured.  
 
For Ang-2 there was a small increase at 24 hours but no significant difference at 
any other time after TACE compared to baseline. VEGF levels rose to a peak at 
day 15 when they were twice that at baseline.  Serum Epo almost doubled at 24 
hours post TACE and remained elevated at 7 days returning to baseline levels at 
21 days. An example of a patient having 3 separate embolisations 
demonstrating Epo rise with each one is shown in Figure 4.5. bFGF did not 
change significantly at any point.   
 
In the control cardiac angiography group, there was a small but significant 
increase in Epo at 24 hours but the change was only 21% compared to the 76% 
rise seen in HCC patients at the same time point suggesting the additional 
hypoxic event in TACE causes a greater rise in Erythropoietin. 
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Table 4.8: Cytokine levels at baseline (Bl) and following TACE. 
For patients with HCC (A) or coronary angiography in control cardiac patients (B) 
(statistically significant changes are in bold).  
 
A 
Times BL 4 hr BL 24 Hr BL 8 days BL  15 
days 
BL 21 
days 
 N = 8 N = 25 N = 7 N = 7 N = 9 
Ang-1 18420 18720 
P=0.62 
15500 15413 
P=0.87 
15565 23733 
P=0.31 
17565 16865 
P=0.31 
17350 17275 
P=0.91 
Ang-2 5123 5813 
P=0.55 
6415 6517 
P=0.03 
6415 6600 
P=0.47 
6415 6880 
P=0.38 
6415 6773 
P=0.43 
VEGF 135 113 
P=0.23 
190 219 
P=0.37 
141 197 
P=0.13 
133 276 
P=0.02 
187 235 
P=0.19 
Epo 11.9 13.3 
P=0.62 
12.6 22.2 
P=0.004 
11 17.2 
P=0.04 
11.5 17.1 
P=0.08 
10.6 11.8 
P=0.84 
bFGF 0.77 1.13 
P=0.055 
1.93 2.65 
P=0.3 
0.7 1.66 
P=0.082 
0.44 0.87 
P=1 
1.31 2.01 
P=0.92 
 
 
B 
 
Cardiac 
patients 
Baseline 24hr 
 n=22 n=22 
Ang-1 30363 
 
32936 
p=0.38 
Ang 2 3180 2853 
p=0.08 
VEGF 232 244 
p=0.4 
Epo 5.3 6.4 
p=0.05 
FGF 4.62 4.71 
p=1 
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Figure 4.5: Example of Erythropoietin post embolisation. 
Arrows represent time of TAE (Trans-arterial embolisation)  
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4.8.6 ROC Curves 
 
ROC (Receiver Operating Characteristic) Curves plot the sensitivity of a test (or 
the true positive rate) against 1-specificity (false positive rate) on each axis. This 
can be used to assess how effective these biomarkers are at distinguishing 
patients with a condition (HCC or cirrhosis) from those without. The test is used 
in two settings, to attempt to distinguish patients with HCC from those with 
cirrhosis alone (Figure 4.6) and to distinguish patients with cirrhosis from 
normal healthy controls (Figure 4.7).  
 
The first set of curves demonstrates little ability for our selected angiogenic 
cytokines to differentiate patients with cirrhosis and HCC from those with 
cirrhosis alone. Only bFGF has a significant p-value (0.033), but with a low AUC 
value of 0.63. The current standard, α-FP, performs much better with a p-value 
of < 0.0001 and an AUC of 0. 85.  
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The second set considers patients with early stage cirrhosis (Child-Pugh A 
disease) and the healthy control group. Here the angiogenic cytokines seem 
more effective. As AFP was not measured in the healthy control group it was 
not possible to compare to that biomarker. Scholz et al considered the 
combination of Ang-2 with AFP in the detection of HCC and found the 
combination more effective than when either Ang-2 or AFP were used alone 
rather than in combination (348). However whether Ang-2 could be useful in 
the diagnosis of cirrhosis was not discussed.  
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Figure 4.6: ROC Curves HCC versus Cirrhosis 
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Figure 4.7 : ROC Curves Control vs. Cirrhosis (Child-Pugh A only) 
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4.9 Conclusions 
 
 
The aim of this study was to identify a blood based biomarker for the acute 
hypoxia induced by VDA’s that could compliment the more expensive and 
technically demanding imaging assessments. We chose to focus on angiogenic 
cytokines that are up-regulated by hypoxia and used the model of TAE for HCC 
to explore the feasibility of this approach. In performing this analysis we also 
discovered significant differences between certain cytokines in patients with 
cirrhosis and HCC compared to healthy controls which may have important 
clinical applications. 
 
Ang-2 appears to be a strong and independent prognostic factor for survival in 
hepatocellular cancer, with the risk of dying increasing fivefold for every 10,000 
units increase in Ang-2. The ratio between Ang-2 and its antagonist, Ang-1, is 
increased in patients with cirrhosis and HCC reflecting a pro-angiogenic milieu 
although there was no significant difference between HCC and cirrhosis for 
either Ang-1 or Ang-2. Higher levels of Ang-2 were associated with more severe 
liver disease, α-FP and an increased size of the largest nodule. Other authors 
have not demonstrated relationships between the angiopoietins and poor 
prognostic clinico-pathological markers. In addition the failure of Ang-2 to rise 
post-embolisation, even with tumour necrosis occurring suggests it may be 
secreted by the surrounding liver rather than tumour. The lack of a rise post-
embolisation suggests it would be an ineffective biomarker for the anti-vascular 
agents.  
 
Serum Ang-1 was reduced in patients with cirrhosis alone and with HCC 
compared to healthy controls. Ang-1 was not found to be a prognostic factor 
and no changes were seen post embolisation. This confirms work from tissue 
expression studies (334, 399). Most reports from other cancers find equivalent 
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serum Ang-1 between controls and cancer patients (344, 345) apart from a 
study in lung cancer where serum Ang-1 was reduced (342). It may be that Ang-
1 levels also are affected by the surrounding cirrhotic tissue. Serum Ang-1 is 
unlikely to represent an effective biomarker. 
 
Previous work has shown an over-expression of VEGF mRNA in HCC (327, 334, 
363, 400). The highest expression was found adjacent to areas of necrosis (392) 
consistent with a response to hypoxia (401). A recent meta-analysis identified 
eight studies that had explored the prognostic value of serum VEGF in HCC (300) 
and all but one were performed in the Asian population. In keeping with this 
analysis, we found that higher levels were significantly associated with a worse 
prognosis. However unlike Poon et al (364) we found no difference between 
VEGF levels in HCC patients and healthy controls. It should be noted that the 
normal range for serum VEGF is wide and a small control cohort may provide 
misleading results.  As predicted serum VEGF did rise post-embolisation 
secondary to tumour ischaemia. The time-course was relatively slow in this 
group of patients and only peaked at 15 days. Potentially changes in VEGF could 
therefore be explored in patients treated with VDAs.  
 
In HCC bFGF is thought to act via the augmentation of VEGF in an autocrine 
manner (402). Previous work demonstrates both an increased tissue expression 
of bFGF in HCC (403) and correlation with the MVD (350). All published studies 
assessing serum bFGF have been done in Asian patents and, while one has 
shown serum bFGF to be associated with a poor survival (364) two other studies 
showed no such correlation (360, 365). In agreement with Poon et al (364) we 
found a significant association between tumour size and serum bFGF but, in 
keeping with the two other studies we did not find an association with 
prognosis. bFGF failed to rise post embolisation and would therefore not 
represent a good biomarker for the anti-vascular agents.  
 
 195 
Erythropoietin has been implicated in angiogenesis (404, 405). Previous studies 
have reported an elevated serum Epo in patients with HCC and considered it a 
likely explanation for the erythrocytosis sometimes observed (406-408).  
 
Erythropoietin over-expression in HCC correlates with a poorer differentiation 
and increased microvessel density (389), however the prognostic significance of 
a raised serum Epo has not been explored. In our study we found that serum 
Epo was significantly elevated in patients with HCC and cirrhotics but no 
significant difference was observed between the two groups. Erythropoietin 
levels were higher in those with a non-viral aetiology but no other association 
with clinical factors was seen, nor any association between Epo levels and 
prognosis. Transcription of Epo is regulated by HIF1α in response to hypoxia and 
it is therefore a potential marker of acute ischemia.  
 
It is of interest that Erythropoietin levels in our study almost doubled in 24 
hours after TACE and remained significantly elevated for at least one week. 
Erythropoietin levels also rose post cardiac angiography but to a lesser extent, 
which may reflect a lower level of ischaemia in patients having this procedure. 
The rapid and consistent rise in erythropoietin levels would merit this cytokine 
being investigated further as a potential biomarker for the anti-vascular agents.  
 
The differing time course of response for VEGF and Erythropoietin to TAE may 
partly be due to the biology of the two cytokines. Erythropoietin is a systemic 
hormone with a half life of approximately 6 hours; whilst VEGF is locally acting 
with a half life in the circulation of 3 minutes. It is likely that additional factors 
explain the late rise in VEGF rather than acute ischaemia. I have investigated 
VEGF using both serum VEGF and also serum VEGF/platelet count as advocated 
by Poon et al (301). In this study both methods appear to give equivalent 
results.  
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Other biomarkers for VDA’s have been considered. These include markers such 
as the serotonin metabolite, 5-hydroxyindoleacetic acid (5-HIAA) which 
becomes elevated post DMXAA administration. This rise is thought to be via 
platelet aggregation secondary to vascular damage with secretion of the 
vasoactive amine serotonin. Both Ang-1 and Ang-2 act via the Tie-2 receptor; 
located mainly on endothelial cells and haematopoietic cells, including a subset 
of monocytes that appear important in tumour angiogenesis. In addition both 
erythropoietin and VEGF are thought to promote the recruitment of endothelial 
progenitor cells (EPC’s) from the bone marrow that may promote angiogenesis. 
These will be considered further in the next chapter.  
 
In addition we have demonstrated that angiogenic cytokines are elevated in 
cirrhosis. Whilst the VEGF/Platelet count was higher in patients with a viral 
aetiology and may be related to inflammation, the other cytokines showed no 
correlation with aetiology and are more likely associated with cirrhosis itself.  
ROC curves show a statistically significant difference between patients with 
early stage cirrhosis (Child-Pugh A) and healthy controls for both angiopoietins 
and erythropoietin. These findings should be considered for further research. 
Angiogenic cytokines such as VEGF and Angiopoietin-2 have already been 
implicated in the development of cirrhosis (348) although the mechanism 
remains obscure. Further investigation in their role in the diagnosis and as a 
marker of prognosis appears warranted.  
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Chapter Five: Tie-2 monocytes and Endothelial Progenitor Cells as 
biomarkers for Vascular Disruptive Agents. 
 
 
In the Introduction I considered two cell types that might act as potential 
biomarkers for vascular shut-down induced physically by embolisation, or 
biologically by the VDA’s. These are the group of monocytes that express the 
Tie-2 receptor and endothelial progenitor cells. I shall briefly recap on their 
properties below before reporting the clinical trial data.  
 
5.1 Tie-2 Expressing Monocytes 
 
Approximately 20% of circulating monocytes are thought to express the Tie-2 
Receptor (158). In addition these cells can be identified by co-expression of the 
classical monocyte markers of CD14, CD16 and CD11b and the lack of 
endothelial cell markers (161) such as VEGFR2. In mouse models they are 
known to localize to sites of angiogenesis and human tumours (159). In humans 
they localize to the peri-vascular space and areas of hypoxia; their distribution 
may reflect that of Angiopoietin-2, released secondary to that hypoxia (158).  
 
Physiologically TEM’s are thought to be involved in tissue growth and 
regeneration (163). In malignancy they are thought to be pro-angiogenic and 
their ablation results in a reduction in tumour growth and angiogenesis (159). 
Tie-2 monocytes respond to Angiopoietin-2 or hypoxia by suppressing secretion 
of IL-12 and TNF-α (165). It is hypothesized in our study that they are recruited 
from the circulation by the hypoxia generated by embolisation. Recruited to 
tumour they would aid angiogenesis and augment tumour growth. They may 
therefore represent a potential biomarker for vascular shut-down.  
 
 
 198 
5.2 Endothelial Progenitor Cells 
 
Endothelial Progenitor cells are thought to be bone-marrow derived cells that 
retain the ability to migrate, form primitive tubes and adhere to substratum as 
well as possessing a high proliferation rate (169). They are thought to be 
recruited to areas of neo-vascularisation guided by the angiogenic cytokines 
where they differentiate into endothelial cells and aid angiogenesis (170). There 
is no standard way to define an EPC. They are thought to express the markers 
VEGFR2, CD34, CD31, CD133 and CD146 (176) although these markers may 
encompass a number of cellular sub-groups with differing properties.  
 
Numbers isolated from the circulation depends on the technique used to isolate 
them. Flow cytometry values are typically 70-210 cells/mL of blood (using 
CD34/133/VEGFR2) (179). In malignancy EPC’s are thought to aid angiogenesis 
and have been associated with tumour progression. Their recruitment from 
bone-marrow is thought to be secondary to hypoxia via the release of HIF1-α 
(206) with blood levels rising within 24 hours. The level of incorporation into the 
tumour-associated vasculature and the effect this has remains controversial and 
may differ depending on stage, grade, animal model and tumour type (189). 
EPC’s have been investigated previously as biomarkers for anti-angiogenic 
agents (178) and for the VDA’s in a mouse model (202) where levels rose 
approximately 4 hours after administration. 
 
In our hypothesis trans-arterial embolisation would generate ischaemic necrosis 
with hypoxia. Subsequently EPC’s would be recruited from the bone marrow. 
Levels would rise in the blood where they could be recorded via flow cytometry 
with the potential of acting as a biomarker for vascular shut-down.  
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With this aim I investigated levels of Tie-2 expressing monocytes and 
Endothelial Progenitor Cells in patients with hepatocellular cancer, both pre and 
post TAE. The results are presented below.  
 
 5.3 Hypothesis 
 
Our hypothesis was that the acute hypoxia induced by embolisation or by VDAs 
would lead to an increase in angiogenic cytokines. An increase in angiopoietin-2 
may cause Tie-2 monocytes to be recruited into tumour from the bone marrow 
and promote further angiogenesis. We attempted a preliminary study to 
evaluate the feasibility of assessing the level of Tie-2 monocytes in the 
peripheral blood as a biomarker that could in future be used to assess the VDA 
agents.  
 
In addition, as endothelial progenitor cells are also recruited to tumours under 
the influence of angiogenic cytokines and may themselves enhance 
angiogenesis, we investigated EPCs as a biomarker in HCC. As no standard 
methodology exists for EPCs three separate methods were explored.  
 
5.4 Methods 
 
I analysed Tie-2 positive monocytes in peripheral blood in a group of patients 
with hepatocellular cancer who were treated with TAE. The technique was 
evaluated for feasibility with 8 patients whose blood was selected anonymously 
who were receiving chemotherapy*. A control group of 11 was selected; 6 of 
these were healthy controls and 5 were undergoing coronary angiography.  
 
* Blood samples collected from the chemotherapy clinic were reviewed in the 
haematology laboratory as per standard clinical practice. The supervising clinical 
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chemist removed all identifying data from the samples including name, sex, 
hospital number and date of birth after completing their standard clinical 
investigations. I then received the remaining blood which would otherwise have 
been discarded with no identifying data present.   
 
5.4.1 Sample collection and analysis 
 
5.4.1.1 Tie-2 monocytes 
 
I analysed the whole blood concentration of Tie-2 positive monocytes using flow 
cytometry. A ‘lyse, no-wash’ protocol was followed due to the likely low 
frequency of positive cells in the blood. The alternative method with density 
gradient separation and washing has been found to be poorly reproducible 
(409). 
 
Each sample was prepared and analysed in triplicate. 4mls of EDTA preserved 
blood was collected and stored until ready to analyse. Flow cytometry was 
performed within 4 hours of blood collection. 200µl samples were aliquoted 
into 3 test-tubes (polypropylene) and mixed with 5µl of each fluorochrome-
conjugated antibody. The combinations of monoclonal antibodies are 
documented below. Antibodies were stored at 2-8˚C in the dark.  
 
The fluorochrome-conjugated antibodies used were: 
 1. PE (Phycoerythrin) stain against CD11b (BD Biosciences code 3331412) 
 2. FITC (Fluorescein Isothiocyanate) stain against CD14 (BD Biosciences 
 code  345784) 
 3. PerCp (Peridinin Chlorophyll) stain against CD45 (BD Biosciences code 
 345809) 
 4. APC (Allophycocyanin) stain against Tie-2 (R&D Systems code 
 FAB3131A) 
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The combination was then mixed using a laboratory vortex shaker and left at 
room temperature for 15 minutes in the dark. The red cells were lysed using 
Easylyse™ (Dako) at a concentration of 1 in 20 with distilled water. The sample 
was then centrifuged at 200G for 5 minutes with brake on. The supernatant 
liquid was discarded and the pellet containing the cells of interest was re-
suspended in 1ml of buffered isotonic salt solution (PBS) for flow cytometry. 
The samples were analysed immediately by flow cytometry. Initially the samples 
were analysed using the FACSCalibur™ model (BD Science) with WinMDI 
software or the FACS Aria™ (BD) Cellsorter. Analysis was done blinded to the 
patient identity or time point of the sample to reduce bias.  
 
The strategy to detect Tie-2 positive monocytes includes the use of CD45 as an 
electronic threshold signal to allow the exclusion of erythrocyte debris from the 
acquisition. Monocytes are medium sized cells and therefore have a medium 
forward scatter. They also have a medium granularity with a medium side 
scatter. They can be identified on a plot of those two variables and an 
“acquisition gate” set around them. These selected cells are confirmed to carry 
the monocyte markers CD14 and CD11b.  
 
As Tie-2 positive monocytes are relatively rare events in peripheral blood, 
leukocytes were continually acquired until > 10,000 events had been collected 
that met criteria for both forward and side scatter. The entire data file was 
approximately 250,000 leukocytes.  
 
5.4.1.2 Gating strategy for Tie-2 monocytes 
 
The gating strategy is shown pictorially in Figure 5.2. Initially forward scatter 
and side scatter was used to distinguish granulocytes, lymphocytes and 
monocytes. A FITC stain for CD14 distinguishes the monocytes which are gated 
in R1. To further confirm the cells are truly monocytes they were gated with 
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CD11b and then back gated to forward and side scatter graphs (not pictured). 
Finally the monocyte population was gated against Tie-2 APC. The distinction 
between positive and negative was judged on where the population clusters of 
Tie-2 negative cells appear to end. If this was indeterminate back- gating could 
be performed to judge from the negative populations of lymphocytes or 
granulocytes.  
 
5.4.1.3 Statistical analysis 
 
The data was analyzed using WinMDI (Version 28). The data was then analysed 
further with GraphPad Prism 5 software (Software, San Diego, CA). Tie-2 
monocyte values were expressed as median values and compared using the 
Mann-Whitney U test. The Kaplan-Meier method was used to estimate overall 
survival curves and survival curves were compared using the log-rank test.  
 
5.4.2 Endothelial Progenitor Cells 
 
Blood was collected and stored using the same protocol described above with 
the Tie-2 positive monocytes. A ‘lyse, no-wash’ procedure was used for flow 
cytometry as explained above. Again 200 µl aliquots of blood was incubated at 
room temperature for 15 minutes with the following combinations of 5 µl each 
of these fluorochrome-conjugated monoclonal antibodies. The procedure 
followed the same method from then as with the Tie-2 expressing monocytes. 
Again the analysis was completed blinded to the identity of the sample and its 
time order to reduce bias.  
 
A number of different combinations of fluorochrome-conjugated antibodies 
were considered for evaluation of EPCs as detailed below: 
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Method One 
  FITC stain against CD34 (BD Biosciences Code no 345804) 
 PE stain against CD133 (Miltenyi Biotech Code no 130-080-801) 
 PerCP stain against CD45 (BD Biosciences Code no 345809) 
 APC stain against VEGFR2 (R&D Systems Code no MAB3572) 
 
Method Two  (Based on a protocol by Dulic-Sills et al (444)) 
 FITC stain against CD2/CD13/ CD22  
 PE stain for CD133 (Miltenyi Biotech Code no 130-080-801) 
 PerCP stain against CD45 (BD Biosciences Code no 345809) 
 APC stain against VEGFR2 (R&D Systems Code no MAB3572) 
 
Method Three  
 FITC stain against CD146 (Serotec Code no MCA2141) 
 PE stain against CD133 (Miltenyi Biotech Code no 130-080-801) 
 PerCP stain against CD45 (BD Biosciences Code no 345809) 
 APC stain against CD34 (R&D Systems Code no MAB3572) 
 
 
CD45 enabled exclusion of erythrocyte debris and ensured that only leukocytes 
were acquired for analysis. Initially it was planned to set an “acquisition gate” 
around cells with a low forward and low side angle scatter (the physical 
characteristics of EPCs) until 10
6 
in that gate had been acquired. In practice 
acquisition was continued until sample depletion. This required the acquisition 
of large data files containing 1-3 x 10
6 
leukocytes was anticipated.  
 
Due to the rarity expected for endothelial progenitor cells (0.01-0.0001% of 
mononuclear cells (410), a file of 10
6
 of these cells would contain between 10-
1000 EPCs (or 70-210 cells/mL (179)). Time would be included as a parameter 
during acquisition to reduce the distortion of electronic noise affecting the 
results. Electronic noise can occur either as multiple events at the same time 
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period or with a regular periodicity rather than rare cell events which occur 
randomly throughout the period of event acquisition (409). The flow cytometer 
was cleaned and washed prior to analysis to remove any residual cells or 
particles.  
 
Using method three the gating strategy was altered after the first 10 patients to 
try and improve the selection of potential EPC events. In this gating strategy, 
200µl of blood was used and lysed carefully. An initial 10000 events were 
assessed and an individual gate was devised to cover the monocytic population. 
Events were then collected in this gate until sample depletion. All events 
outside the gate were discarded and not recorded. This has the advantage of 
reducing the size of the computer files to assess data which were becoming 
unwieldy. 
 
5.4.2.1 Statistical Analysis 
 
Rare event analysis is considered to follow a normal distribution. The coefficient 
of variance can then be determined by cv =100/√N where N is the number of 
positive events analysed. Therefore if a sample contained 100 true events the cv 
should be 10% which was felt to be acceptable for this pilot study (409).  
 
The data was analyzed using WinMDI (Version 28) and GraphPad Prism 5 
software (Software, San Diego, CA) as described above.  
 
5.4.2.2 Gating strategies 
 
The first gating strategy is shown in  Figure 5.7 (179). Initially the physical 
characteristics of forward scatter and side scatter were used to determine 
mononuclear and lymphocytic cells. The second gate was around cells that were 
CD45 negative or dim. The second and third gates isolated cells that were 
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VEGFR2, CD133 and CD34 positive. These cells were then considered to be 
endothelial progenitor cells.  
 
The second strategy was developed by Dulic-Sills et al (411) and is shown in 
Figure 5.8. Here the mononuclear-lymphocyte group is isolated in the same way 
as above. Then a combination of CD2, CD13 and CD33 was used to exclude cells 
of haematopoietic origin. Positivity of CD133 and VEGFR2 should then define 
endothelial progenitor cells.  
 
A third strategy shown in  Figure 5.9 (175) was to start again by defining 
mononuclear and lymphocytic cells followed by those cells that are CD45 low. 
Then a combination of CD146, CD133 and VEGFR2 positivity could define 
endothelial progenitor cells.  
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5.5 Results 
 
5.5.1 Patient Characteristics for Tie-2 monocytes 
 
Between October 2006 and April 2008 blood was collected from 29 patients 
with HCC from the oncology clinics at the Royal Free Hospital. The blood was 
collected from the same patient group studied in Chapter Four. In addition 
anonymised serum was collected from 8 patients undergoing chemotherapy for 
cancer and 11 healthy controls, including staff volunteers. Inclusion criteria for 
the patients with HCC were discussed in the previous chapter. The study was 
approved by the Local Ethics Committee and written informed consent was 
obtained for all subjects. 
 
Patient characteristics are shown below in Table 5.1. The majority of patients 
with HCC were male, had a background of hepatitis C infection and Child-Pugh 
class A disease. Most had multifocal disease confined to the liver with a 
maximum tumour dimension of 20-50mm.  Of these 23 patients had further 
blood samples taken post-embolisation.  
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Table 5.1 Patient Characteristics 
 
 CHARACTERISTICS PATIENTS WITH HCC 
Age (years) 
 
Mean (range) 60 (38-77) 
Sex   Male 
Female 
20 
7 
Aetiology HCV / HBV  
Alcohol 
Cryptogenic 
Autoimmune / NASH 
Haemachromatosis  
Portal vein thrombosis 
13 / 3 
6 
3 
1 / 2 
1 
1 
Albumin (g/dL) 
 
Median (range) 15 (6-56) 
Bilirubin (µmol/L) 
 
Median (range) 39 (28-48) 
Serum αFP (µg/L) 
 
Median (range) 20.6 (2-88,182) 
Platelets (x10
9
/L) 
 
Median (range) 108 (43-349) 
Child-Pugh score A 
B 
18 
9 
Maximum diameter (1 
patient had no scan available 
Median(range) mm 
≤ 2cm (no patients) 
2-5cm 
> 5cm  
35 (14-140) 
2 
15 
10 
Distribution Unifocal  
Multifocal 
10 
17 
Therapy  Embolisation 
Chemoembolisation 
Palliative care 
18 
6 
3 
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5.5.2 Assessing storage of samples 
 
In order to determine the reliability of analysing samples 24 hours after blood 
was collected we compared the number of events recorded when samples were 
analysed immediately compared to storing the blood at 4˚C overnight and 
analysing the following day. As demonstrated in Figure 5.1 there was a 
significant reduction in event count at 24 hours and for subsequent experiments 
analysis was performed immediately.  
 
Figure 5.1 Assessing re-staining on the subsequent day 
 
Total number of cellular events counted by the flow cytometer when analysed 
immediately and at 24 hours after collection.  
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5.5.3 Baseline values for Tie-2 monocytes 
 
The gating strategy for Tie-2 monocytes is demonstrated in Figure 5.2. It 
demonstrates the presence of cells carrying the monocyte markers CD14 and 
CD11b as well as Tie-2 consistent with Tie-2 monocytes.  
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Figure 5.2 Gating strategy for Tie-2 monocytes 
 
A) Gate of side scatter versus forward scatter to delineate cell size and 
morphology; B) Gate of side scatter versus CD14 expression, R1 demonstrates 
the monocyte population; C) Gate side scatter versus CD11b expression to 
confirm monocyte population; D) Gate of side scatter versus Tie-2 showing 
monocyte population only, R3 shows those positive for Tie-2 expression.  
 
 
A B
C D
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Baseline values for Tie-2 monocytes as a percentage of total monocytes are 
provided in Figure 5.3. The values were obtained on two separate flow 
cytometers as a new cytometer superseded the old. The values on the second 
(the BD FACS Aria) are significantly lower, which corresponded to a new batch 
of Tie-2 antibody. The values are therefore detailed separately.  
 
Figure 5.3 Baseline values for Tie-2 monocytes 
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5.5.4 Association between Tie-2 monocytes & clinical parameters 
 
 
Due to the disparity with the two flow cytometers, only the values from the 
FACSCalibur are presented here due to a larger sample size. The FACSCalibur 
data is also closer to previous estimates of the Tie-2 monocyte population in 
cancer e.g. by Venneri et al (158) who estimated them at 3.3% +/- 1.5% of 
monocytes.  
 
In this preliminary sample of only 14 patients one clinical parameter reached 
significance (see Table 5.2). An αFP level of greater than the median of 20.6 
ng/ml was associated with an elevated level of Tie-2 circulating monocytes 
(using the Mann-Whitney U statistical test and median values).  
 
 
Table 5.2 Tie-2 Monocytes and Clinical Parameters 
 
 
CHARACTERISTICS 
PATIENT NUMBER  
TIE-2 MONOCYTES 
(% MONOCYTE POPULATION) 
(FACSCALIBUR ALONE) 
Age < 60 years  6 
> 60 years  8 
3.56 
6.62 
P=0.27 
Sex  Male 7 
Female 7 
3.56 
7.48 
P=0.94 
Aetiology Viral 10 
Other 4 
5.19 
5.29 
P=0.86 
αFP (µg/ml) < 20.6  8 
> 20.6  6 
3.54 
7.98 
P=0.03 
Child-Pugh status A  9 
B/C  5 
5.49 
2.42 
P=0.68 
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5.5.4.1 Associations with angiogenic cytokines 
 
 
Correlation of the angiogenic cytokines against Tie-2 monocytes is shown in 
Figure 5.4. Serum VEGF appears to positively correlate against Tie-2 monocytes 
while angiopoietins 1 & 2 and the angiopoietin ratio show no evidence of any 
correlation. The significance of the correlation between VEGF and Tie-2 
expression in this data-set it remains unclear. The level of correlation is 
relatively low and the data-set is small. As only 1 of 6 values shows such 
correlation it may reflect chance alone. It would need to be corroborated in a 
larger data-set before it could be considered truly significant.  
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Figure 5.4 Correlation with the angiogenic cytokines 
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5.5.5 Tie-2 Monocytes changes with embolisation 
 
 
EDTA-preserved peripheral blood was collected for Tie-2 monocytes pre-
embolisation and at 4 and 24 hours, 8, 15 and 21 days. Not all patients provided 
blood samples so the baseline values are given for each time-point with the 
patient number. With Tie-2 post embolisation the only significant increase was 
seen at day 8 post procedure in this small study group. This has been 
represented by both a Table (Table 5.3) and a Figure (Figure 5.5). Although the 
p-value becomes significant at day 8 the significance of this is unclear.  
 
 
Table 5.3 Percentage of Tie-2 monocytes post embolisation 
Values for Tie-2 monocytes are given in percentages of the monocyte 
population. Each post-embolisation value was compared individually to its pre-
embolisation value to act as its own control using the Mann-Whitney U Test. 
The total value given is the median.  
 
 
 
TIME PRE 4 HRS PRE 
24 
HRS 
PRE 
8 
DAYS 
PRE 
15 
DAYS 
PRE 
21 
DAYS 
No HCC 
patients 
17 22 8 6 8 
Tie-2 
monocytes 
 
1.78 
 
2.55 
p=0.13 
2.02 
 
2.33 
p=0.13 
2.42 
 
4.86 
p=0.03 
2.98 
 
4.44 
p=0.09 
3.96 
 
1.86 
p=0.31 
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Figure 5.5 Percentage of Tie-2 Monocytes Post-embolisation 
Graphs use a Log scale due to wide range of data values. Day 8 presented as 
both linear and log scale.  
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A control group of 5 patients undergoing cardiac angiography showed no 
increase in Tie-2 at 4 hours post procedure (0.4 versus 0.33 Percent monocytes 
p=0.58) but it was not possible to test later time points. 
 
5.5.6 Endothelial Progenitor Cells 
 
5.5.6.1 Assessing sample storage  
 
The samples were either stained and analysed immediately or left overnight to 
be stained and analysed in the morning. Again the readings were unreliable if 
left overnight. The graph below uses a log scale due to the range of values.   
 
Figure 5.6 Assessing re-staining on the subsequent day 
Total number of cellular events counted by the flow cytometer when analysed 
immediately and at 24 hours after collection.  
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5.5.6.2 Endothelial Progenitor cells at baseline 
 
 
Method One:  
 
Figure 5.7 demonstrates the presence of cells defined as endothelial progenitor 
cells by the expression of CD34, CD133 and VEGFR2. According to this method 
EPCs formed 0.015% of mono-lymphocytic cells (range 0.0018-0.05) and 0.79% 
of CD45 low mono-lymphocytes (range 0.47-1.25) in a cohort of seven patients 
attending the oncology clinic. Four patients with HCC had samples analysed with 
similar values (0.013% of mono-lymphocytic cells; range 0.006-0.022%).  
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Figure 5.7 Initial gating strategy for the identification of EPCs 
 
 
A B
C D
 
A: Gating around monocytes and lymphocytes using physical characteristics 
B: CD45 negative / low cells identified. 
C: Cells that are CD34 and VEGFR2 positive gated for  
D: Confirming that they are also CD133 positive.  
 
 
Three patients had samples taken at 24 hours post-embolisation with all three 
having a rise in the percentage of EPC’s from a mean of 0.64% of CD45 positive 
events to 0.99% of CD45 positive events. The extremely small sample size and 
the very low frequency of “positive” events makes this difficult to interpret. 
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Method Two:  
 
An alternative method based on a paper by Dulic-Sills et al (411) was then 
considered. This method used a “dumping” method to eliminate cells carrying 
the haematopoietic progenitor markers of CD2 / CD13 and CD22 before gating 
on the markers for endothelial progenitor cells, CD133 and VEGFR2. This 
“dumping” technique is the main difference from method one.  
 
Initially 8 patients had blood tested using anonymous samples from an oncology 
clinic. These demonstrated that the presumed EPCs were present at 0.0023% of 
mono-lymphocytic cells (range 0-0.04).  
 
In addition 3 patients with HCC had samples measured with this method giving a 
mean value of 0.0037% of mono-lymphocytic cells. After embolisation in 2 
patients no rise was seen at 48 hours with a mean value of 0.005%. These 
values appear lower than previously published values; extrapolating to cells/mL 
would give values of 10-20 cells per ml. In addition cells were often only weakly 
positive for CD133 and VEGFR2.  
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Figure 5.8 Second gating strategy for the identification of EPCs 
 
A B
C D
 
 
A = Isolating mononuclear and lymphocytic cells 
B = Excluding cells that are positive for CD2 / CD13 and CD22 as well as selecting cells that are 
CD133 positive.  
C = Selecting cells that are CD133 positive and VEGFR2 positive.  
D = The final quadrant of CD133 and VEGFR2 positive cells contains 1 event.  
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Method Three 
 
 
This method is similar to the first method but replaced CD34 with CD146. 
Although Asahara et al (171) used the combination of CD34 and VEGFR2 to 
characterise EPCs in 1997, the advent of CD133 to identify primitive stem cells 
meant CD34 was less useful. Cells that are CD133 positive and VEGR2 positive 
have been demonstrated to differentiate into endothelial cells (412), with 
functional properties of endothelial cells. CD34 expression on angiogenic cells is 
now considered to be variable. CD146 is an endothelial cell marker and a 
marker of mesenchymal stem cells and is thought to be expressed in EPCs.  
 
Ten patients with HCC had blood analysed using this method resulting in a 
median value of 0.0046% of mono-lymphocytic cells (range 0.00097-0.1339) and 
0.368% of CD45 low cells (range 0.094-3.82). This gives a median of 100 cells/ml 
(range 10-810). Using the adapted method on a further 6 patients with HCC and 
3 healthy controls patients demonstrated a median value of 0.011% mono-
lymphocytes in the patients with HCC compared to 0.0046% in the controls 
(p=0.024). This sample size is too small to make conclusions from but is 
consistent with other data from Poon et al (213).  
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Figure 5.9 Third gating strategy for the identification of EPCs 
 
A B
C D
 
 
A = Isolating mono-lymphocytic cells  
B = Identifying cells that are CD45 negative or weak positive 
C = Isolating cells that are CD133 and CD146 positive 
D = Isolating those that are CD146 and VEGF2 positive  
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5.5.6.3 EPC events over time post embolisation 
 
Changes post-embolisation are detailed in Table 5.4. Ten patients had blood 
taken pre- and post-embolisation at 4 and 24 hours. In addition 3 patients had 
blood taken at 8 and 15 days post-embolisation. There was no evidence of a rise 
in EPC cells post-embolisation demonstrated in this small series. With the 
adoption of the third method the same pattern was seen with no statistical 
difference observed over time. This may be due to the small sample size. Of the 
2 patients who had chemo-embolisation both had a rise in EPCs of 68% and 
330% respectively at 4 hours before falling to just below baseline at 24 hours.  
 
 
Table 5.4 EPC levels post embolisation  
 
 
HCC 
PATIENTS 
PRE 4 PRE 24 HRS PRE 8 DAYS PRE 
15 
DAYS 
 
 
10 10 3 3 
Median 
EPCs 
(% of ML 
cells)  
0.0047 
 
0.009 
 p=0.69 
0.0047 
 
0.0058 
p=0.43 
0.0049 
 
0.0053 
p=0.75 
0.0049 
 
0.0069 
P=0.5 
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5.6 Conclusions 
 
 
The aim of this chapter was to consider whether Tie-2 positive monocytes or 
endothelial progenitor cells could be investigated as biomarkers for the vascular 
disrupting agents. Our study was designed as a pilot study only, to assess the 
feasibility of these approaches rather than to provide definitive evidence for 
their suitability as biomarkers. As a pilot study, only a small number of patients 
were enrolled over a 2 year period making the data difficult to interpret and any 
conclusions only tentative. Future studies are aimed to investigate promising 
biomarkers on a larger scale. Ideally this project could recruit alongside future 
trials of TAE in malignancy as part of a multi-centre study. As flow cytometry 
cannot be done on stored blood any trial would of necessity be prospective 
 
Tie-2 monocytes are known to localize to sites of angiogenesis (159) under the 
influence of angiopoietin-2 (158). The acute hypoxia from TAE was hypothesized 
to lead to cytokine release and secondary recruitment of Tie-2 positive 
monocytes.  
 
Although there has been interest in targeting tumours using Tie-2 positive 
monocytes, there is little data on its use as a biomarker. In this study we 
considered it in patients with hepatocellular cancer undergoing embolisation. 
Our study was confounded by finding that values for Tie-2 positive cells varied 
between flow cytometers. Initial data recorded on the FACSCalibur machine 
gave a median value of 4.69% of monocytes compared to a value of 0.67% for 
the BD FACSAria. The difference may reflect reduced staining of a new batch of 
the Tie-2 antibody (personal communication R&D 2008). The analysis was 
therefore confined to data obtained from the FACSCalibur since the values 
corresponded to previous data published by Venneri et al. 
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There was no evidence in our data set that Tie-2 positive monocytes were 
statistically more frequent in patients with HCC as compared to healthy 
controls. There was a statistically significant correlation with AFP but not with 
liver function according to Child-Pugh status. Tie-2 monocytes did correlate with 
VEGF but there was no clear correlation between serum angiopoietin-2 and 
circulating Tie-2 monocytes (r = 0.013
2
). Post-embolisation a rise in Tie-2 
monocytes was seen with statistical significance reached by day 8. This could 
reflect recruitment from the bone marrow into the circulation. Recruitment 
may be hypoxia driven which could explain the correlation seen with serum 
VEGF. No relationship was seen with prognosis.  
 
This was a pilot study to consider the feasibility of investigating Tie-2 monocytes 
further as a biomarker. One challenge is the possible variability between 
operators. As expression of Tie-2 is a continuous variable there may be no clear 
cut-off between positive and negative events (defining a cell as Tie-2 positive or 
negative). The other cell populations negative for Tie-2 can assist in defining a 
boundary and computer programs may aid visual inspection but subjectivity 
may remain. This work could be extended to include larger number of patients 
since the sample size was very small. It would also be possible to assess the 
soluble Tie-2 receptor in serum which has recently been shown to be elevated 
in neuroendocrine tumours and to correlate with serum angiopoietin-2 (166).  
 
A second pilot experiment explored the use of EPCs as a possible biomarker. 
EPCs are known to be recruited from the bone marrow by angiogenic cytokines 
such as VEGF, bFGF, SDF-1 and GM-CSF (203). They migrate to the hypoxic 
tumour peripheries in areas of intense angiogenesis (413) as demonstrated by 
MRI tracking of labelled CD133 positive cells. The ablation of EPCs reduces 
tumour growth and vascularity (205). Previous work has shown they are 
elevated in hepatocellular cancer (194). Poon et al has shown that an elevated 
level of circulating EPCs correlated with tumour aggressiveness using a method 
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of scoring colony forming units (CFU’s) in the peripheral blood and quantified 
with FACS (using VEGFR2, CD34 and CD133). EPC levels correlated with serum 
AFP, plasma VEGF and interleukin-8 and were higher in patients with non-
resectable disease and in patients who recurred after potentially curative 
surgery (213). This work suggests EPCs as a potential biomarker in HCC. In 
breast cancer they have been used as a surrogate biomarker for an anti-
angiogenesis drug (414). Our hypothesis was that the acute hypoxia resulting 
from tumour embolisation would lead to EPC mobilisation.  
 
Shaked et al (202) demonstrated rapid mobilisation of EPCs after VDA treatment 
in a mouse model. The cells homed to the viable rim of tumour tissue. This 
increase could be blocked by a VEGFR neutralising antibody with a resulting 
increase in anti-tumour activity. After VDA administration an increase in VEGF, 
G-CSF and SDF-1 was seen. G-CSF contributed to EPC mobilisation and was 
induced by it. In human subjects plasma G-CSF, VEGF and SDF-1 increased 4 
hours after administration of a VDA as measured by ELISA and fell again by 24 
hours (203).  
 
One of the difficulties with research in this area is the lack of a standard 
methodology to define an EPC by flow cytometry. In this study I considered 
three different methods. Initially I used a method based on the original data 
from Asahara et al (171) who used co-expression of CD34 and VEGFR2 to define 
an EPC. Later work questioned the reliance on the haematopoietic stem cell 
marker, CD34 (410) since it is found on both EPCs and more mature endothelial 
cells.  I therefore explored the method described by Macey et al (411) which 
excluded cells on the basis of their expression of haematopoietic markers CD2 / 
CD13 and CD22 before selecting cells with the stem cell marker CD133 and 
VEGFR2. Using this method I found very low numbers of cells with weak staining 
for VEGFR2 and CD133. 
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The final method used the markers CD133 and CD146 instead of CD34, together 
with VEGFR2. Using this method we considered patients pre- and post-
embolisation to assess for changes over 4 and 24 hours. In our small patient 
sample there was no indication of any difference. This differs from data 
published by Shaked et al which demonstrated a rise in EPCs at 4 hours which 
resolved by 24 hours (203). Their method differed from ours using 
CD13
+
VEGFR2
+
CD45
-/dim
CD117
+
. CD13 is known to be expressed on 
haematopoietic progenitor cells and was one of the markers used to exclude 
cells by Macey et al (411). As both VEGR2 and CD117 are also expressed (178) 
on subsets of haematopoietic progenitor cells it is likely they are included in the 
analysis. We used the same time points post embolisation as Shaked et al did 
post VDA. It may be that the EPC response to hypoxia induced by embolisation 
differs from that post VDA with a different time-course. Alternatively the rise 
post VDA may not be induced by tumour hypoxia but be secondary to an 
independent systemic effect of the VDA on bone marrow inducing EPC 
recruitment.  
 
EPCs have potential as biomakers for anti-angiogenic agents. Challenges remain 
with the lack of a standard methodology to identify them. Flow cytometry is a 
valuable tool to identify candidate cells but unless they are cultured it is difficult 
to be certain they are indeed EPCs. The combination of CD133
+
 and VEGFR2
+
 
has been validated by isolating and culturing these cells and demonstrating 
differentiation into endothelial cells with the functional properties of EPCs 
(412). In other papers CD34 has been reported as both positive and negative in 
EPCs (410, 415) as has CD45 (171, 415, 416), which may relate to lack of clarity 
of what constitutes dim expression. To avoid using CD45 Khan et al (410) 
recommends the use of an exclusionary gating strategy such as CD3 / CD19 and 
CD33. An alternative would be the gating strategy we employed in our second 
method of CD2 / CD13 and CD22.  
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The different methodologies employed suggest there are likely to be separate 
groups of cells with endothelial progenitor like properties and overlapping 
phenotypes. Some cells may be derived from monocytes or have monocytoid 
properties (417). Gulati et al (418) considered several cell types having the 
potential to differentiate into EPCs including monocytes expressing CD14 and 
those expressing CD133 and VEGFR. A clearer understanding of the differing cell 
types with angiogenic potential would be useful in determining their best role 
as biomarkers. To this aim  Mellick et al (419) used the transcription factor 
inhibitor of DNA binding 1 in mouse transgenic models and tracked EPCs from 
bone marrow into circulation and then to tumour stroma. Ablation with a 
suicide gene led to a reduced tumour growth secondary to an impaired 
angiogenesis.   
 
Further practical considerations with circulating EPCs are their rarity making it 
difficult to exclude the impact of background noise. In our study we aimed to 
collect 10
6 
events in total. It is likely that collecting even larger number of 
events would be optimal with such rare-event analysis. The lengthy sorting time 
required may restrict EPC use to a research setting. Further work is needed to 
explore the relationship between EPC and malignancy.  
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Chapter Six: Conclusions 
 
 
In this, my final chapter, I shall aim to summarise the key findings of my thesis 
and then consider them further in the context of the expanding field of 
radioimmunotherapy.  
 
The initial hypothesis was that single agent radioimmunotherapy would be 
effective and relatively non-toxic in haematological malignancy. This statement 
appears consistent with the findings of Chapter Two, our Phase I study of 
131
I-
CHT25 in CD25-expressing lymphoma. This study has been published and is now 
progressing to a Phase Two to further assess efficacy and toxicity in a larger 
patient group.  
 
Our initial hypothesis considered that solid tumours were more likely to present 
challenges for single-agent RIT. To date results have remained disappointing, 
particularly in advanced disease (94). To exploit synergy seen in animal models 
(123), RIT was combined with a VDA to induce tumour vascular shut-down. 
However as reported in Chapter Three, results remained disappointing with 
only minor evidence of efficacy and unexpected toxicity. The lack of efficacy 
may at least be partly attributed to the lack of vascular shut-down induced by 
CA4P on DCE-MRI.  
 
This observation emphasised the need for an effective biomarker for the extent 
of vascular shut-down achieved by the VDA’s. There are a number of limitations 
with imaging methods. Serum biomarkers have the advantage of being 
quantifiable, less operator-dependent, and repeatable. A biomarker would 
allow an optimal protocol to be developed to allow maximum synergy to occur 
and to minimise the risk of vascular shut-down preventing RIT access to tumour. 
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Chapters 4 and 5 report pilot studies on various compounds as potential 
biomarkers.  
 
Two hypotheses were considered in Chapters 4 and 5. Both are investigated in 
preliminary pilot studies to consider whether further more definitive work 
would be feasible and desirable. The first hypothesis was that an appropriate 
model for vascular shut-down secondary to a VDA would be vascular shut-down 
secondary to physical means (TAE). Both are known to cause ischaemic necrosis 
with secondary hypoxia. TAE has the advantage of larger patient numbers and a 
more consistent time and level of vascular occlusion.  
 
The second hypothesis was that this hypoxia would generate the secretion of 
angiogenic cytokines, Tie-2 expressing monocytes and Endothelial Progenitor 
Cells (EPC’s) and that these would have potential to act as biomarkers. As a pilot 
study only, definitive answers were not anticipated but promising substances 
could be considered for further investigation in multi-centre studies. Evaluating 
our results in the context of prior research is important for our small studies. I 
shall then consider how this research relates to future work. 
 
Currently RIT has been most successful in haematological malignancy, as 
predicted by the radiobiology. Much of the previous research has been in 
indolent B-cell lymphomas and targeted the CD20 cell surface antigen. This 
research has led to 2 licensed agents, 
90
Y-ibritumomab tiuxetan (Zevalin®) (74) 
and 
131
I-tositumomab (Bexxar®) (84). Both have shown clinical benefit at non-
myeloablative doses. Although most patients relapse within 6-15 months (420) 
approximately 15-20% attain long term remissions and a proportion may be 
cured. RIT with more aggressive lymphomas, such as DLBCL, have typically been 
less successful, attributed to their higher proliferative rate failing to be 
controlled by the low dose rate of RIT.  
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Our study of 
131
I-CHT25 in CD25-expressing lymphoma (mainly Hodgkin’s 
lymphoma) demonstrated that, at the MTD, it was relatively well tolerated and 
showed some evidence of efficacy. The single-agent efficacy observed here is 
encouraging considering the higher proliferative rate of HL or T-cell lymphoma 
compared with indolent lymphoma. The toxicity profile was similar although a 
high rate of non-neutropenic infection was seen, whether this was due to an 
immunomodulatory effect of the RIC or due to the heavily pre-treated patient 
group is not clear.  
 
Previous attempts at RIT in HL have used murine antibodies against the CD30 
receptor (237) with limited evidence of efficacy. Our paper is important as it 
uses a chimeric antibody and demonstrates manageable toxicity. Although 
chimeric and humanized antibodies (233-234) have been used in their unlabeled 
form in HL, concerns about their longer half-lives exposing patients to greater 
bone marrow suppression have so far limited their use in RIT. Our study also 
targets CD25, a receptor which has not been explored as a target in HL, 
although Waldmann et al have investigated it in ATLL (244). The advantage of 
targeting CD25 over CD30 may relate to its expression on the surrounding 
inflammatory cells as well as malignant cells. These inflammatory cells are 
thought to consist of predominantly CD25 positive T-regulatory cells that may 
protect the malignant cells from the host response and aid their malignant 
potential (255). Further studies will aim to clarify the immunomodulatory effect 
of 
131
I-CHT25, particularly on these T-regulatory and Natural Killer cells.  
 
Due to the results of the Phase I study presented here, 
131
I-CHT25 is due to 
enter further Phase II trials in patients with relapsed HL. This trial should help 
determine whether single-agent RIT can deliver long-term remissions in HL. 
However if the experience of indolent B-cell lymphomas are typical most 
patients will either fail to respond or have short-lived responses therefore 
improving RIT remains vital. Different strategies can be considered. RIT may be 
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more effective if combined with chemotherapy or other targeted agents, if 
given with high-dose therapies such as ASCT or allogeneic transplant, if it is 
given earlier in the disease course, if multiple antigens are targeted or if pre-
targeting two-step methods are used to increase the dose delivered to tumour.  
Methods to better predict haematological toxicity such as FLT-3L may aid dosing 
and even allow dose escalation in a sub-group of patients (254).  
 
Our Phase II study will plan to investigate some of these strategies. It will 
administer unlabeled CD25 antibody prior to the RIC to remove any ‘sink’ of 
soluble IL-2 from the circulation. The initial Phase II study will remain in patients 
with relapsed HL but eventually it may be feasible to administer it earlier, either 
in first relapse in high-risk patients with HL or first-line in patients with poor 
prognosis T-cell lymphoma. Using this strategy in NHL Kaminski et al improved 
response rate, but more importantly increased the number of durable 
responses, with a time to progression of over 5 years (83).  
 
RIT can be combined with chemotherapy or other targeted agents. Press et al 
administered RIT after standard chemotherapy for follicular lymphoma and 
found an increase in CR and molecular remission rate with little additional 
toxicity (421) producing a 5 year progression free survival of 67%. Combinations 
include either ASCT or allogeneic bone marrow transplants. With allogeneic 
transplants Press et al has replaced total body irradiation used in conditioning 
regimens with myeloablative RIT. Results have been promising with high and 
durable responses rates (422) including in patients with DLBCL. RIT can be 
included as part of the conditioning for autologous transplantation. Devizzi et al 
has published interesting results in a range of B-cell lymphomas (423) and a 
phase III study is currently underway considering the addition of 
131
I-
tositimomab to a standard autologous regimen in DLBCL. In our own study 2 
patients went on to receive high-dose therapy (1 autograft; 1 allograft). No 
excess toxicity was seen and both transplants engrafted satisfactorily. We 
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intend to further investigate the potential of 
131
I-CHT25 in the conditioning 
regimens of ASCT in relapsed HL.  
 
In contrast to haematological malignancy, radiobiology predicted that single-
agent RIT is likely to be disappointing in solid tumours, particularly in patients 
with bulky, resistant disease (94). A variety of methods have been attempted to 
improve RIT. The development of antibody fragments has improved tumour 
uptake and clearance (45), chimeric and humanized antibodies have reduced 
immunogenicity (54), pre-targeting two-step methods have allowed an 
improved tumour to blood ratio (60) and various combinations of agents have 
been tried including chemotherapeutics and cytokines. Our group hoped to 
exploit the synergy seen in animal models between RIT and the VDA’s to 
improve the efficacy of RIT in solid tumours (119).  
 
The 
131
I-A5B7 Phase II study is reported in Chapter 3. Synergy between the RIT 
and VDA was anticipated due to their differing mechanisms and sites of action, 
with the VDA targeting the poorly perfused centre and the RIT the tumour rim. 
In animal models a sub-curative therapy was transformed into a curative one 
with this combination. No unacceptable toxicities were seen (119). Although no 
additive toxicity was anticipated in this study the starting doses were below the 
MTD’s derived from the single agent data. However dose-limiting 
myelosuppression was seen with the first cohort. Even after reducing the 
administered activity further toxicity occurred and the study was stopped.  
 
This toxicity was unexpected. It may reflect an independent cytotoxic effect of 
the CA4P similar to other chemotherapeutics that interact with tubulin such as 
the vinca alkaloids (277). The combination of a VDA with RIT is novel so there 
are no equivalent clinical trials to compare to. However a significant 
myelosuppressive effect has not been identified in any of the single agent 
studies (265-267) or when in combination with chemotherapy (279) apart from 
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a single study where CA4P was administered 60 minutes post carboplatin. The 
subsequent vascular shut down was thought to impede the renal clearance of 
the carboplatin (280). There was no evidence from our study that the 
pharmacokinetics of the 
131
I-A5B7 were altered by the CA4P when comparisons 
were made with the single agent study (94) or that the administration of the 
CA4P two weeks prior to the first infusion of the RIC had any impact on tumour 
uptake. It is possible that the pharmacokinetics of the CA4P administered post 
RIC administration were affected since data was collected from the preceding 
administration due to radiation protection issues. It may simply represent the 
more heavily pre-treated patient group when compared to earlier studies when 
fewer chemotherapeutic agents were available (94).  
 
No objective responses were seen although one patient who had a reduction in 
blood flow on DCE-MRI post CA4P and a high tumour absorbed radiation dose 
did show a minor radiological response associated with a fall in tumour markers. 
The lack of responses may be secondary to the low VDA dose administered and 
a failure of adequate vascular shut-down. It may also be due to chance in a 
small patient group, more heavily pre-treated patients losing antigen expression 
secondary to tumour de-differentiation or the lower tumour absorbed dose 
compared to Lane et al (94) which may itself be secondary to de-differentiation. 
The problems with ensuring that the biological outcome of vascular shut down 
was met highlighted the necessity of an improved biomarker in these multi-
modality trials.  
 
The future of RIT combined with a VDA remains uncertain due to the 
unexpected toxicity encountered. Future animal work may help to delineate 
why this unexpected toxicity occurred. Currently multiple studies are in process 
investigating the combinations of a VDA with chemotherapy, anti-angiogenic 
agents and targeted agents. In addition newer, more potent VDA’s are in 
development (424) that may induce vascular shut-down more efficiently. The 
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RIT may be delivered using pre-targeting methods where the delivery of the 
antibody is separated from that of the radioisotope. This has the advantage of 
improving the tumour to normal body ratio and reducing the risk of toxicity or 
of allowing a safer escalation of injected activity (60). Antibody engineering and 
the use of fragments including minibodies and SIP’s may also help to increase 
tumour uptake and clearance and therefore improve the tumour to normal 
tissue ratios (50).  
 
 
As described earlier one of the current difficulties of combining RIT with a VDA 
is the lack of a good biomarker to measure the effects on the vasculature. This is 
particularly problematic when issues of scheduling therapies are crucial to both 
efficacy and toxicity. Current imaging methods are time-consuming, costly and 
exclude many patients. They cannot be used in a radio-active patient after 
radioisotope administration. A reliable surrogate marker would be of 
tremendous benefit in drug development, particularly if a serum marker could 
be identified which was easily reproducible and quantifiable.  
 
Chapters 4 and 5 present pilot studies considering the angiogenic cytokines, Tie-
2 expressing monocytes and Endothelial Progenitor Cells as possible biomarkers 
for the VDA’s and other agents causing vascular shut-down. Trans-arterial 
embolisation was used as a model for vascular shut down induced by the VDA’s. 
It was hypothesised that TAE would induce ischaemic necrosis (141) leading to 
the release of HIF1-α and subsequently the angiogenic cytokines, EPC’s and Tie-
2 monocytes. TAE was chosen as a model due to its more consistent extent of 
and time duration of vascular shut-down together with the possibility of a larger 
patient group. Even as a pilot study it was anticipated it would take 
approximately 2 years to collect the data.  
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As a pilot study our data can not be considered definitive but instead aimed to 
provide directions for future research. Serum Angiopoietin-2 is known to be 
elevated in HCC (348) and be an independent prognostic factor. Our data 
confirms that of Scholz et al that Angiopoietin-2 levels did not correlate with 
tumour characteristics but did with markers of severity of liver disease (348). In 
addition our study found no difference in Ang-2 levels between patients with 
cirrhosis and those with HCC alone. This differs from Scholz et al and may 
represent chance in a small study. Alternatively it could reflect the differences 
between the patient groups, the respective AFP’s suggest that Scholz et al 
includes more patients with an advanced tumour stage than in our study. The 
data presented here and in Scholz et al (348) suggest that the source of 
Angiopoietin-2 may not be tumour but the surrounding cirrhotic liver. 
Histological studies have been contradictory (346-347), which may relate to 
heterogeneity in tumour expression.  
 
Serum angiopoietin-1 has been less studied than angiopoietin-2 and our study is 
the first I am aware of in HCC. I report a lower level of serum Ang-1 in patients 
with HCC compared to healthy controls. The high Ang-2 and low Ang-1 levels 
are consistent with a pro-angiogenic environment. Tissue expression studies 
have either found a stable level of Ang-1 ((331, 334) or an elevated one (306, 
425) although in all these studies the Ang2:Ang1 ratio was elevated. It is not 
clear what causes the discrepancy between these findings; further studies on 
serum Angiopoietin-1 in HCC are indicated. Of note Park et al did find a reduced 
serum level in NSCLC (342). In our study serum Ang-1 was not of prognostic 
significance and no difference was observed in serum levels post-embolisation 
suggesting Ang-1 may be derived at least partly from the surrounding cirrhotic 
liver. This finding does fit in with the expression data where levels between 
tumour and cirrhotic liver were similar (331).  
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Studies have shown an elevated serum VEGF in patients with HCC (307). Higher 
levels were associated with a poorer prognosis post TAE (309). In a meta-
analysis of 8 studies, all but 1 in the Asian population, serum VEGF was 
associated with a poorer outcome (300). However in our study no difference 
could be determined between serum VEGF in HCC and healthy controls. 
Although HCC values appeared consistent with those obtained in Poon et al 
(309) the control values were higher. This highlights the difficulty of using serum 
VEGF which is known to have a comparatively wide range in the normal healthy 
population, a challenge for small studies such as ours. Our study did find a 
poorer prognosis for patients with high serum VEGF levels consistent with the 
meta-analysis (300). Although serum VEGF rose post embolisation the rise in 
our study was relatively late, becoming significant by day 15. Other studies have 
shown an earlier rise by day 7 (395).  
 
Few studies have considered bFGF in HCC and they all are in the Asian 
population. Our data confirms that from Poon et al (364) who did not find any 
difference between serum bFGF in patients with HCC and controls. However 
their group found a correlation between high bFGF levels and a poorer outcome 
which in common with another group (365) we could not replicate. Values did 
not change post-embolisation and no other studies have considered this.  
 
Erythrocytosis is relatively common in patients with HCC (2-12%) (406) and 
thought to be secondary to an elevated erythropoietin level. Few studies have 
assessed serum erythropoietin levels in HCC and those that do tend to consist of 
case studies or small series (390, 406). Our data is consistent with that work, 
showing erythropoietin levels are elevated in HCC and in patients with cirrhosis 
alone. In our small data series levels did not seem to affect prognosis. Levels 
consistently doubled post-embolisation remaining elevated for 1 week. This rise 
is likely secondary to vascular shut down causing ischaemia and a smaller rise 
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was seen post coronary angiography. I am aware of no other study that has 
considered erythropoietin levels post TAE.  
 
My hypothesis with the angiogenic cytokines was that the ischaemic necrosis 
induced by embolisation would cause them to be secreted secondary to 
hypoxia. Their rise would therefore be a biological marker for the extent of 
vascular shutdown. Serum angiogenic cytokines have the advantage of being 
determined by ELISA, which is a relatively straightforward validated assay and 
allows samples to be stored and analysed later.  
 
Of the angiogenic cytokines studied serum erythropoietin has the most 
potential as a biomarker with a consistent rise post embolisation. The 
Angiopoietins failed to rise and may be secreted by the surrounding cirrhosis 
rather than the tumour as did bFGF. Although VEGF levels did increase they did 
so late and remained very variable between different patients making them less 
useful. This study is only a pilot, so potential biomarkers need to be further 
evaluated in larger series. To expand patient numbers this may require multi-
centre studies and include trials of the VDA’s as they move into later phase 
clinical studies. Whilst erythropoietin merits further evaluation other 
substances are interesting. These include TGF-beta1 and its co-receptor CD105 
which are thought to enhance the malignant potential and angiogenesis (426). 
Shaked et al have considered SDF-1 (stromal derived factor-1) and G-CSF 
(granulocyte colony-stimulating factor) (203) post VDA in both animal models 
and patients and demonstrated rapid rises within 4 hours of administration.  
 
Tie-2 monocytes are known to be recruited from bone marrow secondary to 
hypoxia and directed to sites of angiogenesis under the influence of 
angiopoietin-2 (158). This led to the hypothesis that they may have potential as 
a biomarker for vascular shut down. Although Tie-2 monocytes have been 
detected in the blood of patients with a variety of malignancies including lung, 
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kidney, colon, pancreas and neuroendocrine tumours (165) they have not been 
studied in hepatocellular cancer or been investigated as a biomarker. 
Unfortunately our study was limited by poor Tie-2 staining (R&D Personal 
Communication) limiting patient numbers to 16. In this very small cohort, levels 
of Tie-2 monocytes were not elevated in patients with HCC, although they were 
higher in HCC patients with an elevated AFP. A correlation was seen between 
serum VEGF and Tie-2 and both rose from day 8 post-embolisation. This late rise 
may reflect their recruitment induced by hypoxia. Both VEGF and Tie-2 
monocytes are more likely to be responding to the same stimulus rather than 
being dependent on each other since in-vitro work has not shown Tie-2 
recruitment to be dependent on VEGF (427). Although these observations are 
interesting for further study they cannot be considered definitive due to the 
extremely small sample size and the lack of other corroborating studies in this 
area.  
 
Our study demonstrates the feasibility of using flow cytometry to assess Tie-2 
monocytes and found these cells present in HCC. Future larger studies would be 
required to optimize and standardize the flow cytometry protocol and then 
investigate their role as a potential biomarker for vascular shut down more 
definitively. Tie-2 expressing monocytes have the ability to hone to tumours. 
Studies are currently in progress using them as delivery agents for cytotoxics 
(167).  
 
Considerable controversy exists about endothelial progenitor cells and the role 
they play in promoting tumour angiogenesis. They are thought to be recruited 
to tumours under the influence of the angiogenic cytokines and secondary to 
hypoxia. A single study by Ho et al (213) has shown they are elevated in HCC 
and correlate with a poorer prognosis. In mouse models levels have been shown 
to increase at 4 hours post VDA administration together with VEGF (203). 
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Our study could not replicate these findings. This may be due to the small 
sample size of our study together with the variability in EPC levels between 
patients. A rise in EPC levels may be a transient event and its time-course may 
differ after administration of a VDA or post-TAE. It may also be explained if the 
rise post VDA was not secondary to hypoxia but a direct effect of the drug on 
the bone marrow.  
 
One of the difficulties currently with EPC assessment is the lack of a standard 
methodology to define them. There is currently no universally accepted 
combination of cell surface markers that define an EPC and different groups use 
different combinations that are often mutually exclusive. For example Shaked et 
al (203) reported that EPCs rose post VDA administration. But the combination 
of cell markers selected would also select subgroups of haematopoietic 
progenitor cells and would have been excluded by Macey et al (411). Therefore 
it is difficult to compare different papers as they are often not comparing the 
same cell population.  
 
Before EPC’s can be considered as a viable proposition as a biomarker more 
information is therefore needed to define what is an endothelial progenitor cell. 
Currently combinations used should be restricted to those that have been 
validated with cell culture work such as the combination of CD133 and VEGFR2 
(171), and found to have the functional properties of EPC’s. Future work 
considering the genetic differences between these overlapping cell populations 
look may provide some clarity (419).  
 
In practical terms EPC acquisition involves rare event analysis with a resulting 
difficulty in excluding background noise from the data. Large numbers of events 
are required which take a long time to acquire. The lack of true clustering of 
events means automation is difficult and variability between operators can 
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introduce bias. These difficulties reduce its potential as a biomarker for 
standard clinical practice.  
 
In summary and with consideration of both my own studies presented here and 
the previous published research RIT remains a promising treatment for 
haematological malignancy. The 
131
I-CHT25 clinical trial demonstrated efficacy 
and was relatively well tolerated at the MTD. This trial is now entering 
recruitment as part of Phase II. In contrast RIT in advanced solid tumours has 
remained disappointing. My thesis describes a novel approach to this problem, 
of combining a VDA with RIT to exploit the synergy previously noted in animal 
models. Unfortunately unexpected toxicity was seen whilst the dose of CA4P 
remained sub-optimal to allow effective vascular shutdown. The limited 
shutdown may have contributed to the lack of clinical efficacy. The problems of 
combining these two agents have highlighted the need for an effective 
biomarker for the VDAs. I have considered the angiogenic cytokines, Tie-2 
expressing monocytes and the endothelial progenitor cells in preliminary 
feasibility studies using TAE as a model. The study identified promising 
compounds to investigate further in future studies.  
  
 
 
 
 
 
 
 
 
 
 
 
 242 
 
Reference List 
 
 (1)  Mathis KL, Nelson H, Pemberton JH, Haddock MG, Gunderson LL. 
Unresectable colorectal cancer can be cured with multimodality 
therapy. Ann Surg 2008 Oct;248(4):592-598. 
 (2)  Tannock IF. Conventional cancer therapy: promise broken or promise 
delayed? Lancet 1998 May;351 Suppl 2:SII9-16. 
 (3)  Samson MK, Rivkin SE, Jones SE, Costanzi JJ, LoBuglio AF, Stephens RL, 
et al. Dose-response and dose-survival advantage for high versus low-
dose cisplatin combined with vinblastine and bleomycin in 
disseminated testicular cancer. A Southwest Oncology Group study. 
Cancer 1984 Mar 1;53(5):1029-1035. 
 (4)  Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui CH, Abromowitch 
M, et al. Improved outcome in childhood acute lymphoblastic 
leukaemia with reinforced early treatment and rotational combination 
chemotherapy. Lancet 1991 Jan 12;337(8733):61-66. 
 (5)  Hanrahan EO, Broglio K, Frye D, Buzdar AU, Theriault RL, Valero V, et 
al. Randomized trial of high-dose chemotherapy and autologous 
hematopoietic stem cell support for high-risk primary breast 
carcinoma: follow-up at 12 years. Cancer 2006 Jun 1;106(11):2327-
2336. 
 (6)  Mort D, Lansdown M, Smith N, Protopapa K, Mason M. Systemic Anti-
Cancer Therapy: For better, for worse?  2008 Nov. Report No.: 1. 
 (7)  Wilder RB, Denardo GL, DeNardo SJ. Radioimmunotherapy: recent 
results and future directions. J Clin Oncol 1996 Apr;14(4):1383-1400. 
 (8)  Belyakov OV, Mitchell SA, Parikh D, Randers-Pehrson G, Marino SA, 
Amundson SA, et al. Biological effects in unirradiated human tissue 
induced by radiation damage up to 1 mm away. Proc Natl Acad Sci U S 
A 2005 Oct 4;102(40):14203-14208. 
 (9)  Lim SM, Denardo GL, DeNardo DA, Shen S, Yuan A, O'Donnell RT, et al. 
Prediction of myelotoxicity using radiation doses to marrow from 
body, blood and marrow sources. J Nucl Med 1997 Sep;38(9):1374-
1378. 
 243 
 (10)  Srivastava S, Dadachova E. Recent advances in radionuclide therapy. 
Semin Nucl Med 2001 Oct;31(4):330-341. 
 (11)  Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor 
therapy. J Nucl Med 1986 Sep;27(9):1490-1497. 
 (12)  Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, 
Oyen WJ, et al. Biodistribution and therapeutic efficacy of (125/131)I-, 
(186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to 
carcinoembryonic antigen in mice with small peritoneal metastases of 
colorectal origin. J Nucl Med 2004 Jul;45(7):1224-1232. 
 (13)  O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor 
size and curability for uniformly targeted therapy with beta-emitting 
radionuclides. J Nucl Med 1995 Oct;36(10):1902-1909. 
 (14)  Denardo GL, DeNardo SJ, O'Donnell RT, Kroger LA, Kukis DL, Meares 
CF, et al. Are radiometal-labeled antibodies better than iodine-131-
labeled antibodies: comparative pharmacokinetics and dosimetry of 
copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in 
patients with non-Hodgkin's lymphoma. Clin Lymphoma 2000 
Sep;1(2):118-126. 
 (15)  Boswell CA, Brechbiel MW. Development of radioimmunotherapeutic 
and diagnostic antibodies: an inside-out view. Nucl Med Biol 2007 
Oct;34(7):757-778. 
 (16)  Carrasquillo JA, White JD, Paik CH, Raubitschek A, Le N, Rotman M, et 
al. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA 
antiTac monoclonal antibody distribution. J Nucl Med 1999 
Feb;40(2):268-276. 
 (17)  Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, et al. 
Targeted alpha particle immunotherapy for myeloid leukemia. Blood 
2002 Aug 15;100(4):1233-1239. 
 (18)  Allen BJ, Raja C, Rizvi S, Song EY, Graham P. Tumour anti-vascular alpha 
therapy: a mechanism for the regression of solid tumours in metastatic 
cancer. Phys Med Biol 2007 Jul 7;52(13):L15-L19. 
 (19)  McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, et al. 
Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 
1998 Sep;25(9):1341-1351. 
 244 
 (20)  Adams GP, Shaller CC, Chappell LL, Wu C, Horak EM, Simmons HH, et 
al. Delivery of the alpha-emitting radioisotope bismuth-213 to solid 
tumors via single-chain Fv and diabody molecules. Nucl Med Biol 2000 
May;27(4):339-346. 
 (21)  Raja C, Graham P, bbas Rizvi SM, Song E, Goldsmith H, Thompson J, et 
al. Interim analysis of toxicity and response in phase 1 trial of systemic 
targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 
2007 Jun;6(6):846-852. 
 (22)  Kassis AI, Harapanhalli RS, Adelstein SJ. Strand breaks in plasmid DNA 
after positional changes of Auger electron-emitting iodine-125: direct 
compared to indirect effects. Radiat Res 1999 Nov;152(5):530-538. 
 (23)  Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, 
McCarthy KE. Indium-111-pentetreotide prolongs survival in 
gastroenteropancreatic malignancies. Semin Nucl Med 2002 
Apr;32(2):123-132. 
 (24)  Costantini DL, Chan C, Cai Z, Vallis KA, Reilly RM. (111)In-labeled 
trastuzumab (Herceptin) modified with nuclear localization sequences 
(NLS): an Auger electron-emitting radiotherapeutic agent for 
HER2/neu-amplified breast cancer. J Nucl Med 2007 Aug;48(8):1357-
1368. 
 (25)  Costantini DL, McLarty K, Lee H, Done SJ, Vallis KA, Reilly RM. 
Antitumor effects and normal-tissue toxicity of 111In-nuclear 
localization sequence-trastuzumab in athymic mice bearing HER-
positive human breast cancer xenografts. J Nucl Med 2010 
Jul;51(7):1084-1091. 
 (26)  Llewelyn MB, Hawkins RE, Russell SJ. Discovery of antibodies. BMJ 
1992 Nov 21;305(6864):1269-1272. 
 (27)  Kohler G, Milstein C. Continuous cultures of fused cells secreting 
antibody of predefined specificity. Nature 1975 Aug 7;256(5517):495-
497. 
 (28)  Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant 
lymphoma clones with altered cell signaling and cross-resistance to 
chemotherapy. Cancer Res 2007 Feb 1;67(3):1270-1281. 
 245 
 (29)  Kim R, Emi M, Tanabe K. Cancer immunosuppression and autoimmune 
disease: beyond immunosuppressive networks for tumour immunity. 
Immunology 2006 Oct;119(2):254-264. 
 (30)  Fowler JF. Radiobiological aspects of low dose rates in 
radioimmunotherapy. Int J Radiat Oncol Biol Phys 1990 
May;18(5):1261-1269. 
 (31)  Wheldon TE, O'Donoghue JA. The radiobiology of targeted 
radiotherapy. Int J Radiat Biol 1990 Jul;58(1):1-21. 
 (32)  Griffith MH, Yorke ED, Wessels BW, Denardo GL, Neacy WP. Direct 
dose confirmation of quantitative autoradiography with micro-TLD 
measurements for radioimmunotherapy. J Nucl Med 1988 
Nov;29(11):1795-1809. 
 (33)  Bacher K, Thierens HM. Accurate dosimetry: an essential step towards 
good clinical practice in nuclear medicine. Nucl Med Commun 2005 
Jul;26(7):581-586. 
 (34)  Denardo GL, Siantar CL, DeNardo SJ. Radiation dosimetry for 
radionuclide therapy in a nonmyeloablative strategy. Cancer Biother 
Radiopharm 2002 Feb;17(1):107-118. 
 (35)  Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation 
personal computer software for internal dose assessment in nuclear 
medicine. J Nucl Med 2005 Jun;46(6):1023-1027. 
 (36)  Tagesson M, Ljungberg M, Strand SE. A Monte-Carlo program 
converting activity distributions to absorbed dose distributions in a 
radionuclide treatment planning system. Acta Oncol 1996;35(3):367-
372. 
 (37)  Kassis AI. The MIRD approach: remembering the limitations. J Nucl 
Med 1992 May;33(5):781-782. 
 (38)  Rajendran JG, Fisher DR, Gopal AK, Durack LD, Press OW, Eary JF. High-
dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-
Hodgkin's lymphoma: adjusting radiation absorbed dose to actual 
organ volumes. J Nucl Med 2004 Jun;45(6):1059-1064. 
 (39)  Dewaraja YK, Wilderman SJ, Ljungberg M, Koral KF, Zasadny K, 
Kaminiski MS. Accurate dosimetry in 131I radionuclide therapy using 
 246 
patient-specific, 3-dimensional methods for SPECT reconstruction and 
absorbed dose calculation. J Nucl Med 2005 May;46(5):840-849. 
 (40)  Tuttle RM, Leboeuf R, Robbins RJ, Qualey R, Pentlow K, Larson SM, et 
al. Empiric radioactive iodine dosing regimens frequently exceed 
maximum tolerated activity levels in elderly patients with thyroid 
cancer. J Nucl Med 2006 Oct;47(10):1587-1591. 
 (41)  Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK, 
et al. Practical dosimetry of peptide receptor radionuclide therapy with 
(90)Y-labeled somatostatin analogs. J Nucl Med 2005 Jan;46 Suppl 
1:92S-98S. 
 (42)  Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, et al. 
Correlation of tumor and whole-body dosimetry with tumor response 
and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J 
Nucl Med 2001 Nov;42(11):1713-1721. 
 (43)  Dillman RO. Radiolabeled anti-CD20 monoclonal antibodies for the 
treatment of B-cell lymphoma. J Clin Oncol 2002 Aug 15;20(16):3545-
3557. 
 (44)  Dearling JL, Flynn AA, Qureshi U, Whiting S, Boxer GM, Green A, et al. 
Localization of radiolabeled anti-CEA antibody in subcutaneous and 
intrahepatic colorectal xenografts: influence of tumor size and location 
within host organ on antibody uptake. Nucl Med Biol 2009 
Nov;36(8):883-894. 
 (45)  Huhalov A, Chester KA. Engineered single chain antibody fragments for 
radioimmunotherapy. Q J Nucl Med Mol Imaging 2004 Dec;48(4):279-
288. 
 (46)  Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, 
Margolies MN, et al. Protein engineering of antibody binding sites: 
recovery of specific activity in an anti-digoxin single-chain Fv analogue 
produced in Escherichia coli. Proc Natl Acad Sci U S A 1988 
Aug;85(16):5879-5883. 
 (47)  Begent RH, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP, et 
al. Clinical evidence of efficient tumor targeting based on single-chain 
Fv antibody selected from a combinatorial library. Nat Med 1996 
Sep;2(9):979-984. 
 247 
 (48)  Wu AM, Yazaki PJ. Designer genes: recombinant antibody fragments 
for biological imaging. Q J Nucl Med 2000 Sep;44(3):268-283. 
 (49)  Yazaki PJ, Wu AM, Tsai SW, Williams LE, Ikler DN, Wong JY, et al. 
Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 
diabody and t84.66 minibody: comparison to radioiodinated 
fragments. Bioconjug Chem 2001 Mar;12(2):220-228. 
 (50)  Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, et al. 
Expression of the oncofetal ED-B-containing fibronectin isoform in 
hematologic tumors enables ED-B-targeted 131I-L19SIP 
radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009 Mar 
5;113(10):2265-2274. 
 (51)  Graff CP, Chester K, Begent R, Wittrup KD. Directed evolution of an 
anti-carcinoembryonic antigen scFv with a 4-day monovalent 
dissociation half-time at 37 degrees C. Protein Eng Des Sel 2004 
Apr;17(4):293-304. 
 (52)  Osbourn JK, Field A, Wilton J, Derbyshire E, Earnshaw JC, Jones PT, et 
al. Generation of a panel of related human scFv antibodies with high 
affinities for human CEA. Immunotechnology 1996 Sep;2(3):181-196. 
 (53)  Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, 
et al. High affinity restricts the localization and tumor penetration of 
single-chain fv antibody molecules. Cancer Res 2001 Jun 
15;61(12):4750-4755. 
 (54)  Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 
2006 May;6(5):343-357. 
 (55)  Ledermann JA, Begent RH, Massof C, Kelly AM, Adam T, Bagshawe KD. 
A phase-I study of repeated therapy with radiolabelled antibody to 
carcinoembryonic antigen using intermittent or continuous 
administration of cyclosporin A to suppress the immune response. Int J 
Cancer 1991 Mar 12;47(5):659-664. 
 (56)  Sakahara H, Reynolds JC, Carrasquillo JA, Lora ME, Maloney PJ, Lotze 
MT, et al. In vitro complex formation and biodistribution of mouse 
antitumor monoclonal antibody in cancer patients. J Nucl Med 1989 
Aug;30(8):1311-1317. 
 248 
 (57)  Hasholzner U, Stieber P, Meier W, Lamerz R. Value of HAMA--
determination in clinical practice--an overview. Anticancer Res 1997 
Jul;17(4B):3055-3058. 
 (58)  Hwang WY, Foote J. Immunogenicity of engineered antibodies. 
Methods 2005 May;36(1):3-10. 
 (59)  Gautherot E, Bouhou J, Le Doussal JM, Manetti C, Martin M, Rouvier E, 
et al. Therapy for colon carcinoma xenografts with bispecific antibody-
targeted, iodine-131-labeled bivalent hapten. Cancer 1997 Dec 
15;80(12 Suppl):2618-2623. 
 (60)  Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody 
pretargeting advances cancer radioimmunodetection and 
radioimmunotherapy. J Clin Oncol 2006 Feb 10;24(5):823-834. 
 (61)  Sharkey RM, Goldenberg DM. Use of antibodies and 
immunoconjugates for the therapy of more accessible cancers. Adv 
Drug Deliv Rev 2008 Sep;60(12):1407-1420. 
 (62)  Cairns R, Papandreou I, Denko N. Overcoming physiologic barriers to 
cancer treatment by molecularly targeting the tumor 
microenvironment. Mol Cancer Res 2006 Feb;4(2):61-70. 
 (63)  Fukumura D, Jain RK. Tumor microvasculature and microenvironment: 
targets for anti-angiogenesis and normalization. Microvasc Res 2007 
Sep;74(2-3):72-84. 
 (64)  Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure 
- an obstacle in cancer therapy. Nat Rev Cancer 2004 Oct;4(10):806-
813. 
 (65)  Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, 
biologic, and molecular aspects. J Natl Cancer Inst 2001 Feb 
21;93(4):266-276. 
 (66)  Russell SJ, Llewelyn MB, Hawkins RE. Principles of antibody therapy. 
BMJ 1992 Dec 5;305(6866):1424-1429. 
 (67)  Carter P, Smith L, Ryan M. Identification and validation of cell surface 
antigens for antibody targeting in oncology. Endocr Relat Cancer 2004 
Dec;11(4):659-687. 
 249 
 (68)  Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and 
resistance. Semin Oncol 2002 Feb;29(1 Suppl 2):2-9. 
 (69)  Maxwell P. Carcinoembryonic antigen: cell adhesion molecule and 
useful diagnostic marker. Br J Biomed Sci 1999;56(3):209-214. 
 (70)  Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and 
its potential as a target for mAb therapy. Curr Dir Autoimmun 
2005;8:140-174. 
 (71)  Zhang Y, Pastan I. High shed antigen levels within tumors: an additional 
barrier to immunoconjugate therapy. Clin Cancer Res 2008 Dec 
15;14(24):7981-7986. 
 (72)  Press MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, Zhou JY, et 
al. Diagnostic evaluation of HER-2 as a molecular target: an assessment 
of accuracy and reproducibility of laboratory testing in large, 
prospective, randomized clinical trials. Clin Cancer Res 2005 Sep 
15;11(18):6598-6607. 
 (73)  Behr TM, Salib AL, Liersch T, Behe M, Angerstein C, Blumenthal RD, et 
al. Radioimmunotherapy of small volume disease of colorectal cancer 
metastatic to the liver: preclinical evaluation in comparison to 
standard chemotherapy and initial results of a phase I clinical study. 
Clin Cancer Res 1999 Oct;5(10 Suppl):3232s-3242s. 
 (74)  Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, 
Joyce R, et al. Randomized controlled trial of yttrium-90-labeled 
ibritumomab tiuxetan radioimmunotherapy versus rituximab 
immunotherapy for patients with relapsed or refractory low-grade, 
follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 
2002 May 15;20(10):2453-2463. 
 (75)  Johnson PW, Rohatiner AZ, Whelan JS, Price CG, Love S, Lim J, et al. 
Patterns of survival in patients with recurrent follicular lymphoma: a 
20-year study from a single center. J Clin Oncol 1995 Jan;13(1):140-
147. 
 (76)  Tsang RW, Gospodarowicz MK. Radiation therapy for localized low-
grade non-Hodgkin's lymphomas. Hematol Oncol 2005 Mar;23(1):10-
17. 
 250 
 (77)  Horning SJ. Natural history of and therapy for the indolent non-
Hodgkin's lymphomas. Semin Oncol 1993 Oct;20(5 Suppl 5):75-88. 
 (78)  Hunault-Berger M, Ifrah N, Solal-Celigny P. Intensive therapies in 
follicular non-Hodgkin lymphomas. Blood 2002 Aug 15;100(4):1141-
1152. 
 (79)  Adachi S, Leoni LM, Carson DA, Nakahata T. Apoptosis induced by 
molecular targeting therapy in hematological malignancies. Acta 
Haematol 2004;111(1-2):107-123. 
 (80)  McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams 
ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy 
for relapsed indolent lymphoma: half of patients respond to a four-
dose treatment program. J Clin Oncol 1998 Aug;16(8):2825-2833. 
 (81)  Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh 
MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy 
in patients with rituximab-refractory follicular non-Hodgkin's 
lymphoma. J Clin Oncol 2002 Aug 1;20(15):3262-3269. 
 (82)  Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, et al. 
Radioimmunotherapy with iodine (131)I tositumomab for relapsed or 
refractory B-cell non-Hodgkin lymphoma: updated results and long-
term follow-up of the University of Michigan experience. Blood 2000 
Aug 15;96(4):1259-1266. 
 (83)  Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. 
131I-tositumomab therapy as initial treatment for follicular lymphoma. 
N Engl J Med 2005 Feb 3;352(5):441-449. 
 (84)  Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, 
Fehrenbacher L, et al. Pivotal study of iodine I 131 tositumomab for 
chemotherapy-refractory low-grade or transformed low-grade B-cell 
non-Hodgkin's lymphomas. J Clin Oncol 2001 Oct 1;19(19):3918-3928. 
 (85)  Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, 
et al. Assessment of treatment-related myelodysplastic syndromes and 
acute myeloid leukemia in patients with non-Hodgkin lymphoma 
treated with tositumomab and iodine I131 tositumomab. Blood 2005 
Jun 15;105(12):4576-4582. 
 251 
 (86)  Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, et 
al. Radiation dosimetry results and safety correlations from 90Y-
ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory 
non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl 
Med 2003 Mar;44(3):465-474. 
 (87)  Emmanouilides C, Witzig TE, Gordon LI, Vo K, Wiseman GA, Flinn IW, et 
al. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is 
safe and effective in patients with previously treated B-cell non-
Hodgkin's lymphoma. Leuk Lymphoma 2006 Apr;47(4):629-636. 
 (88)  Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, 
Murray JL, et al. Safety of yttrium-90 ibritumomab tiuxetan 
radioimmunotherapy for relapsed low-grade, follicular, or transformed 
non-hodgkin's lymphoma. J Clin Oncol 2003 Apr 1;21(7):1263-1270. 
 (89)  Emmanouilides C, Witzig TE, White CA, Gordon LI, Wiseman GA, 
Murray JL, et al. Rapid immune reconstitution after Zevalin is 
associated with low infectious risk., 3 ed 2002. p. 346-347. 
 (90)  Czuczman MS, Emmanouilides C, Darif M, Witzig TE, Gordon LI, Revell 
S, et al. Treatment-related myelodysplastic syndrome and acute 
myelogenous leukemia in patients treated with ibritumomab tiuxetan 
radioimmunotherapy. J Clin Oncol 2007 Sep 20;25(27):4285-4292. 
 (91)  Emmanouilides C, Witzig TE, Wiseman GA, Gordon LI, Wang H, Schilder 
R, et al. Safety and efficacy of yttrium-90 ibritumomab tiuxetan in 
older patients with non-Hodgkin's lymphoma. Cancer Biother 
Radiopharm 2007 Oct;22(5):684-691. 
 (92)  Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE. 
Subsequent chemotherapy regimens are well tolerated after 
radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-
Hodgkin's lymphoma. J Clin Oncol 2002 Sep 15;20(18):3885-3890. 
 (93)  Koppe MJ, Bleichrodt RP, Oyen WJ, Boerman OC. 
Radioimmunotherapy and colorectal cancer. Br J Surg 2005 
Mar;92(3):264-276. 
 (94)  Lane DM, Eagle KF, Begent RH, Hope-Stone LD, Green AJ, Casey JL, et 
al. Radioimmunotherapy of metastatic colorectal tumours with iodine-
131-labelled antibody to carcinoembryonic antigen: phase I/II study 
with comparative biodistribution of intact and F(ab')2 antibodies. Br J 
Cancer 1994 Sep;70(3):521-525. 
 252 
 (95)  Padera TP, Stoll BR, Tooredman JB, Capen D, di TE, Jain RK. Pathology: 
cancer cells compress intratumour vessels. Nature 2004 Feb 
19;427(6976):695. 
 (96)  Itzkowitz SH, Shi ZR, Kim YS. Heterogeneous expression of two 
oncodevelopmental antigens, CEA and SSEA-1, in colorectal cancer. 
Histochem J 1986 Apr;18(4):155-163. 
 (97)  Kaanders JH, Bussink J, van der Kogel AJ. Clinical studies of hypoxia 
modification in radiotherapy. Semin Radiat Oncol 2004 Jul;14(3):233-
240. 
 (98)  Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with 
radiolabeled monoclonal antibodies. J Nucl Med 2005 Jan;46 Suppl 
1:115S-127S. 
 (99)  Jhanwar YS, Divgi C. Current status of therapy of solid tumors. J Nucl 
Med 2005 Jan;46 Suppl 1:141S-150S. 
 (100)  Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging 
and follow-up of patients with colorectal cancer. Cancer Invest 
2005;23(4):338-351. 
 (101)  Behr TM, Sharkey RM, Juweid MI, Dunn RM, Ying Z, Zhang CH, et al. 
Factors influencing the pharmacokinetics, dosimetry, and diagnostic 
accuracy of radioimmunodetection and radioimmunotherapy of 
carcinoembryonic antigen-expressing tumors. Cancer Res 1996 Apr 
15;56(8):1805-1816. 
 (102)  Kraeber-Bodere F, Bardet S, Hoefnagel CA, Vieira MR, Vuillez JP, Murat 
A, et al. Radioimmunotherapy in medullary thyroid cancer using 
bispecific antibody and iodine 131-labeled bivalent hapten: 
preliminary results of a phase I/II clinical trial. Clin Cancer Res 1999 
Oct;5(10 Suppl):3190s-3198s. 
 (103)  Begent RH, Ledermann JA, Green AJ, Bagshawe KD, Riggs SJ, Searle F, 
et al. Antibody distribution and dosimetry in patients receiving 
radiolabelled antibody therapy for colorectal cancer. Br J Cancer 1989 
Sep;60(3):406-412. 
 (104)  Behr TM, Sharkey RM, Juweid ME, Dunn RM, Vagg RC, Ying Z, et al. 
Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-
 253 
carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl 
Med 1997 Jun;38(6):858-870. 
 (105)  Juweid ME, Sharkey RM, Behr T, Swayne LC, Dunn R, Siegel J, et al. 
Radioimmunotherapy of patients with small-volume tumors using 
iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2. J Nucl 
Med 1996 Sep;37(9):1504-1510. 
 (106)  Meredith RF, Khazaeli MB, Plott WE, Grizzle WE, Liu T, Schlom J, et al. 
Phase II study of dual 131I-labeled monoclonal antibody therapy with 
interferon in patients with metastatic colorectal cancer. Clin Cancer 
Res 1996 Nov;2(11):1811-1818. 
 (107)  Mittal BB, Zimmer MA, Sathiaseelan V, Benson AB, III, Mittal RR, Dutta 
S, et al. Phase I/II trial of combined 131I anti-CEA monoclonal antibody 
and hyperthermia in patients with advanced colorectal 
adenocarcinoma. Cancer 1996 Nov 1;78(9):1861-1870. 
 (108)  Ychou M, Pelegrin A, Faurous P, Robert B, Saccavini JC, Guerreau D, et 
al. Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-
CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable 
liver metastases from colorectal cancer. Int J Cancer 1998 Feb 
9;75(4):615-619. 
 (109)  Juweid M, Sharkey RM, Swayne LC, Griffiths GL, Dunn R, Goldenberg 
DM. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled 
anti-carcinoembryonic antigen monoclonal antibody, MN-14, in 
gastrointestinal cancer. J Nucl Med 1998 Jan;39(1):34-42. 
 (110)  Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, et al. 
A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-
carcinoembryonic antigen (CEA) chimeric T84.66 in patients with 
metastatic CEA-producing malignancies. Clin Cancer Res 2000 
Oct;6(10):3855-3863. 
 (111)  Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, et al. A Phase I 
trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 
radioimmunotherapy with 5-fluorouracil in patients with metastatic 
colorectal cancer. Clin Cancer Res 2003 Dec 1;9(16 Pt 1):5842-5852. 
 (112)  Hajjar G, Sharkey RM, Burton J, Zhang CH, Yeldell D, Matthies A, et al. 
Phase I radioimmunotherapy trial with iodine-131--labeled humanized 
MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients 
 254 
with metastatic gastrointestinal and colorectal cancer. Clin Colorectal 
Cancer 2002 May;2(1):31-42. 
 (113)  Williams LE, Duda RB, Proffitt RT, Beatty BG, Beatty JD, Wong JY, et al. 
Tumor uptake as a function of tumor mass: a mathematic model. J 
Nucl Med 1988 Jan;29(1):103-109. 
 (114)  Mayer A, Tsiompanou E, Flynn AA, Pedley RB, Dearling J, Boden R, et 
al. Higher dose and dose-rate in smaller tumors result in improved 
tumor control. Cancer Invest 2003 Jun;21(3):382-388. 
 (115)  Fidarova EF, El-Emir E, Boxer GM, Qureshi U, Dearling JL, Robson MP, 
et al. Microdistribution of targeted, fluorescently labeled anti-
carcinoembryonic antigen antibody in metastatic colorectal cancer: 
implications for radioimmunotherapy. Clin Cancer Res 2008 May 
1;14(9):2639-2646. 
 (116)  Behr TM, Liersch T, Greiner-Bechert L, Griesinger F, Behe M, Markus 
PM, et al. Radioimmunotherapy of small-volume disease of metastatic 
colorectal cancer. Cancer 2002 Feb 15;94(4 Suppl):1373-1381. 
 (117)  Liersch T, Meller J, Bittrich M, Kulle B, Becker H, Goldenberg DM. 
Update of carcinoembryonic antigen radioimmunotherapy with (131)I-
labetuzumab after salvage resection of colorectal liver metastases: 
comparison of outcome to a contemporaneous control group. Ann 
Surg Oncol 2007 Sep;14(9):2577-2590. 
 (118)  Ychou M, Azria D, Menkarios C, Faurous P, Quenet F, Saint-Aubert B, et 
al. Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-
carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after 
resection of liver metastases from colorectal cancer. Clin Cancer Res 
2008 Jun 1;14(11):3487-3493. 
 (119)  Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin 
Cancer Res 2004 Jan 15;10(2):415-427. 
 (120)  Konerding MA, Malkusch W, Klapthor B, van AC, Fait E, Hill SA, et al. 
Evidence for characteristic vascular patterns in solid tumours: 
quantitative studies using corrosion casts. Br J Cancer 1999 May;80(5-
6):724-732. 
 (121)  Tozer GM, meer-Beg SM, Baker J, Barber PR, Hill SA, Hodgkiss RJ, et al. 
Intravital imaging of tumour vascular networks using multi-photon 
 255 
fluorescence microscopy. Adv Drug Deliv Rev 2005 Jan 2;57(1):135-
152. 
 (122)  Amir E, Hughes S, Blackhall F, Thatcher N, Ostoros G, Timar J, et al. 
Targeting blood vessels for the treatment of non-small cell lung cancer. 
Curr Cancer Drug Targets 2008 Aug;8(5):392-403. 
 (123)  Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, et al. 
Eradication of colorectal xenografts by combined radioimmunotherapy 
and combretastatin a-4 3-O-phosphate. Cancer Res 2001 Jun 
15;61(12):4716-4722. 
 (124)  Pedley RB, El-Emir E, Flynn AA, Boxer GM, Dearling J, Raleigh JA, et al. 
Synergy between vascular targeting agents and antibody-directed 
therapy. Int J Radiat Oncol Biol Phys 2002 Dec 1;54(5):1524-1531. 
 (125)  Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: 
current status and future directions. J Magn Reson Imaging 2002 
Oct;16(4):407-422. 
 (126)  Knopp MV, Weiss E, Sinn HP, Mattern J, Junkermann H, Radeleff J, et 
al. Pathophysiologic basis of contrast enhancement in breast tumors. J 
Magn Reson Imaging 1999 Sep;10(3):260-266. 
 (127)  Anderson H, Price P. Clinical measurement of blood flow in tumours 
using positron emission tomography: a review. Nucl Med Commun 
2002 Feb;23(2):131-138. 
 (128)  Raichle ME, Martin WR, Herscovitch P, Mintun MA, Markham J. Brain 
blood flow measured with intravenous H2(15)O. II. Implementation 
and validation. J Nucl Med 1983 Sep;24(9):790-798. 
 (129)  Mineura K, Sasajima T, Itoh Y, Sasajima H, Kowada M, Tomura N, et al. 
Blood flow and metabolism of central neurocytoma: a positron 
emission tomography study. Cancer 1995 Oct 1;76(7):1224-1232. 
 (130)  Wilson CB, Lammertsma AA, McKenzie CG, Sikora K, Jones T. 
Measurements of blood flow and exchanging water space in breast 
tumors using positron emission tomography: a rapid and noninvasive 
dynamic method. Cancer Res 1992 Mar 15;52(6):1592-1597. 
 (131)  Kubo S, Yamamoto K, Magata Y, Iwasaki Y, Tamaki N, Yonekura Y, et al. 
Assessment of pancreatic blood flow with positron emission 
 256 
tomography and oxygen-15 water. Ann Nucl Med 1991 Nov;5(4):133-
138. 
 (132)  Yamaguchi A, Taniguchi H, Kunishima S, Koh T, Yamagishi H. 
Correlation between angiographically assessed vascularity and blood 
flow in hepatic metastases in patients with colorectal carcinoma. 
Cancer 2000 Sep 15;89(6):1236-1244. 
 (133)  Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. 
Assessment of pharmacodynamic vascular response in a phase I trial of 
combretastatin A4 phosphate. J Clin Oncol 2003 Aug 1;21(15):2823-
2830. 
 (134)  Nagengast WB, Lub-de Hooge MN, Oosting SF, den Dunnen WF, 
Warnders FJ, Brouwers AH, et al. VEGF-PET imaging is a noninvasive 
biomarker showing differential changes in the tumor during sunitinib 
treatment. Cancer Res 2011 Jan 1;71(1):143-153. 
 (135)  Frackowiak RS, Jones T, Lenzi GL, Heather JD. Regional cerebral oxygen 
utilization and blood flow in normal man using oxygen-15 and positron 
emission tomography. Acta Neurol Scand 1980 Dec;62(6):336-344. 
 (136)  Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient 
supply, and metabolic microenvironment of human tumors: a review. 
Cancer Res 1989 Dec 1;49(23):6449-6465. 
 (137)  Semenza GL. Hypoxia-inducible factor 1: oxygen homeostasis and 
disease pathophysiology. Trends Mol Med 2001 Aug;7(8):345-350. 
 (138)  Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, et al. 
The expression and distribution of the hypoxia-inducible factors HIF-
1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-
associated macrophages. Am J Pathol 2000 Aug;157(2):411-421. 
 (139)  Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003 
Dec 6;362(9399):1907-1917. 
 (140)  Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW. Increased expression 
of vascular endothelial growth factor in hepatocellular carcinoma after 
transcatheter arterial chemoembolization. Acta Radiol 2008 
Jun;49(5):523-529. 
 257 
 (141)  Virmani S, Rhee TK, Ryu RK, Sato KT, Lewandowski RJ, Mulcahy MF, et 
al. Comparison of hypoxia-inducible factor-1alpha expression before 
and after transcatheter arterial embolization in rabbit VX2 liver 
tumors. J Vasc Interv Radiol 2008 Oct;19(10):1483-1489. 
 (142)  Llovet JM, Bruix J. Systematic review of randomized trials for 
unresectable hepatocellular carcinoma: Chemoembolization improves 
survival. Hepatology 2003 Feb;37(2):429-442. 
 (143)  Pang RW, Joh JW, Johnson PJ, Monden M, Pawlik TM, Poon RT. Biology 
of hepatocellular carcinoma. Ann Surg Oncol 2008 Apr;15(4):962-971. 
 (144)  Hopfner M, Schuppan D, Scherubl H. Growth factor receptors and 
related signalling pathways as targets for novel treatment strategies of 
hepatocellular cancer. World J Gastroenterol 2008 Jan 7;14(1):1-14. 
 (145)  Ribatti D, Vacca A, Nico B, Sansonno D, Dammacco F. Angiogenesis and 
anti-angiogenesis in hepatocellular carcinoma. Cancer Treat Rev 2006 
Oct;32(6):437-444. 
 (146)  Tanaka H, Yamamoto M, Hashimoto N, Miyakoshi M, Tamakawa S, 
Yoshie M, et al. Hypoxia-independent overexpression of hypoxia-
inducible factor 1alpha as an early change in mouse 
hepatocarcinogenesis. Cancer Res 2006 Dec 1;66(23):11263-11270. 
 (147)  Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells 
in the promotion of tumour angiogenesis. Nat Rev Cancer 2008 
Aug;8(8):618-631. 
 (148)  Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat 
Rev Immunol 2005 Dec;5(12):953-964. 
 (149)  Lewis C, Murdoch C. Macrophage responses to hypoxia: implications 
for tumor progression and anti-cancer therapies. Am J Pathol 2005 
Sep;167(3):627-635. 
 (150)  Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and 
function of tumor-associated macrophages. Immunol Today 1992 
Jul;13(7):265-270. 
 (151)  Balkwill F, Charles KA, Mantovani A. Smoldering and polarized 
inflammation in the initiation and promotion of malignant disease. 
Cancer Cell 2005 Mar;7(3):211-217. 
 258 
 (152)  Bingle L, Brown NJ, Lewis CE. The role of tumour-associated 
macrophages in tumour progression: implications for new anticancer 
therapies. J Pathol 2002 Mar;196(3):254-265. 
 (153)  Saccani A, Schioppa T, Porta C, Biswas SK, Nebuloni M, Vago L, et al. 
p50 nuclear factor-kappaB overexpression in tumor-associated 
macrophages inhibits M1 inflammatory responses and antitumor 
resistance. Cancer Res 2006 Dec 1;66(23):11432-11440. 
 (154)  Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage 
polarization: tumor-associated macrophages as a paradigm for 
polarized M2 mononuclear phagocytes. Trends Immunol 2002 
Nov;23(11):549-555. 
 (155)  Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell 
migration, invasion, and metastasis. Cell 2006 Jan 27;124(2):263-266. 
 (156)  Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, et al. Tumor-
associated macrophages: the double-edged sword in cancer 
progression. J Clin Oncol 2005 Feb 10;23(5):953-964. 
 (157)  Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH, Dolman C, et al. Targeting 
tumor-associated macrophages as a novel strategy against breast 
cancer. J Clin Invest 2006 Aug;116(8):2132-2141. 
 (158)  Venneri MA, De PM, Ponzoni M, Pucci F, Scielzo C, Zonari E, et al. 
Identification of proangiogenic TIE2-expressing monocytes (TEMs) in 
human peripheral blood and cancer. Blood 2007 Jun 15;109(12):5276-
5285. 
 (159)  De PM, Venneri MA, Galli R, Sergi SL, Politi LS, Sampaolesi M, et al. 
Tie2 identifies a hematopoietic lineage of proangiogenic monocytes 
required for tumor vessel formation and a mesenchymal population of 
pericyte progenitors. Cancer Cell 2005 Sep;8(3):211-226. 
 (160)  De PM, Naldini L. Tie2-expressing monocytes (TEMs): novel targets and 
vehicles of anticancer therapy? Biochim Biophys Acta 2009 
Aug;1796(1):5-10. 
 (161)  Murdoch C, Tazzyman S, Webster S, Lewis CE. Expression of Tie-2 by 
human monocytes and their responses to angiopoietin-2. J Immunol 
2007 Jun 1;178(11):7405-7411. 
 259 
 (162)  Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM, 
et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released 
upon stimulation from endothelial cell Weibel-Palade bodies. Blood 
2004 Jun 1;103(11):4150-4156. 
 (163)  De PM, Venneri MA, Roca C, Naldini L. Targeting exogenous genes to 
tumor angiogenesis by transplantation of genetically modified 
hematopoietic stem cells. Nat Med 2003 Jun;9(6):789-795. 
 (164)  Jeong JO, Kim MO, Kim H, Lee MY, Kim SW, Ii M, et al. Dual angiogenic 
and neurotrophic effects of bone marrow-derived endothelial 
progenitor cells on diabetic neuropathy. Circulation 2009 Feb 
10;119(5):699-708. 
 (165)  Ribatti D. The paracrine role of Tie-2-expressing monocytes in tumor 
angiogenesis. Stem Cells Dev 2009 Jun;18(5):703-706. 
 (166)  Figueroa-Vega N, Diaz A, Adrados M, varez-Escola C, Paniagua A, 
Aragones J, et al. The association of the angiopoietin/Tie-2 system with 
the development of metastasis and leukocyte migration in 
neuroendocrine tumors. Endocr Relat Cancer 2010;17(4):897-908. 
 (167)  De PM, Mazzieri R, Politi LS, Pucci F, Zonari E, Sitia G, et al. Tumor-
targeted interferon-alpha delivery by Tie2-expressing monocytes 
inhibits tumor growth and metastasis. Cancer Cell 2008 Oct 
7;14(4):299-311. 
 (168)  Lee CY, Tien HF, Hu CY, Chou WC, Lin LI. Marrow angiogenesis-
associated factors as prognostic biomarkers in patients with acute 
myelogenous leukaemia. Br J Cancer 2007 Oct 8;97(7):877-882. 
 (169)  Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, et al. 
Increase in circulating endothelial progenitor cells by statin therapy in 
patients with stable coronary artery disease. Circulation 2001 Jun 
19;103(24):2885-2890. 
 (170)  Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al. 
Bone marrow origin of endothelial progenitor cells responsible for 
postnatal vasculogenesis in physiological and pathological 
neovascularization. Circ Res 1999 Aug 6;85(3):221-228. 
 260 
 (171)  Asahara T, Murohara T, Sullivan A, Silver M, van der ZR, Li T, et al. 
Isolation of putative progenitor endothelial cells for angiogenesis. 
Science 1997 Feb 14;275(5302):964-967. 
 (172)  Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. 
Resting and activated endothelial cells are increased in the peripheral 
blood of cancer patients. Blood 2001 Jun 1;97(11):3658-3661. 
 (173)  Beaudry P, Force J, Naumov GN, Wang A, Baker CH, Ryan A, et al. 
Differential effects of vascular endothelial growth factor receptor-2 
inhibitor ZD6474 on circulating endothelial progenitors and mature 
circulating endothelial cells: implications for use as a surrogate marker 
of antiangiogenic activity. Clin Cancer Res 2005 May 1;11(9):3514-
3522. 
 (174)  Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating 
endothelial cells and endothelial outgrowth from blood. J Clin Invest 
2000 Jan;105(1):71-77. 
 (175)  Pathak AP, Hochfeld WE, Goodman SL, Pepper MS. Circulating and 
imaging markers for angiogenesis. Angiogenesis 2008;11(4):321-335. 
 (176)  Dome B, Dobos J, Tovari J, Paku S, Kovacs G, Ostoros G, et al. 
Circulating bone marrow-derived endothelial progenitor cells: 
characterization, mobilization, and therapeutic considerations in 
malignant disease. Cytometry A 2008 Mar;73(3):186-193. 
 (177)  Elshal MF, Khan SS, Takahashi Y, Solomon MA, McCoy JP, Jr. CD146 
(Mel-CAM), an adhesion marker of endothelial cells, is a novel marker 
of lymphocyte subset activation in normal peripheral blood. Blood 
2005 Oct 15;106(8):2923-2924. 
 (178)  Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted 
circulating endothelial cell in cancer: towards marker and target 
identification. Nat Rev Cancer 2006 Nov;6(11):835-845. 
 (179)  Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, et al. 
Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells 
identifies a population of functional endothelial precursors. Blood 
2000 Feb 1;95(3):952-958. 
 (180)  Kalka C, Masuda H, Takahashi T, Gordon R, Tepper O, Gravereaux E, et 
al. Vascular endothelial growth factor(165) gene transfer augments 
 261 
circulating endothelial progenitor cells in human subjects. Circ Res 
2000 Jun 23;86(12):1198-1202. 
 (181)  Ingram DA, Caplice NM, Yoder MC. Unresolved questions, changing 
definitions, and novel paradigms for defining endothelial progenitor 
cells. Blood 2005 Sep 1;106(5):1525-1531. 
 (182)  Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, 
et al. Circulating endothelial progenitor cells, vascular function, and 
cardiovascular risk. N Engl J Med 2003 Feb 13;348(7):593-600. 
 (183)  Dimmeler S, Zeiher AM. Endothelial cell apoptosis in angiogenesis and 
vessel regression. Circ Res 2000 Sep 15;87(6):434-439. 
 (184)  Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, et al. 
Redefining endothelial progenitor cells via clonal analysis and 
hematopoietic stem/progenitor cell principals. Blood 2007 Mar 
1;109(5):1801-1809. 
 (185)  Monestiroli S, Mancuso P, Burlini A, Pruneri G, Dell'Agnola C, Gobbi A, 
et al. Kinetics and viability of circulating endothelial cells as surrogate 
angiogenesis marker in an animal model of human lymphoma. Cancer 
Res 2001 Jun 1;61(11):4341-4344. 
 (186)  Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, et al. Genetic 
heterogeneity of the vasculogenic phenotype parallels angiogenesis; 
Implications for cellular surrogate marker analysis of antiangiogenesis. 
Cancer Cell 2005 Jan;7(1):101-111. 
 (187)  Zengin E, Chalajour F, Gehling UM, Ito WD, Treede H, Lauke H, et al. 
Vascular wall resident progenitor cells: a source for postnatal 
vasculogenesis. Development 2006 Apr;133(8):1543-1551. 
 (188)  Ding YT, Kumar S, Yu DC. The role of endothelial progenitor cells in 
tumour vasculogenesis. Pathobiology 2008;75(5):265-273. 
 (189)  Sangai T, Ishii G, Kodama K, Miyamoto S, Aoyagi Y, Ito T, et al. Effect of 
differences in cancer cells and tumor growth sites on recruiting bone 
marrow-derived endothelial cells and myofibroblasts in cancer-
induced stroma. Int J Cancer 2005 Jul 20;115(6):885-892. 
 (190)  Crosby JR, Kaminski WE, Schatteman G, Martin PJ, Raines EW, Seifert 
RA, et al. Endothelial cells of hematopoietic origin make a significant 
 262 
contribution to adult blood vessel formation. Circ Res 2000 Oct 
27;87(9):728-730. 
 (191)  Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-
Friedman A, et al. Tumor response to radiotherapy regulated by 
endothelial cell apoptosis. Science 2003 May 16;300(5622):1155-1159. 
 (192)  Duda DG, Cohen KS, Kozin SV, Perentes JY, Fukumura D, Scadden DT, 
et al. Evidence for incorporation of bone marrow-derived endothelial 
cells into perfused blood vessels in tumors. Blood 2006 Apr 
1;107(7):2774-2776. 
 (193)  Vajkoczy P, Blum S, Lamparter M, Mailhammer R, Erber R, Engelhardt 
B, et al. Multistep nature of microvascular recruitment of ex vivo-
expanded embryonic endothelial progenitor cells during tumor 
angiogenesis. J Exp Med 2003 Jun 16;197(12):1755-1765. 
 (194)  Yu D, Sun X, Qiu Y, Zhou J, Wu Y, Zhuang L, et al. Identification and 
clinical significance of mobilized endothelial progenitor cells in tumor 
vasculogenesis of hepatocellular carcinoma. Clin Cancer Res 2007 Jul 
1;13(13):3814-3824. 
 (195)  Purhonen S, Palm J, Rossi D, Kaskenpaa N, Rajantie I, Yla-Herttuala S, et 
al. Bone marrow-derived circulating endothelial precursors do not 
contribute to vascular endothelium and are not needed for tumor 
growth. Proc Natl Acad Sci U S A 2008 May 6;105(18):6620-6625. 
 (196)  Kerbel RS, Benezra R, Lyden DC, Hattori K, Heissig B, Nolan DJ, et al. 
Endothelial progenitor cells are cellular hubs essential for 
neoangiogenesis of certain aggressive adenocarcinomas and 
metastatic transition but not adenomas. Proc Natl Acad Sci U S A 2008 
Aug 26;105(34):E54. 
 (197)  Rajantie I, Ilmonen M, Alminaite A, Ozerdem U, Alitalo K, Salven P. 
Adult bone marrow-derived cells recruited during angiogenesis 
comprise precursors for periendothelial vascular mural cells. Blood 
2004 Oct 1;104(7):2084-2086. 
 (198)  Gothert JR, Gustin SE, van Eekelen JA, Schmidt U, Hall MA, Jane SM, et 
al. Genetically tagging endothelial cells in vivo: bone marrow-derived 
cells do not contribute to tumor endothelium. Blood 2004 Sep 
15;104(6):1769-1777. 
 263 
 (199)  Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, et al. Impaired 
recruitment of bone-marrow-derived endothelial and hematopoietic 
precursor cells blocks tumor angiogenesis and growth. Nat Med 2001 
Nov;7(11):1194-1201. 
 (200)  Spring H, Schuler T, Arnold B, Hammerling GJ, Ganss R. Chemokines 
direct endothelial progenitors into tumor neovessels. Proc Natl Acad 
Sci U S A 2005 Dec 13;102(50):18111-18116. 
 (201)  Stoll BR, Migliorini C, Kadambi A, Munn LL, Jain RK. A mathematical 
model of the contribution of endothelial progenitor cells to 
angiogenesis in tumors: implications for antiangiogenic therapy. Blood 
2003 Oct 1;102(7):2555-2561. 
 (202)  Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, et al. 
Therapy-induced acute recruitment of circulating endothelial 
progenitor cells to tumors. Science 2006 Sep 22;313(5794):1785-1787. 
 (203)  Shaked Y, Tang T, Woloszynek J, Daenen LG, Man S, Xu P, et al. 
Contribution of granulocyte colony-stimulating factor to the acute 
mobilization of endothelial precursor cells by vascular disrupting 
agents. Cancer Res 2009 Oct 1;69(19):7524-7528. 
 (204)  Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De MM, et 
al. Synergism between vascular endothelial growth factor and 
placental growth factor contributes to angiogenesis and plasma 
extravasation in pathological conditions. Nat Med 2001 May;7(5):575-
583. 
 (205)  Nolan DJ, Ciarrocchi A, Mellick AS, Jaggi JS, Bambino K, Gupta S, et al. 
Bone marrow-derived endothelial progenitor cells are a major 
determinant of nascent tumor neovascularization. Genes Dev 2007 Jun 
15;21(12):1546-1558. 
 (206)  Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, et al. HIF1alpha 
induces the recruitment of bone marrow-derived vascular modulatory 
cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008 
Mar;13(3):206-220. 
 (207)  Miyata T, Iizasa H, Sai Y, Fujii J, Terasaki T, Nakashima E. Platelet-
derived growth factor-BB (PDGF-BB) induces differentiation of bone 
marrow endothelial progenitor cell-derived cell line TR-BME2 into 
mural cells, and changes the phenotype. J Cell Physiol 2005 
Sep;204(3):948-955. 
 264 
 (208)  Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, et al. 
Recruitment of stem and progenitor cells from the bone marrow niche 
requires MMP-9 mediated release of kit-ligand. Cell 2002 May 
31;109(5):625-637. 
 (209)  Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, et al. 
VEGF contributes to postnatal neovascularization by mobilizing bone 
marrow-derived endothelial progenitor cells. EMBO J 1999 Jul 
15;18(14):3964-3972. 
 (210)  Kollet O, Spiegel A, Peled A, Petit I, Byk T, Hershkoviz R, et al. Rapid 
and efficient homing of human CD34(+)CD38(-/low)CXCR4(+) stem and 
progenitor cells to the bone marrow and spleen of NOD/SCID and 
NOD/SCID/B2m(null) mice. Blood 2001 May 15;97(10):3283-3291. 
 (211)  Bahlmann FH, de GK, Spandau JM, Landry AL, Hertel B, Duckert T, et al. 
Erythropoietin regulates endothelial progenitor cells. Blood 2004 Feb 
1;103(3):921-926. 
 (212)  Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, et 
al. Erythropoietin is a potent physiologic stimulus for endothelial 
progenitor cell mobilization. Blood 2003 Aug 15;102(4):1340-1346. 
 (213)  Ho JW, Pang RW, Lau C, Sun CK, Yu WC, Fan ST, et al. Significance of 
circulating endothelial progenitor cells in hepatocellular carcinoma. 
Hepatology 2006 Oct;44(4):836-843. 
 (214)  Goon PK, Lip GY, Boos CJ, Stonelake PS, Blann AD. Circulating 
endothelial cells, endothelial progenitor cells, and endothelial 
microparticles in cancer. Neoplasia 2006 Feb;8(2):79-88. 
 (215)  Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC, et al. 
Contribution of bone marrow-derived endothelial cells to human 
tumor vasculature. Nat Med 2005 Mar;11(3):261-262. 
 (216)  Dome B, Timar J, Dobos J, Meszaros L, Raso E, Paku S, et al. 
Identification and clinical significance of circulating endothelial 
progenitor cells in human non-small cell lung cancer. Cancer Res 2006 
Jul 15;66(14):7341-7347. 
 (217)  Sussman LK, Upalakalin JN, Roberts MJ, Kocher O, Benjamin LE. Blood 
markers for vasculogenesis increase with tumor progression in patients 
with breast carcinoma. Cancer Biol Ther 2003 May;2(3):255-256. 
 265 
 (218)  Naik RP, Jin D, Chuang E, Gold EG, Tousimis EA, Moore AL, et al. 
Circulating endothelial progenitor cells correlate to stage in patients 
with invasive breast cancer. Breast Cancer Res Treat 2008 
Jan;107(1):133-138. 
 (219)  Willett CG, Boucher Y, di TE, Duda DG, Munn LL, Tong RT, et al. Direct 
evidence that the VEGF-specific antibody bevacizumab has 
antivascular effects in human rectal cancer. Nat Med 2004 
Feb;10(2):145-147. 
 (220)  Igreja C, Courinha M, Cachaco AS, Pereira T, Cabecadas J, da Silva MG, 
et al. Characterization and clinical relevance of circulating and biopsy-
derived endothelial progenitor cells in lymphoma patients. 
Haematologica 2007 Apr;92(4):469-477. 
 (221)  Zhang H, Vakil V, Braunstein M, Smith EL, Maroney J, Chen L, et al. 
Circulating endothelial progenitor cells in multiple myeloma: 
implications and significance. Blood 2005 Apr 15;105(8):3286-3294. 
 (222)  Wierzbowska A, Robak T, Krawczynska A, Wrzesien-Kus A, Pluta A, 
Cebula B, et al. Circulating endothelial cells in patients with acute 
myeloid leukemia. Eur J Haematol 2005 Dec;75(6):492-497. 
 (223)  Johnston JA, Bacon CM, Riedy MC, O'Shea JJ. Signaling by IL-2 and 
related cytokines: JAKs, STATs, and relationship to immunodeficiency. J 
Leukoc Biol 1996 Oct;60(4):441-452. 
 (224)  Sharfe N, Dadi HK, Shahar M, Roifman CM. Human immune disorder 
arising from mutation of the alpha chain of the interleukin-2 receptor. 
Proc Natl Acad Sci U S A 1997 Apr 1;94(7):3168-3171. 
 (225)  Waldmann TA, Leonard WJ, Depper JM, Kronke M, Goldman CK, Oh T, 
et al. Interleukin-2 receptor expression in retrovirus associated adult T-
cell leukemia. Princess Takamatsu Symp 1984;15:259-268. 
 (226)  Sheibani K, Winberg CD, van d, V, Blayney DW, Rappaport H. 
Distribution of lymphocytes with interleukin-2 receptors (TAC 
antigens) in reactive lymphoproliferative processes, Hodgkin's disease, 
and non-Hodgkin's lymphomas. An immunohistologic study of 300 
cases. Am J Pathol 1987 Apr;127(1):27-37. 
 266 
 (227)  Strauchen JA, Breakstone BA. IL-2 receptor expression in human 
lymphoid lesions. Immunohistochemical study of 166 cases. Am J 
Pathol 1987 Mar;126(3):506-512. 
 (228)  Waldmann TA, Pastan IH, Gansow OA, Junghans RP. The multichain 
interleukin-2 receptor: a target for immunotherapy. Ann Intern Med 
1992 Jan 15;116(2):148-160. 
 (229)  Kuppers R, Rajewsky K, Zhao M, Simons G, Laumann R, Fischer R, et al. 
Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from 
histological sections show clonal immunoglobulin gene 
rearrangements and appear to be derived from B cells at various 
stages of development. Proc Natl Acad Sci U S A 1994 Nov 
8;91(23):10962-10966. 
 (230)  Majhail NS, Weisdorf DJ, DeFor TE, Miller JS, McGlave PB, Slungaard A, 
et al. Long-term results of autologous stem cell transplantation for 
primary refractory or relapsed Hodgkin's lymphoma. Biol Blood 
Marrow Transplant 2006 Oct;12(10):1065-1072. 
 (231)  Freytes CO, Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo MS, et 
al. Myeloablative allogeneic hematopoietic stem cell transplantation in 
patients who experience relapse after autologous stem cell 
transplantation for lymphoma: a report of the International Bone 
Marrow Transplant Registry. Blood 2004 Dec 1;104(12):3797-3803. 
 (232)  Lenhard RE, Jr., Order SE, Spunberg JJ, Asbell SO, Leibel SA. Isotopic 
immunoglobulin: a new systemic therapy for advanced Hodgkin's 
disease. J Clin Oncol 1985 Oct;3(10):1296-1300. 
 (233)  Bartlett NL, Younes A, Carabasi MH, Forero A, Rosenblatt JD, Leonard 
JP, et al. A phase 1 multidose study of SGN-30 immunotherapy in 
patients with refractory or recurrent CD30+ hematologic malignancies. 
Blood 2008 Feb 15;111(4):1848-1854. 
 (234)  Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, et al. Phase 
I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's 
lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007 Jul 
1;25(19):2764-2769. 
 (235)  Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, 
et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E 
conjugate with potent and selective antitumor activity. Blood 2003 
Aug 15;102(4):1458-1465. 
 267 
 (236)  Oflazoglu E, Kissler KM, Sievers EL, Grewal IS, Gerber HP. Combination 
of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with 
chemotherapy improves antitumour activity in Hodgkin lymphoma. Br 
J Haematol 2008 Jul;142(1):69-73. 
 (237)  Schnell R, Dietlein M, Staak JO, Borchmann P, Schomaecker K, Fischer 
T, et al. Treatment of refractory Hodgkin's lymphoma patients with an 
iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin 
Oncol 2005 Jul 20;23(21):4669-4678. 
 (238)  Rizvi MA, Evens AM, Tallman MS, Nelson BP, Rosen ST. T-cell non-
Hodgkin lymphoma. Blood 2006 Feb 15;107(4):1255-1264. 
 (239)  Rudiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, 
MacLennan KA, et al. Peripheral T-cell lymphoma (excluding anaplastic 
large-cell lymphoma): results from the Non-Hodgkin's Lymphoma 
Classification Project. Ann Oncol 2002 Jan;13(1):140-149. 
 (240)  Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington 
W, Jr., et al. Definition, prognostic factors, treatment, and response 
criteria of adult T-cell leukemia-lymphoma: a proposal from an 
international consensus meeting. J Clin Oncol 2009 Jan 20;27(3):453-
459. 
 (241)  Matutes E, Taylor GP, Cavenagh J, Pagliuca A, Bareford D, Domingo A, 
et al. Interferon alpha and zidovudine therapy in adult T-cell leukaemia 
lymphoma: response and outcome in 15 patients. Br J Haematol 2001 
Jun;113(3):779-784. 
 (242)  Hermine O, Allard I, Levy V, Arnulf B, Gessain A, Bazarbachi A. A 
prospective phase II clinical trial with the use of zidovudine and 
interferon-alpha in the acute and lymphoma forms of adult T-cell 
leukemia/lymphoma. Hematol J 2002;3(6):276-282. 
 (243)  Waldmann TA, Goldman CK, Bongiovanni KF, Sharrow SO, Davey MP, 
Cease KB, et al. Therapy of patients with human T-cell lymphotrophic 
virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal 
antibody to the receptor for interleukin-2. Blood 1988 Nov;72(5):1805-
1816. 
 (244)  Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow 
OA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing 
adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood 1995 Dec 
1;86(11):4063-4075. 
 268 
 (245)  Amlot PL, Rawlings E, Fernando ON, Griffin PJ, Heinrich G, Schreier MH, 
et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) 
monoclonal antibody used in cadaveric renal transplantation. 
Transplantation 1995 Oct 15;60(7):748-756. 
 (246)  Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou 
JP. Randomised trial of basiliximab versus placebo for control of acute 
cellular rejection in renal allograft recipients. CHIB 201 International 
Study Group. Lancet 1997 Oct 25;350(9086):1193-1198. 
 (247)  Adam T. Radioiodination for therapy. Ann Clin Biochem 1989 May;26 ( 
Pt 3):244-245. 
 (248)  Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, 
Guermazi A, et al. Use of positron emission tomography for response 
assessment of lymphoma: consensus of the Imaging Subcommittee of 
International Harmonization Project in Lymphoma. J Clin Oncol 2007 
Feb 10;25(5):571-578. 
 (249)  Cheson BD. The International Harmonization Project for response 
criteria in lymphoma clinical trials. Hematol Oncol Clin North Am 2007 
Oct;21(5):841-854. 
 (250)  de Jong WK, van der Heijden HF, Pruim J, Dalesio O, Oyen WJ, Groen 
HJ. Prognostic value of different metabolic measurements with 
fluorine-18 fluorodeoxyglucose positron emission tomography in 
resectable non-small cell lung cancer: a two-center study. J Thorac 
Oncol 2007 Nov;2(11):1007-1012. 
 (251)  Green AJ, Francis RJ, Baig S, Begent RH. Semiautomatic volume of 
interest drawing for (18)F-FDG image analysis-method and preliminary 
results. Eur J Nucl Med Mol Imaging 2008 Feb;35(2):393-406. 
 (252)  Gause A, Roschansky V, Tschiersch A, Smith K, Hasenclever D, Schmits 
R, et al. Low serum interleukin-2 receptor levels correlate with a good 
prognosis in patients with Hodgkin's lymphoma. Ann Oncol 1991 Feb;2 
Suppl 2:43-47. 
 (253)  Baechler S, Hobbs RF, Jacene HA, Bochud FO, Wahl RL, Sgouros G. 
Predicting hematologic toxicity in patients undergoing 
radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-
tositumomab. J Nucl Med 2010 Dec;51(12):1878-1884. 
 269 
 (254)  Siegel JA, Yeldell D, Goldenberg DM, Stabin MG, Sparks RB, Sharkey 
RM, et al. Red marrow radiation dose adjustment using plasma FLT3-L 
cytokine levels: improved correlations between hematologic toxicity 
and bone marrow dose for radioimmunotherapy patients. J Nucl Med 
2003 Jan;44(1):67-76. 
 (255)  Koenecke C, Ukena SN, Ganser A, Franzke A. Regulatory T cells as 
therapeutic target in Hodgkin's lymphoma. Expert Opin Ther Targets 
2008 Jun;12(6):769-782. 
 (256)  Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. 
Aggressive conventional chemotherapy compared with high-dose 
chemotherapy with autologous haemopoietic stem-cell 
transplantation for relapsed chemosensitive Hodgkin's disease: a 
randomised trial. Lancet 2002 Jun 15;359(9323):2065-2071. 
 (257)  Lin CM, Singh SB, Chu PS, Dempcy RO, Schmidt JM, Pettit GR, et al. 
Interactions of tubulin with potent natural and synthetic analogs of the 
antimitotic agent combretastatin: a structure-activity study. Mol 
Pharmacol 1988 Aug;34(2):200-208. 
 (258)  Kanthou C, Tozer GM. The tumor vascular targeting agent 
combretastatin A-4-phosphate induces reorganization of the actin 
cytoskeleton and early membrane blebbing in human endothelial cells. 
Blood 2002 Mar 15;99(6):2060-2069. 
 (259)  Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, et 
al. Effects of combretastatin A4 phosphate on endothelial cell 
morphology in vitro and relationship to tumour vascular targeting 
activity in vivo. Anticancer Res 2001 Jan;21(1A):93-102. 
 (260)  Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, et al. 
Combretastatin A4 phosphate induces rapid regression of tumor 
neovessels and growth through interference with vascular endothelial-
cadherin signaling. J Clin Invest 2005 Nov;115(11):2992-3006. 
 (261)  Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. 
Combretastatin A-4, an agent that displays potent and selective 
toxicity toward tumor vasculature. Cancer Res 1997 May 
15;57(10):1829-1834. 
 (262)  Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, et al. 
Combretastatin A-4 phosphate as a tumor vascular-targeting agent: 
 270 
early effects in tumors and normal tissues. Cancer Res 1999 Apr 
1;59(7):1626-1634. 
 (263)  Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, et al. 
Mechanisms associated with tumor vascular shut-down induced by 
combretastatin A-4 phosphate: intravital microscopy and 
measurement of vascular permeability. Cancer Res 2001 Sep 
1;61(17):6413-6422. 
 (264)  El-Emir E, Boxer GM, Petrie IA, Boden RW, Dearling JL, Begent RH, et al. 
Tumour parameters affected by combretastatin A-4 phosphate 
therapy in a human colorectal xenograft model in nude mice. Eur J 
Cancer 2005 Mar;41(5):799-806. 
 (265)  Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, et 
al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical 
and pharmacokinetic results. J Clin Oncol 2003 Aug 1;21(15):2815-
2822. 
 (266)  Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, et 
al. Phase I trial of the antivascular agent combretastatin A4 phosphate 
on a 5-day schedule to patients with cancer: magnetic resonance 
imaging evidence for altered tumor blood flow. J Clin Oncol 2003 Dec 
1;21(23):4428-4438. 
 (267)  Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger 
J, et al. A phase I pharmacokinetic and translational study of the novel 
vascular targeting agent combretastatin a-4 phosphate on a single-
dose intravenous schedule in patients with advanced cancer. Cancer 
Res 2002 Jun 15;62(12):3408-3416. 
 (268)  Pedley RB, Begent RH, Boden JA, Boxer GM, Boden R, Keep PA. 
Enhancement of radioimmunotherapy by drugs modifying tumour 
blood flow in a colonic xenograft model. Int J Cancer 1994 Jun 
15;57(6):830-835. 
 (269)  Pedley RB, Boden JA, Boden R, Boxer GM, Flynn AA, Keep PA, et al. 
Ablation of colorectal xenografts with combined radioimmunotherapy 
and tumor blood flow-modifying agents. Cancer Res 1996 Jul 
15;56(14):3293-3300. 
 (270)  Boxer GM, Abassi AM, Pedley RB, Begent RH. Localisation of 
monoclonal antibodies reacting with different epitopes on 
 271 
carcinoembryonic antigen (CEA)--implications for targeted therapy. Br 
J Cancer 1994 Feb;69(2):307-314. 
 (271)  Harwood PJ, Britton DW, Southall PJ, Boxer GM, Rawlins G, Rogers GT. 
Mapping epitope characteristics on carcinoembryonic antigen. Br J 
Cancer 1986 Jul;54(1):75-82. 
 (272)  Pedley RB, Boden J, Keep PA, Harwood PJ, Green AJ, Rogers GT. 
Relationship between tumour size and uptake of radiolabelled anti-
CEA in a colon tumour xenograft. Eur J Nucl Med 1987;13(4):197-202. 
 (273)  Tofts PS, Kermode AG. Measurement of the blood-brain barrier 
permeability and leakage space using dynamic MR imaging. 1. 
Fundamental concepts. Magn Reson Med 1991 Feb;17(2):357-367. 
 (274)  Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, et 
al. Combretastatin A4 phosphate has tumor antivascular activity in rat 
and man as demonstrated by dynamic magnetic resonance imaging. J 
Clin Oncol 2003 Aug 1;21(15):2831-2842. 
 (275)  Maxwell RJ, Wilson J, Prise VE, Vojnovic B, Rustin GJ, Lodge MA, et al. 
Evaluation of the anti-vascular effects of combretastatin in rodent 
tumours by dynamic contrast enhanced MRI. NMR Biomed 2002 
Apr;15(2):89-98. 
 (276)  Meyer T, Gaya AM, Dancey G, Stratford MR, Othman S, Sharma SK, et 
al. A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA 
antibody in combination with combretastatin-A4-phosphate in 
advanced gastrointestinal carcinomas. Clin Cancer Res 2009 Jul 
1;15(13):4484-4492. 
 (277)  Quan H, Xu Y, Lou L. p38 MAPK, but not ERK1/2, is critically involved in 
the cytotoxicity of the novel vascular disrupting agent combretastatin 
A4. Int J Cancer 2008 Apr 15;122(8):1730-1737. 
 (278)  Akerley WL, Schabel M, Morrell G, Horrath E, Yu M, Johnsson B, et al. A 
randomized phase 2 trial of combretatstatin A4 phosphate (CA4P) in 
combination with paclitaxel and carboplatin to evaluate safety and 
efficacy in subjects with advanced imageable malignancies. 2007. 
 (279)  Rustin GJ, Shreeves G, Nathan PD, Gaya A, Ganesan TS, Wang D, et al. 
A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, 
 272 
and paclitaxel in patients with advanced cancer. Br J Cancer 2010 Apr 
27;102(9):1355-1360. 
 (280)  Bilenker JH, Flaherty KT, Rosen M, Davis L, Gallagher M, Stevenson JP, 
et al. Phase I trial of combretastatin a-4 phosphate with carboplatin. 
Clin Cancer Res 2005 Feb 15;11(4):1527-1533. 
 (281)  Horsman MR, Siemann DW. Pathophysiologic effects of vascular-
targeting agents and the implications for combination with 
conventional therapies. Cancer Res 2006 Dec 15;66(24):11520-11539. 
 (282)  Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, et al. 
Selective targeting of tumoral vasculature: comparison of different 
formats of an antibody (L19) to the ED-B domain of fibronectin. Int J 
Cancer 2002 Nov 1;102(1):75-85. 
 (283)  Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005 
Dec 15;438(7070):932-936. 
 (284)  Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic 
factors in cancer patients. J Clin Oncol 2001 Feb 15;19(4):1207-1225. 
 (285)  Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 
1971 Nov 18;285(21):1182-1186. 
 (286)  Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 
2000 Sep 14;407(6801):249-257. 
 (287)  Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor 
pathway in tumor growth and angiogenesis. J Clin Oncol 2005 Feb 
10;23(5):1011-1027. 
 (288)  Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. 
Tumor cells secrete a vascular permeability factor that promotes 
accumulation of ascites fluid. Science 1983 Feb 25;219(4587):983-985. 
 (289)  Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular 
endothelial growth factor is a secreted angiogenic mitogen. Science 
1989 Dec 8;246(4935):1306-1309. 
 (290)  Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, et al. Vascular 
permeability factor, an endothelial cell mitogen related to PDGF. 
Science 1989 Dec 8;246(4935):1309-1312. 
 273 
 (291)  Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, et al. 
Heterozygous embryonic lethality induced by targeted inactivation of 
the VEGF gene. Nature 1996 Apr 4;380(6573):439-442. 
 (292)  Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, et al. 
Impact of vascular endothelial growth factor-A expression, 
thrombospondin-2 expression, and microvessel density on the 
treatment effect of bevacizumab in metastatic colorectal cancer. J Clin 
Oncol 2006 Jan 10;24(2):217-227. 
 (293)  Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG. Prognostic 
significance of vascular endothelial growth factor protein levels in oral 
and oropharyngeal squamous cell carcinoma. J Clin Oncol 2000 
May;18(10):2046-2052. 
 (294)  Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki H, Kitamura M, et 
al. Concentrations of vascular endothelial growth factor in the sera of 
normal controls and cancer patients. Clin Cancer Res 1996 
May;2(5):821-826. 
 (295)  Fuhrmann-Benzakein E, Ma MN, Rubbia-Brandt L, Mentha G, 
Ruefenacht D, Sappino AP, et al. Elevated levels of angiogenic 
cytokines in the plasma of cancer patients. Int J Cancer 2000 Jan 
1;85(1):40-45. 
 (296)  Hyodo I, Doi T, Endo H, Hosokawa Y, Nishikawa Y, Tanimizu M, et al. 
Clinical significance of plasma vascular endothelial growth factor in 
gastrointestinal cancer. Eur J Cancer 1998 Dec;34(13):2041-2045. 
 (297)  Linder C, Linder S, Munck-Wikland E, Strander H. Independent 
expression of serum vascular endothelial growth factor (VEGF) and 
basic fibroblast growth factor (bFGF) in patients with carcinoma and 
sarcoma. Anticancer Res 1998 May;18(3B):2063-2068. 
 (298)  Kitamura M, Toi M, Arai K, Iwasaki Y, Suzuki H, Matsuo K. 
Concentrations of vascular endothelial growth factor in the sera of 
gastric cancer patients. Oncol Rep 1998 Nov;5(6):1419-1424. 
 (299)  Mahner S, Woelber L, Eulenburg C, Schwarz J, Carney W, Jaenicke F, et 
al. TIMP-1 and VEGF-165 serum concentration during first-line therapy 
of ovarian cancer patients. BMC Cancer 2010;10:139. 
 274 
 (300)  Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ. 
Prognostic role of vascular endothelial growth factor in hepatocellular 
carcinoma: systematic review and meta-analysis. Br J Cancer 2009 May 
5;100(9):1385-1392. 
 (301)  Poon RT, Lau CP, Cheung ST, Yu WC, Fan ST. Quantitative correlation of 
serum levels and tumor expression of vascular endothelial growth 
factor in patients with hepatocellular carcinoma. Cancer Res 2003 Jun 
15;63(12):3121-3126. 
 (302)  Salven P, Orpana A, Joensuu H. Leukocytes and platelets of patients 
with cancer contain high levels of vascular endothelial growth factor. 
Clin Cancer Res 1999 Mar;5(3):487-491. 
 (303)  George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI. Correlation of 
plasma and serum vascular endothelial growth factor levels with 
platelet count in colorectal cancer: clinical evidence of platelet 
scavenging? Clin Cancer Res 2000 Aug;6(8):3147-3152. 
 (304)  Yoshiji H, Kuriyama S, Yoshii J, Yamazaki M, Kikukawa M, Tsujinoue H, 
et al. Vascular endothelial growth factor tightly regulates in vivo 
development of murine hepatocellular carcinoma cells. Hepatology 
1998 Dec;28(6):1489-1496. 
 (305)  Wada H, Nagano H, Yamamoto H, Yang Y, Kondo M, Ota H, et al. 
Expression pattern of angiogenic factors and prognosis after hepatic 
resection in hepatocellular carcinoma: importance of angiopoietin-2 
and hypoxia-induced factor-1 alpha. Liver Int 2006 May;26(4):414-423. 
 (306)  Moon WS, Rhyu KH, Kang MJ, Lee DG, Yu HC, Yeum JH, et al. 
Overexpression of VEGF and angiopoietin 2: a key to high vascularity of 
hepatocellular carcinoma? Mod Pathol 2003 Jun;16(6):552-557. 
 (307)  Li X, Feng GS, Zheng CS, Zhuo CK, Liu X. Expression of plasma vascular 
endothelial growth factor in patients with hepatocellular carcinoma 
and effect of transcatheter arterial chemoembolization therapy on 
plasma vascular endothelial growth factor level. World J Gastroenterol 
2004 Oct 1;10(19):2878-2882. 
 (308)  Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST. Prognostic significance 
of serum vascular endothelial growth factor and endostatin in patients 
with hepatocellular carcinoma. Br J Surg 2004 Oct;91(10):1354-1360. 
 275 
 (309)  Poon RT, Lau C, Yu WC, Fan ST, Wong J. High serum levels of vascular 
endothelial growth factor predict poor response to transarterial 
chemoembolization in hepatocellular carcinoma: a prospective study. 
Oncol Rep 2004 May;11(5):1077-1084. 
 (310)  Poon RT, Lau C, Pang R, Ng KK, Yuen J, Fan ST. High serum vascular 
endothelial growth factor levels predict poor prognosis after 
radiofrequency ablation of hepatocellular carcinoma: importance of 
tumor biomarker in ablative therapies. Ann Surg Oncol 2007 
Jun;14(6):1835-1845. 
 (311)  Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, 
Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that 
disrupts in vivo angiogenesis. Science 1997 Jul 4;277(5322):55-60. 
 (312)  Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG. The Tie-2 ligand 
angiopoietin-2 destabilizes quiescent endothelium through an internal 
autocrine loop mechanism. J Cell Sci 2005 Feb 15;118(Pt 4):771-780. 
 (313)  Procopio WN, Pelavin PI, Lee WM, Yeilding NM. Angiopoietin-1 and -2 
coiled coil domains mediate distinct homo-oligomerization patterns, 
but fibrinogen-like domains mediate ligand activity. J Biol Chem 1999 
Oct 15;274(42):30196-30201. 
 (314)  Benest AV, Augustin HG. Cancer: Blood vessels kept quiet. Nature 2009 
Mar 5;458(7234):41-42. 
 (315)  Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, et al. 
Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during 
embryonic angiogenesis. Cell 1996 Dec 27;87(7):1171-1180. 
 (316)  Stoeltzing O, Ahmad SA, Liu W, McCarty MF, Parikh AA, Fan F, et al. 
Angiopoietin-1 inhibits tumour growth and ascites formation in a 
murine model of peritoneal carcinomatosis. Br J Cancer 2002 Nov 
4;87(10):1182-1187. 
 (317)  Stoeltzing O, Ahmad SA, Liu W, McCarty MF, Wey JS, Parikh AA, et al. 
Angiopoietin-1 inhibits vascular permeability, angiogenesis, and 
growth of hepatic colon cancer tumors. Cancer Res 2003 Jun 
15;63(12):3370-3377. 
 276 
 (318)  Eklund L, Olsen BR. Tie receptors and their angiopoietin ligands are 
context-dependent regulators of vascular remodeling. Exp Cell Res 
2006 Mar 10;312(5):630-641. 
 (319)  Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, et 
al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate 
VEGF-induced postnatal neovascularization. Circ Res 1998 Aug 
10;83(3):233-240. 
 (320)  Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, et 
al. Increased vascularization in mice overexpressing angiopoietin-1. 
Science 1998 Oct 16;282(5388):468-471. 
 (321)  Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, et al. 
Angiopoietin-2 is required for postnatal angiogenesis and lymphatic 
patterning, and only the latter role is rescued by Angiopoietin-1. Dev 
Cell 2002 Sep;3(3):411-423. 
 (322)  Scappaticci FA. Mechanisms and future directions for angiogenesis-
based cancer therapies. J Clin Oncol 2002 Sep 15;20(18):3906-3927. 
 (323)  Leach L, Babawale MO, Anderson M, Lammiman M. Vasculogenesis, 
angiogenesis and the molecular organisation of endothelial junctions 
in the early human placenta. J Vasc Res 2002 May;39(3):246-259. 
 (324)  Tait CR, Jones PF. Angiopoietins in tumours: the angiogenic switch. J 
Pathol 2004 Sep;204(1):1-10. 
 (325)  Bach F, Uddin FJ, Burke D. Angiopoietins in malignancy. Eur J Surg 
Oncol 2007 Feb;33(1):7-15. 
 (326)  Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M. Angiopoietin-
2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo 
regulation via induction of proteases. Cancer Res 2001 Mar 
1;61(5):2145-2153. 
 (327)  Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, et al. 
Angiopoietin 2 displays a vascular endothelial growth factor 
dependent synergistic effect in hepatocellular carcinoma development 
in mice. Gut 2005 Dec;54(12):1768-1775. 
 (328)  Nasarre P, Thomas M, Kruse K, Helfrich I, Wolter V, Deppermann C, et 
al. Host-derived angiopoietin-2 affects early stages of tumor 
 277 
development and vessel maturation but is dispensable for later stages 
of tumor growth. Cancer Res 2009 Feb 15;69(4):1324-1333. 
 (329)  Hayes AJ, Huang WQ, Yu J, Maisonpierre PC, Liu A, Kern FG, et al. 
Expression and function of angiopoietin-1 in breast cancer. Br J Cancer 
2000 Nov;83(9):1154-1160. 
 (330)  Oka N, Yamamoto Y, Takahashi M, Nishitani M, Kanayama HO, Kagawa 
S. Expression of angiopoietin-1 and -2, and its clinical significance in 
human bladder cancer. BJU Int 2005 Mar;95(4):660-663. 
 (331)  Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. 
Biologic significance of angiopoietin-2 expression in human 
hepatocellular carcinoma. J Clin Invest 1999 Feb;103(3):341-345. 
 (332)  Hata K, Udagawa J, Fujiwaki R, Nakayama K, Otani H, Miyazaki K. 
Expression of angiopoietin-1, angiopoietin-2, and Tie2 genes in normal 
ovary with corpus luteum and in ovarian cancer. Oncology 
2002;62(4):340-348. 
 (333)  Ahmad SA, Liu W, Jung YD, Fan F, Reinmuth N, Bucana CD, et al. 
Differential expression of angiopoietin-1 and angiopoietin-2 in colon 
carcinoma. A possible mechanism for the initiation of angiogenesis. 
Cancer 2001 Sep 1;92(5):1138-1143. 
 (334)  Mitsuhashi N, Shimizu H, Ohtsuka M, Wakabayashi Y, Ito H, Kimura F, 
et al. Angiopoietins and Tie-2 expression in angiogenesis and 
proliferation of human hepatocellular carcinoma. Hepatology 2003 
May;37(5):1105-1113. 
 (335)  Wong MP, Chan SY, Fu KH, Leung SY, Cheung N, Yuen ST, et al. The 
angiopoietins, tie2 and vascular endothelial growth factor are 
differentially expressed in the transformation of normal lung to non-
small cell lung carcinomas. Lung Cancer 2000 Jul;29(1):11-22. 
 (336)  Sallinen H, Heikura T, Laidinen S, Kosma VM, Heinonen S, Yla-Herttuala 
S, et al. Preoperative angiopoietin-2 serum levels: a marker of 
malignant potential in ovarian neoplasms and poor prognosis in 
epithelial ovarian cancer. Int J Gynecol Cancer 2010 Dec;20(9):1498-
1505. 
 (337)  Volkova E, Willis JA, Wells JE, Robinson BA, Dachs GU, Currie MJ. 
Association of angiopoietin-2, C-reactive protein and markers of 
 278 
obesity and insulin resistance with survival outcome in colorectal 
cancer. Br J Cancer 2011 Jan 4;104(1):51-59. 
 (338)  Jo MJ, Lee JH, Nam BH, Kook MC, Ryu KW, Choi IJ, et al. Preoperative 
serum angiopoietin-2 levels correlate with lymph node status in 
patients with early gastric cancer. Ann Surg Oncol 2009 Jul;16(7):2052-
2057. 
 (339)  Kopczynska E, Makarewicz R, Biedka M, Kaczmarczyk A, Kardymowicz 
H, Tyrakowski T. Plasma concentration of angiopoietin-1, angiopoietin-
2 and Tie-2 in cervical cancer. Eur J Gynaecol Oncol 2009;30(6):646-
649. 
 (340)  Helfrich I, Edler L, Sucker A, Thomas M, Christian S, Schadendorf D, et 
al. Angiopoietin-2 levels are associated with disease progression in 
metastatic malignant melanoma. Clin Cancer Res 2009 Feb 
15;15(4):1384-1392. 
 (341)  Srirajaskanthan R, Dancey G, Hackshaw A, Luong T, Caplin ME, Meyer 
T. Circulating angiopoietin-2 is elevated in patients with 
neuroendocrine tumours and correlates with disease burden and 
prognosis. Endocr Relat Cancer 2009 Sep;16(3):967-976. 
 (342)  Park JH, Choi H, Kim YB, Kim YS, Sheen SS, Choi JH, et al. Serum 
angiopoietin-1 as a prognostic marker in resected early stage lung 
cancer. Lung Cancer 2009 Dec;66(3):359-364. 
 (343)  Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, 
Koslowsky TC, et al. Identification of serum angiopoietin-2 as a 
biomarker for clinical outcome of colorectal cancer patients treated 
with bevacizumab-containing therapy. Br J Cancer 2010 Oct 
26;103(9):1407-1414. 
 (344)  Anargyrou K, Terpos E, Vassilakopoulos TP, Pouli A, Sachanas S, Tzenou 
T, et al. Normalization of the serum angiopoietin-1 to angiopoietin-2 
ratio reflects response in refractory/resistant multiple myeloma 
patients treated with bortezomib. Haematologica 2008 Mar;93(3):451-
454. 
 (345)  Naumnik W, Chyczewska E, Ossolinska M. Serum levels of 
angiopoietin-1, angiopoietin-2, and their receptor tie-2 in patients with 
nonsmall cell lung cancer during chemotherapy. Cancer Invest 2009 
Aug;27(7):741-746. 
 279 
 (346)  Torimura T, Ueno T, Kin M, Harada R, Taniguchi E, Nakamura T, et al. 
Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular 
carcinoma. J Hepatol 2004 May;40(5):799-807. 
 (347)  Zeng W, Gouw AS, van den Heuvel MC, Zwiers PJ, Zondervan PE, 
Poppema S, et al. The angiogenic makeup of human hepatocellular 
carcinoma does not favor vascular endothelial growth 
factor/angiopoietin-driven sprouting neovascularization. Hepatology 
2008 Nov;48(5):1517-1527. 
 (348)  Scholz A, Rehm VA, Rieke S, Derkow K, Schulz P, Neumann K, et al. 
Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis 
and hepatocellular carcinoma. Am J Gastroenterol 2007 
Nov;102(11):2471-2481. 
 (349)  Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast 
growth factor receptor activation. Cytokine Growth Factor Rev 2005 
Apr;16(2):107-137. 
 (350)  El-Assal ON, Yamanoi A, Ono T, Kohno H, Nagasue N. The 
clinicopathological significance of heparanase and basic fibroblast 
growth factor expressions in hepatocellular carcinoma. Clin Cancer Res 
2001 May;7(5):1299-1305. 
 (351)  Zhou M, Sutliff RL, Paul RJ, Lorenz JN, Hoying JB, Haudenschild CC, et 
al. Fibroblast growth factor 2 control of vascular tone. Nat Med 1998 
Feb;4(2):201-207. 
 (352)  Bosse Y, Rola-Pleszczynski M. FGF2 in asthmatic airway-smooth-
muscle-cell hyperplasia. Trends Mol Med 2008 Jan;14(1):3-11. 
 (353)  Ware JA, Simons M. Angiogenesis in ischemic heart disease. Nat Med 
1997 Feb;3(2):158-164. 
 (354)  Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N, et al. 
Synergistic effect of vascular endothelial growth factor and basic 
fibroblast growth factor on angiogenesis in vivo. Circulation 1995 Nov 
1;92(9 Suppl):II365-II371. 
 (355)  Grose R, Dickson C. Fibroblast growth factor signaling in tumorigenesis. 
Cytokine Growth Factor Rev 2005 Apr;16(2):179-186. 
 280 
 (356)  Colomer R, Aparicio J, Montero S, Guzman C, Larrodera L, Cortes-Funes 
H. Low levels of basic fibroblast growth factor (bFGF) are associated 
with a poor prognosis in human breast carcinoma. Br J Cancer 
1997;76(9):1215-1220. 
 (357)  Obermair A, Speiser P, Reisenberger K, Ullrich R, Czerwenka K, Kaider 
A, et al. Influence of intratumoral basic fibroblast growth factor 
concentration on survival in ovarian cancer patients. Cancer Lett 1998 
Aug 14;130(1-2):69-76. 
 (358)  Pichon MF, Moulin G, Pallud C, Pecking A, Floiras JL. Serum bFGF (basic 
fibroblast growth factor) and CA 15.3 in the monitoring of breast 
cancer patients. Anticancer Res 2000 Mar;20(2B):1189-1194. 
 (359)  Brattstrom D, Bergqvist M, Larsson A, Holmertz J, Hesselius P, 
Rosenberg L, et al. Basic fibroblast growth factor and vascular 
endothelial growth factor in sera from non-small cell lung cancer 
patients. Anticancer Res 1998 Mar;18(2A):1123-1127. 
 (360)  Hsu PI, Chow NH, Lai KH, Yang HB, Chan SH, Lin XZ, et al. Implications 
of serum basic fibroblast growth factor levels in chronic liver diseases 
and hepatocellular carcinoma. Anticancer Res 1997 Jul;17(4A):2803-
2809. 
 (361)  Dietz A, Rudat V, Conradt C, Weidauer H, Ho A, Moehler T. Prognostic 
relevance of serum levels of the angiogenic peptide bFGF in advanced 
carcinoma of the head and neck treated by primary 
radiochemotherapy. Head Neck 2000 Oct;22(7):666-673. 
 (362)  Sliutz G, Tempfer C, Obermair A, Reinthaller A, Gitsch G, Kainz C. 
Serum evaluation of basic fibroblast growth factor in cervical cancer 
patients. Cancer Lett 1995 Aug 1;94(2):227-231. 
 (363)  Mise M, Arii S, Higashituji H, Furutani M, Niwano M, Harada T, et al. 
Clinical significance of vascular endothelial growth factor and basic 
fibroblast growth factor gene expression in liver tumor. Hepatology 
1996 Mar;23(3):455-464. 
 (364)  Poon RT, Ng IO, Lau C, Yu WC, Fan ST, Wong J. Correlation of serum 
basic fibroblast growth factor levels with clinicopathologic features 
and postoperative recurrence in hepatocellular carcinoma. Am J Surg 
2001 Sep;182(3):298-304. 
 281 
 (365)  Chao Y, Li CP, Chau GY, Chen CP, King KL, Lui WY, et al. Prognostic 
significance of vascular endothelial growth factor, basic fibroblast 
growth factor, and angiogenin in patients with resectable 
hepatocellular carcinoma after surgery. Ann Surg Oncol 2003 
May;10(4):355-362. 
 (366)  Sasaki R, Masuda S, Nagao M. Erythropoietin: multiple physiological 
functions and regulation of biosynthesis. Biosci Biotechnol Biochem 
2000 Sep;64(9):1775-1793. 
 (367)  Leyland-Jones B. Evidence for erythropoietin as a molecular targeting 
agent. Semin Oncol 2002 Jun;29(3 Suppl 11):145-154. 
 (368)  Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, et al. 
Erythropoietin regulates tumour growth of human malignancies. 
Carcinogenesis 2003 Jun;24(6):1021-1029. 
 (369)  Jelkmann W. Erythropoietin: structure, control of production, and 
function. Physiol Rev 1992 Apr;72(2):449-489. 
 (370)  Lacombe C, Mayeux P. The molecular biology of erythropoietin. 
Nephrol Dial Transplant 1999;14 Suppl 2:22-28. 
 (371)  Wu H, Lee SH, Gao J, Liu X, Iruela-Arispe ML. Inactivation of 
erythropoietin leads to defects in cardiac morphogenesis. 
Development 1999 Aug;126(16):3597-3605. 
 (372)  Nakamatsu K, Nishimura Y, Suzuki M, Kanamori S, Maenishi O, Yasuda 
Y. Erythropoietin/erythropoietin-receptor system as an angiogenic 
factor in chemically induced murine hepatic tumors. Int J Clin Oncol 
2004 Jun;9(3):184-188. 
 (373)  Bianchi R, Buyukakilli B, Brines M, Savino C, Cavaletti G, Oggioni N, et 
al. Erythropoietin both protects from and reverses experimental 
diabetic neuropathy. Proc Natl Acad Sci U S A 2004 Jan 20;101(3):823-
828. 
 (374)  Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. 
Erythropoietin has a mitogenic and positive chemotactic effect on 
endothelial cells. Proc Natl Acad Sci U S A 1990 Aug;87(15):5978-5982. 
 (375)  Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, et al. Human 
erythropoietin induces a pro-angiogenic phenotype in cultured 
 282 
endothelial cells and stimulates neovascularization in vivo. Blood 1999 
Apr 15;93(8):2627-2636. 
 (376)  Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-
Raj S. Impact of therapy with epoetin alfa on clinical outcomes in 
patients with nonmyeloid malignancies during cancer chemotherapy in 
community oncology practice. Procrit Study Group. J Clin Oncol 1997 
Mar;15(3):1218-1234. 
 (377)  Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, 
Manikhas G, et al. Maintaining normal hemoglobin levels with epoetin 
alfa in mainly nonanemic patients with metastatic breast cancer 
receiving first-line chemotherapy: a survival study. J Clin Oncol 2005 
Sep 1;23(25):5960-5972. 
 (378)  Henke M, Mattern D, Pepe M, Bezay C, Weissenberger C, Werner M, et 
al. Do erythropoietin receptors on cancer cells explain unexpected 
clinical findings? J Clin Oncol 2006 Oct 10;24(29):4708-4713. 
 (379)  Acs G, Zhang PJ, Rebbeck TR, Acs P, Verma A. Immunohistochemical 
expression of erythropoietin and erythropoietin receptor in breast 
carcinoma. Cancer 2002 Sep 1;95(5):969-981. 
 (380)  Kumar SM, Acs G, Fang D, Herlyn M, Elder DE, Xu X. Functional 
erythropoietin autocrine loop in melanoma. Am J Pathol 2005 
Mar;166(3):823-830. 
 (381)  Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, et al. 
Hypoxia-inducible erythropoietin signaling in squamous dysplasia and 
squamous cell carcinoma of the uterine cervix and its potential role in 
cervical carcinogenesis and tumor progression. Am J Pathol 2003 
Jun;162(6):1789-1806. 
 (382)  Rosti V, Pedrazzoli P, Ponchio L, Zibera C, Novella A, Lucotti C, et al. 
Effect of recombinant human erythropoietin on hematopoietic and 
non-hematopoietic malignant cell growth in vitro. Haematologica 1993 
Jul;78(4):208-212. 
 (383)  Westphal G, Niederberger E, Blum C, Wollman Y, Knoch TA, Rebel W, 
et al. Erythropoietin and G-CSF receptors in human tumor cells: 
expression and aspects regarding functionality. Tumori 2002 
Mar;88(2):150-159. 
 283 
 (384)  Selzer E, Wacheck V, Kodym R, Schlagbauer-Wadl H, Schlegel W, 
Pehamberger H, et al. Erythropoietin receptor expression in human 
melanoma cells. Melanoma Res 2000 Oct;10(5):421-426. 
 (385)  Berdel WE, Oberberg D, Reufi B, Thiel E. Studies on the role of 
recombinant human erythropoietin in the growth regulation of human 
nonhematopoietic tumor cells in vitro. Ann Hematol 1991 Jul;63(1):5-
8. 
 (386)  Blackwell KL, Kirkpatrick JP, Snyder SA, Broadwater G, Farrell F, Jolliffe 
L, et al. Human recombinant erythropoietin significantly improves 
tumor oxygenation independent of its effects on hemoglobin. Cancer 
Res 2003 Oct 1;63(19):6162-6165. 
 (387)  Thews O, Koenig R, Kelleher DK, Kutzner J, Vaupel P. Enhanced 
radiosensitivity in experimental tumours following erythropoietin 
treatment of chemotherapy-induced anaemia. Br J Cancer 1998 
Sep;78(6):752-756. 
 (388)  Thews O, Kelleher DK, Vaupel P. Erythropoietin restores the anemia-
induced reduction in cyclophosphamide cytotoxicity in rat tumors. 
Cancer Res 2001 Feb 15;61(4):1358-1361. 
 (389)  Ribatti D, Marzullo A, Gentile A, Longo V, Nico B, Vacca A, et al. 
Erythropoietin/erythropoietin-receptor system is involved in 
angiogenesis in human hepatocellular carcinoma. Histopathology 2007 
Apr;50(5):591-596. 
 (390)  Matsuyama M, Yamazaki O, Horii K, Higaki I, Kawai S, Mikami S, et al. 
Erythrocytosis caused by an erythropoietin-producing hepatocellular 
carcinoma. J Surg Oncol 2000 Nov;75(3):197-202. 
 (391)  Fisher B, Redmond C, Poisson R, Margolese R, Wolmark N, Wickerham 
L, et al. Eight-year results of a randomized clinical trial comparing total 
mastectomy and lumpectomy with or without irradiation in the 
treatment of breast cancer. N Engl J Med 1989 Mar 30;320(13):822-
828. 
 (392)  Kim YB, Park YN, Park C. Increased proliferation activities of vascular 
endothelial cells and tumour cells in residual hepatocellular carcinoma 
following transcatheter arterial embolization. Histopathology 2001 
Feb;38(2):160-166. 
 284 
 (393)  Cabrera R, Pannu DS, Caridi J, Firpi RJ, Soldevila-Pico C, Morelli G, et al. 
The combination of sorafenib with transarterial chemoembolisation 
for hepatocellular carcinoma. Aliment Pharmacol Ther 2011 
Jul;34(2):205-213. 
 (394)  Yang ZF, Poon RT, To J, Ho DW, Fan ST. The potential role of hypoxia 
inducible factor 1alpha in tumor progression after hypoxia and 
chemotherapy in hepatocellular carcinoma. Cancer Res 2004 Aug 
1;64(15):5496-5503. 
 (395)  Shim JH, Park JW, Kim JH, An M, Kong SY, Nam BH, et al. Association 
between increment of serum VEGF level and prognosis after 
transcatheter arterial chemoembolization in hepatocellular carcinoma 
patients. Cancer Sci 2008 Oct;99(10):2037-2044. 
 (396)  Bruix J, Sherman M. Management of hepatocellular carcinoma. 
Hepatology 2005 Nov;42(5):1208-1236. 
 (397)  Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et 
al. Natural history of hepatocellular carcinoma and prognosis in 
relation to treatment. Study of 850 patients. Cancer 1985 Aug 
15;56(4):918-928. 
 (398)  A new prognostic system for hepatocellular carcinoma: a retrospective 
study of 435 patients: the Cancer of the Liver Italian Program (CLIP) 
investigators. Hepatology 1998 Sep;28(3):751-755. 
 (399)  Zhang ZL, Liu ZS, Sun Q. Expression of angiopoietins, Tie2 and vascular 
endothelial growth factor in angiogenesis and progression of 
hepatocellular carcinoma. World J Gastroenterol 2006 Jul 
14;12(26):4241-4245. 
 (400)  Deli G, Jin CH, Mu R, Yang S, Liang Y, Chen D, et al. 
Immunohistochemical assessment of angiogenesis in hepatocellular 
carcinoma and surrounding cirrhotic liver tissues. World J 
Gastroenterol 2005 Feb 21;11(7):960-963. 
 (401)  Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of 
the HIF system. Nat Med 2003 Jun;9(6):677-684. 
 (402)  Ogasawara S, Yano H, Iemura A, Hisaka T, Kojiro M. Expressions of 
basic fibroblast growth factor and its receptors and their relationship 
 285 
to proliferation of human hepatocellular carcinoma cell lines. 
Hepatology 1996 Jul;24(1):198-205. 
 (403)  Motoo Y, Sawabu N, Yamaguchi Y, Terada T, Nakanuma Y. Sinusoidal 
capillarization of human hepatocellular carcinoma: possible promotion 
by fibroblast growth factor. Oncology 1993 Jul;50(4):270-274. 
 (404)  Ribatti D, Vacca A, Roccaro AM, Crivellato E, Presta M. Erythropoietin 
as an angiogenic factor. Eur J Clin Invest 2003 Oct;33(10):891-896. 
 (405)  Masuda S, Nagao M, Sasaki R. Erythropoietic, neurotrophic, and 
angiogenic functions of erythropoietin and regulation of erythropoietin 
production. Int J Hematol 1999 Jul;70(1):1-6. 
 (406)  Kew MC, Fisher JW. Serum erythropoietin concentrations in patients 
with hepatocellular carcinoma. Cancer 1986 Dec 1;58(11):2485-2488. 
 (407)  Malaguarnera M, Bentivegna P, Di F, I, Laurino A, Romano M, Trovato 
BA. [Erythropoietin in hepatocellular carcinoma]. Bull Cancer 1996 
Dec;83(12):977-980. 
 (408)  Sakisaka S, Watanabe M, Tateishi H, Harada M, Shakado S, Mimura Y, 
et al. Erythropoietin production in hepatocellular carcinoma cells 
associated with polycythemia: immunohistochemical evidence. 
Hepatology 1993 Dec;18(6):1357-1362. 
 (409)  Lowdell MW. Experimental design, data analysis and fluorescence 
quantitation. In: Macey M, editor. Flow Cytometry: Principles and 
Applications, 1 ed Humana Press; 2007. p. 133-147. 
 (410)  Khan SS, Solomon MA, McCoy JP, Jr. Detection of circulating 
endothelial cells and endothelial progenitor cells by flow cytometry. 
Cytometry B Clin Cytom 2005 Mar;64(1):1-8. 
 (411)  Dulic-Sills A, Blunden MJ, Mawdsley J, Bastin AJ, McAuley D, Griffiths 
M, et al. New flow cytometric technique for the evaluation of 
circulating endothelial progenitor cell levels in various disease groups. 
J Immunol Methods 2006 Oct 20;316(1-2):107-115. 
 (412)  Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M, et 
al. In vitro differentiation of endothelial cells from AC133-positive 
progenitor cells. Blood 2000 May 15;95(10):3106-3112. 
 286 
 (413)  Arbab AS, Janic B, Knight RA, Anderson SA, Pawelczyk E, Rad AM, et al. 
Detection of migration of locally implanted AC133+ stem cells by 
cellular magnetic resonance imaging with histological findings. FASEB J 
2008 Sep;22(9):3234-3246. 
 (414)  Furstenberger G, von MR, Lucas R, Thurlimann B, Senn HJ, Hamacher J, 
et al. Circulating endothelial cells and angiogenic serum factors during 
neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 2006 
Feb 27;94(4):524-531. 
 (415)  Quirici N, Soligo D, Caneva L, Servida F, Bossolasco P, Deliliers GL. 
Differentiation and expansion of endothelial cells from human bone 
marrow CD133(+) cells. Br J Haematol 2001 Oct;115(1):186-194. 
 (416)  Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, Hwang KK, et al. 
Characterization of two types of endothelial progenitor cells and their 
different contributions to neovasculogenesis. Arterioscler Thromb Vasc 
Biol 2004 Feb;24(2):288-293. 
 (417)  Rehman J, Li J, Orschell CM, March KL. Peripheral blood "endothelial 
progenitor cells" are derived from monocyte/macrophages and 
secrete angiogenic growth factors. Circulation 2003 Mar 
4;107(8):1164-1169. 
 (418)  Gulati R, Jevremovic D, Peterson TE, Chatterjee S, Shah V, Vile RG, et 
al. Diverse origin and function of cells with endothelial phenotype 
obtained from adult human blood. Circ Res 2003 Nov 28;93(11):1023-
1025. 
 (419)  Mellick AS, Plummer PN, Nolan DJ, Gao D, Bambino K, Hahn M, et al. 
Using the transcription factor inhibitor of DNA binding 1 to selectively 
target endothelial progenitor cells offers novel strategies to inhibit 
tumor angiogenesis and growth. Cancer Res 2010 Sep 15;70(18):7273-
7282. 
 (420)  Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, et al. 
Tositumomab and iodine-131 tositumomab produces durable 
complete remissions in a subset of heavily pretreated patients with 
low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 
2005 Oct 20;23(30):7565-7573. 
 (421)  Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, et 
al. A phase 2 trial of CHOP chemotherapy followed by 
tositumomab/iodine I 131 tositumomab for previously untreated 
 287 
follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol 
S9911. Blood 2003 Sep 1;102(5):1606-1612. 
 (422)  Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG, et al. A 
phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, 
cyclophosphamide, and autologous stem cell transplantation for 
relapsed B-cell lymphomas. Blood 2000 Nov 1;96(9):2934-2942. 
 (423)  Devizzi L, Guidetti A, Tarella C, Magni M, Matteucci P, Seregni E, et al. 
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell 
reinfusion: an outpatient preparative regimen for autologous 
hematopoietic cell transplantation. J Clin Oncol 2008 Nov 
10;26(32):5175-5182. 
 (424)  Salmon HW, Siemann DW. Effect of the second-generation vascular 
disrupting agent OXi4503 on tumor vascularity. Clin Cancer Res 2006 
Jul 1;12(13):4090-4094. 
 (425)  Sugimachi K, Tanaka S, Taguchi K, Aishima S, Shimada M, Tsuneyoshi 
M. Angiopoietin switching regulates angiogenesis and progression of 
human hepatocellular carcinoma. J Clin Pathol 2003 Nov;56(11):854-
860. 
 (426)  Benetti A, Berenzi A, Gambarotti M, Garrafa E, Gelati M, Dessy E, et al. 
Transforming growth factor-beta1 and CD105 promote the migration 
of hepatocellular carcinoma-derived endothelium. Cancer Res 2008 
Oct 15;68(20):8626-8634. 
 (427)  De PM, Murdoch C, Venneri MA, Naldini L, Lewis CE. Tie2-expressing 
monocytes: regulation of tumor angiogenesis and therapeutic 
implications. Trends Immunol 2007 Dec;28(12):519-524. 
 
 
